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Summary 
The use of complementary products has increased dramatically over the last few 
decades. These products are not subjected to the same safety and toxicity testing 
that we demand of our conventional medicines, yet they are consumed without 
medical supervision or advice. The concurrent use of these products with 
conventional medicines raises the potential for drug interactions to occur. We 
investigated the potential for complementary products to interact with three key 
pharmacokinetic parameters. The displacement of drugs bound to plasma proteins; 
inhibition of the transporter p-glycoprotein; and inhibition of the quantitative most 
important class of drug metabolising enzymes, the cytochrome P450s. 
 
Complementary products selected for investigation are likely to be concurrently 
used with a therapeutic drug for which, if an interaction was to occur, the outcome 
could be life threatening. This is based on the properties of the drug and the 
reported traditional therapeutic indication.  
  
Site-specific fluorescent probes were employed for albumin and alpha-1-acid 
glycoprotein to determine the binding and displacement of previously bound 
compounds. Of the 5 products investigated significant binding (Kd < 1mg/ml) 
occurred at site I on human serum albumin for 1 extract (the methanolic extract of 
Goldenseal). A greater level of significant binding was seen at site II with 1 aqueous 
extract (CoEnzyme Q10) and 4 methanolic extracts (CoEnzyme Q10, Danshen, 
Ginkgo Biloba, Goldenseal) all binding with a dissociation constant less than 1 
mg/ml. Investigations into binding to alpha-1-acid glycoprotein revealed that 1 
product bund with significance (the methanolic extract of Echinacea). 
  xxi 
Inhibition of the transcellular membrane pump p-glycoprotein was investigated 
with 5 products utilizing a rapid fluorescent assay and the data confirmed with the 
enzyme based ATPase assay. Significant inhibition (IC50 <100 μg/ml) was seen for 
4 extracts (the aqueous extract of Cordyceps, the methanolic extract of Milk Thistle 
and both aqueous and methanolic extracts for Slippery Elm). 
 
The inhibition of cytochrome P450 was determined for 9 isoforms of the enzyme. 
Two methods were used; HPLC analysis combined with fluorometry with single 
substrates and their metabolites, and the N-in-one cocktail, which allows for the 
simultaneous monitoring of the 9 enzymes in a single incubation.  The N-in-one 
assay was a more reliable assay with these complex products. Of the ten 
investigated products, Valerian was the most widely inhibitory as it inhibited all 9 
of the isoenzymes to some degree. The inhibition of CYP3A4 by the methanolic 
extract was the most significant finding (IC50 3.5g/ml). Reliable extrapolation of 
in vitro findings to in vivo situation is still an unsurmountable challenge. 
 
Due to the large number of complementary products available, their variability in 
chemical composition and the requirement of ongoing monitoring, we have utilised 
assays that can provide rapid, cost-effective and reliable information with regards to 
the potential of these products to cause drug interaction. We have demonstrated the 
ability for rapid, accurate and reproducible assays to provide information on the 
potential for complementary products to cause drug interactions and presented a 
rationale basis for screening these products.   
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Chapter 1 - General Introduction: 
Complementary products, the risk associated with use, 
current regulations and considerations for investigations. 
 
1.1 Introduction 
Complementary and alternative products are available to consumers without 
evaluation of their efficacy or safety, yet they are a widely used health care product. 
With a market value of $1.2 billion per year in Australia alone (Department of 
Innovation, 2011), it would reasonable to expect adequate safety evaluations of 
these products to be conducted. Our focus here is the potential for these products to 
cause drug interactions. 
 
With self-administration of complementary products an increasingly common trend 
(Eisenberg et al., 1998, MacLennan et al., 2002), there is concern regarding 
simultaneous administration with therapeutic drugs. The concurrent administration 
of these products and prescription drugs or over-the-counter medications 
significantly increases the risk for clinically serious adverse reactions. Adding 
concern to this is the public’s attitude regarding these products.  Consumers feel 
that these products are natural and therefore safe and often do not report their use 
to medical professionals (Eisenberg et al., 1998).  
 
Because of the variable nature of these products, it is not feasible to subject them to 
the same safety evaluation criteria as therapeutic drugs.  
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However, a rational basis can be formulated for essential studies to improve patient 
safety. With the large number of products available, prioritising safety studies 
becomes essential. The selection criteria for which product is to be investigated is 
best started considering the therapeutic drug for which interactions may be of 
clinical significance.  
 
These therapeutic drugs have at least one of the following characteristics: 
 Narrow therapeutic index;  
 High potential for toxicity; and/or  
 Life-threatening outcome from therapeutic failure. 
 
The next step is to identify complementary products that are market leaders and on 
the basis of volume likely to be concurrently used with drugs that meet the above 
criteria. The products for investigation are then selected based on their particular 
traditional therapeutic indication.  
 
1.2 Complementary and Alternative Products 
The wide acceptance of these products and the advent of internet trading has 
contributed to their increase in use, reported to be as high as 18% of the adult 
population in the USA (Barnes and Bloom, 2008). Similar figures have been 
reported in Australia with 25% reportedly using complementary products (Xue et 
al., 2007), this figure rises to two-thirds of the population when  therapies such as 
chiropractic and energy based modalities are included (NICM., 2009). In England, 
use of herbal products has been reported to be as high as 22% (Thomas et al., 2001).  
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The World Health Organization (WHO) reports that the use of traditional medicine 
accounts for 80-95% of primary health care in Africa and Asia, but this figure 
includes other forms of traditional medicine such as acupuncture and homeopathy 
(World Health Organization, 2008). The global market for these products was 
estimated at US$83 billion annually in 2008 (Robinson and Zhang, 2011).   
 
Increasing the need for investigations into drug interactions is the use of 
complementary products in patient populations with chronic and/or terminal 
illness. There is a higher proportion of use of complementary products, 70-80%, in 
this patient group (Lee et al., 2006, Molassiotis et al., 2005).  These patients are at a 
greater risk of drug interactions as not only do they often consume multiple 
therapeutic drugs (or conventional medicines) as part of their treatment, but also 
therapeutic failure could be life threatening. 
 
1.2.1 Concerns Relating to Complementary Products 
In the framework of safety, reliance on historical use of these products is no longer 
valid, as issues such as self-administration, concurrent use with therapeutic agents 
and a much more diverse genetic population being exposed all need to be 
considered. Traditionally many of these products were administered or prescribed 
by healers and physicians in the cultures where they were used but in today’s 
society these products are re-packaged into tablets and capsules and sold to 
consumers with no consultation. 
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Misidentification of plant material is also an area of concern. In 1993 over 100 
cases of irreversible nephropathy were reported in young women attending a 
slimming clinic in Belgium. The nephrotoxicity was traced to the accidental 
substitution of Stephania tetrandra with the highly toxic Aristolochia fangchi 
(Vanherwghem, 1994). The misidentification of other Aristolochia species has 
occurred in the United Kingdom, China and France (Stengel and Jones, 1998, 
Cosyns et al., 1999).  
 
Assessment of delayed toxicity including carcinogenesis is difficult, even with the 
strict monitoring of conventional medicines. Given the unregulated use of 
complementary products, any incidences of delayed toxicity including reproductive 
and developmental toxicity, would be extremely difficult to identify. 
 
Deliberate substitution with other herbal and complementary products or illegal 
“fortification” with prescription medications is known to occur and may have 
serious consequences. The illegal and unlisted addition of corticosteroids in creams 
for the treatment of eczema (Kinsunthorn et al., 2011) and prescription medications 
such as sildenafil (Low et al., 2009), glibenclamide (Ching et al., 2011), and 
alprazolam (Rao et al., 2004) have all been reported in complementary products. 
These illegal additions could be responsible for pharmacodynamic interactions in 
patients already consuming similar medications, leading to synergistic effects, 
which may be toxic. These added medications may also cause allergic reactions in 
susceptible patients. 
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In the modern mass marketing of complementary products quality standards in 
manufacturing are important, as poor manufacturing is a health threat to the 
consumer. In January 2003, questions into the manufacturing and quality control 
processes were raised by the regulatory body in Australia with respect to a very 
large Australian manufacturer, Pan Pharmaceuticals. Investigations revealed a 
large number of irregular practices including: 
 Misidentification of raw material, especially herbal materials, which could 
lead to severe organ damage, including renal and hepatic damage. 
 Manipulation of assay results of finished products in order to comply with 
specifications. 
 Fabrication of assay results of a finished vitamin product for export in order 
to comply with specifications. 
 Cross-contamination or substitution of ingredients due to inadequate 
operating procedures and poor compliance with existing procedures which 
could lead to severe allergic reactions including anaphylaxis. 
 Microbiological contamination through poor raw material sourcing and 
handling, poor cleaning practices, and inadequate operating procedures, 
potentially leading to infections. 
 Substitution of shark cartilage for bovine cartilage, which could cause 
serious allergic reactions, in fish-protein sensitive individuals. 
 Substitution of bovine cartilage for shark cartilage where the bovine cartilage 
has been sourced without any assurance that it is TSE-free, and the country 
of origin is unknown. 
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This investigation lead to a large-scale recall of medicines (both generic and 
complementary) involving as many as 219 products (Therapeutic Goods 
Administration, 2003). The manufacturing license of Pan Pharmaceuticals was 
subsequently suspended.  
 
Heavy metal contamination of complementary products has been documented 
(Rao et al., 2011). The heavy metal content may rise above a safe level due to 
contaminated raw materials, from processing and manufacturing practices or it can 
be added deliberately. In the latter case it may be declared as a constituent of a 
complementary product. The Chinese Pharmacopoeia lists formulations for nearly 
fifty products that include heavy metals such as arsenic and mercury.  
 
1.3 Investigating Complementary Products for Drug Interactions 
Studying complementary products in the context of drug interactions presents a 
number of challenges, including the fact that these products are complex 
preparations of variable composition and multiple therapeutic targets. This 
variability in dose, strength and formulation makes the evaluation for safety in 
animal and/or clinical models both time and cost prohibitive.  
 
Isolating individual components is one method that can be used to assist in the 
determination of the pharmacokinetic profiles of these products, though this is time 
consuming and in the end may not provide the answers required as these products 
are not taken as isolated components but as complex mixtures.  
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The many components of complementary products are not considered in isolation, 
instead the multiple components present are often considered integral to the action 
with “a concerted pharmacological intervention of multiple compounds interacting 
with multiple targets and possessing mutually interdependent activities that are 
required for an optimal effect” (Chan, 1995). 
 
As variability is known to occur with these products between the manufacturers 
and even between the seasons and geographic locations of the raw materials, 
ongoing screening for potential drug interactions is required. By using a system that 
is rapid and reproducible, monitoring of the products can occur and fluctuations 
and variability in product composition can be detected. 
 
Another challenge associated with complementary products is the choice of 
extraction method used for assays in the laboratory. Extractions may use a variety 
of solvents, heat, time, drying and crushing. Separation techniques may also utilize 
HPLC, GCMS and electrospray ionization. 
 
1.4 Current Regulations 
The regulation of complementary and alternative products differs from the 
regulation of therapeutic agents. Regional variation in the testing and marketing of 
these products also exists. It is important to understand how the regulations differ, 
as internet trading and unregulated or inconsistent export and import laws mean 
that these products are globally available. Consistent regulations would provide 
regulators, importers and manufacturers with clear guidelines and a regulated 
framework.  
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1.4.1 Europe 
The European Medicines Agency (EMA) has within its body, the Committee on 
Herbal Medicinal Products (HMPC). Under EMA there are three classifications for 
complementary products: 
 A herbal medicinal product is any medicinal product, exclusively containing 
as active ingredients one or more herbal substances or one or more herbal 
preparations, or one or more such herbal substances in combination with 
one or more such herbal preparations. 
 A herbal substances is all mainly whole, fragmented or cut plants, plant 
parts, algae, fungi, lichen in an unprocessed, usually dried, form, but 
sometimes fresh. Certain exudates that have not been subjected to a specific 
treatment are also considered to be herbal substances. Herbal substances are 
precisely defined by the plant part used and the botanical name. 
 Finally, herbal preparations are obtained by subjecting herbal substances to 
treatments such as extraction, distillation, expression, fractionation, 
purification, concentration or fermentation. These include comminuted or 
powdered herbal substances, tinctures, extracts, essential oils, expressed 
juices and processed exudates. 
 
Under European medicines legislation (Directive 2004/24/EC), medicinal products 
containing herbal substances/preparations must fall within one of the following 
three categories to reach the market: 
 A product can be classified under traditional medicinal use provisions 
(‘traditional use’) accepted on the basis of sufficient safety data and plausible 
efficacy: the product is granted a traditional use registration. 
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 A product can be classified under well-established medicinal use provisions 
(‘well-established use’). This is demonstrated with sufficient safety and 
efficacy data. As a result the product is granted a marketing authorization.  
 A product can be authorized after evaluation of a marketing authorization 
application consisting of only product-specific safety and efficacy data (‘full 
dossier’). As a result the product is granted a marketing authorization. 
 
1.4.2 United States of America 
The National Centre for Complementary and Alternative Medicine (NCCAM), a 
centre within the National Institutes of Health (NIH) advises the U.S Food and 
Drug Administration (FDA) on issues relating to complementary products. The 
regulation of these products is under the control of the FDA.  
 
NCCAM classifies complementary and alternative products and therapies into four 
categories: 
 Biologically-based practices; 
 Energy therapies; 
 Manipulative and body-based methods; and 
 Mind-body medicine. 
 
Many of the complementary products fall under the regulation of the Dietary 
Supplement Health and Education Act (DSHEA) of 1994. This act regulates 
products that are intended to supplement the diets and include vitamins, minerals, 
herbs or other botanicals, amino acids, and substances such as enzymes, organ 
tissues, glandular, and metabolites.  
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Under this act, the manufacturer is responsible for ensuring that the ingredient is 
safe before it is marketed, though products do not need to be registered with the 
FDA, or gain approval prior to selling.  
 
Manufacturers must make sure that product label information is truthful and not 
misleading, and products are manufactured under Good Manufacturing Practices 
(GMP). The FDA is responsible for taking action against any unsafe dietary 
supplement product after it reaches the market.  
 
1.4.3 Australia 
In Australia the regulation of complementary and alternative products is the 
responsibility of the Therapeutic Goods Administration (TGA). Complementary 
products are often referred to as complementary medicines; this classification 
includes vitamins, minerals, herbal, aromatherapy and homeopathic products. 
These are all regulated under the Therapeutic Goods Act 1989.  
 
The TGA defines a complementary medicine as a therapeutic good consisting 
wholly or principally of one or more designated active ingredients each of which 
has a clearly established identity and a traditional use.  
 
Traditional use means use that is well documented, or otherwise established, 
according to the accumulated experience of many traditional healthcare 
practitioners over an extended period; and accords with well-established procedures 
of preparation, application and dosage.  
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All products imported into, supplied in or exported from Australia, must be listed 
on the Australian Register of Therapeutic Goods (ARTG). The legal responsibilities 
of sponsors who wish to register a product include the assessment of the product as 
low risk-, which means that the product is a Listed product, or higher risk-, which 
means that the product becomes a Registered product.  
 
Listed products are restricted to claims relating to health maintenance, health 
enhancement or non-serious, self-limiting conditions. Importantly Listed medicines 
are not assessed individually for efficacy, though any direct therapeutic claims must 
have supporting evidence. Registered complementary medicines are assessed 
individually for quality, safety and efficacy. 
 
All products imported and exported must be manufactured under the Good 
Manufacturing Practice (GMP). Post-marketing surveillance and reporting of 
adverse effects is the responsibility of the product sponsor. 
 
 
1.5 Project Rationale 
The advocates for these products raise obstacles and objections as to why they 
should not be subjected to the safety tests that we expect of our health-care 
products. We have addressed these claims with the aim of developing a basic 
framework for testing that can and should be undertaken. The obstacles raised and 
the responses to these obstacles are presented in Table ‎1-1. 
 
 Chapter 1: General Introduction 12 
This project approaches the field of drug interactions with complementary products 
from the basis of adverse interactions with therapeutic agents. A rational basis for 
the selection of products of products is presented and the potential for interactions 
assessed. The methods of assessment all allow for rapid screening of the products as 
complex mixtures to provide accurate and reproducible data. This data can be used 
to prioritise the products that require further investigation and as starting for 
monitoring the variation in the products. 
 
Interaction potential based on three mechanisms were addressed: 
 Protein binding (Chapter 2). 
 P-glycoprotein inhibition (Chapter 3). 
 CYP inhibition (Chapter 4). 
The specific aims of each of these areas are detailed in each chapter. These 
individual areas have been targeted as clinical studies and case reports have 
identified these areas as key for interactions with herbs and conventional medicine 
(Chen et al., 2011, Shaojun and Ulrich, 2012).  
 
Many attempts have been made to determine the frequency of adverse events that 
can be attributed to an interaction involving a complementary product but this is 
complicated not only because of self-medication and under-reported use of these 
products but also because of the wide variability (Farah et al., 2000). Additionally 








Table ‎1-1: The proposed obstacles and objections to safety testing for complementary products and the response to discredit the validity of the 
claim. 
Proposed Obstacle Response 
High cost of testing- this would cripple the industry. The complementary products industry has an estimated value of US$83 billion annually. 
Safety testing could increase the market share as consumers who currently avoid these 
products due to concerns, may decide to start using them or be given permission by medical 
professionals to use them concurrently with conventional medicine, once the safety has been 
confirmed. 
Complexity of products does not lend these products to standard 
safety testing. 
Products do not need to be studied in isolation or as single components; they can be 
investigated in their complex form. 
Historical use of these products demonstrates safety. The use of these products and the population exposed has changed. More patients are now 
exposed, including patients with complex and chronic medical conditions and multiple drug 
therapies. Delayed toxicities (cancer and genotoxicity) are very difficult to study in users. 
Practitioners are experienced and know which products may be 
toxic and how to “personalise” treatment for patients. 
Consumers purchase these products off supermarket shelves and from the internet with no 
supervision or guidance. Practitioners may not have an understanding of western 
therapeutic drugs and the potential for interactions. 
 Chapter 2- Protein Binding 14 
Chapter 2 - Protein Binding: 




Binding to plasma proteins can influence the distribution, metabolism and 
excretion behaviour of many endogenous and exogenous compounds. In vivo, drug 
molecules are either bound to proteins and lipids in plasma and tissues, or are free. 
These free drug molecules diffuse in the aqueous environment of the blood and 
tissues (Smith et al., 2010).  
 
Because of their high molecular weights, plasma proteins and the compounds 
bound to them cannot cross capillary walls. Consequently, the fraction of the 
compound bound to plasma protein is not immediately available for distribution 
into the extra-vascular space or for filtration by the kidneys. In most cases, only the 
free drug (unbound) molecules interact with the therapeutic target to produce an 
effect. The unbound fraction is also important as it will affect the distribution, 
steady state concentration, rate of metabolism, and the rate of excretion of a drug 
(Noctor et al., 1993, Vallner, 1977). 
 
Protein binding is important when predictions and investigations into the toxicity of 
a compound are undertaken, as typically the toxicity is manifested by the unbound 
fraction.  
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Therefore a compound with a high degree of plasma protein binding may not show 
toxicity when compared to one that is less extensively bound to plasma proteins. 
Paradoxically a high degree of protein binding increases the risk of adverse effects 
resulting from displacement interactions with other compounds and the binding 
site. Due to the transient increase in the concentration as a result of one compound 
displacing the other (section ‎2.1.1).  
 
Several key proteins found in human serum are capable of binding drugs; albumin 
(HSA) and alpha-1-acid glycoprotein (AGP) are of greatest importance (Fournier T 
et al., 2000). As a general rule acidic drugs bind to HSA and basic and neutral drugs 
bind to AGP. Protein-ligand interactions occur primarily as a result of hydrophobic 
forces, hydrogen bonding, and Van der Waals forces (Casarett L et al., 2008). This 
interaction is usually reversible and as unbound drug diffuses out of the capillaries, 
bound drug disassociates from the protein until the free fraction reaches equilibrium 
with the extra-vascular and the vascular space. 
 
2.1.1 Displacement from Protein 
The concentration of a drug or ligand bound to protein can alter significantly due to 
co-administered drugs/ligands. Thus the ability to bind to protein and to displace a 
previously bound compound from protein is an important consideration in drug 
development and in the prediction of drug interactions. 
 
Simultaneous binding of drugs and/or endogenous ligands to protein can give rise 
to various potential interactions. The binding of the ligands can be independent; 
and therefore not influence the affinity of each other.  
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The binding may be cooperative; that is the binding of one ligand increases the 
affinity of the other. The binding may be anti-cooperative; where the binding of one 
ligand decreases the affinity of the other, and finally the binding may be 
competitive; where the two ligands bind to the same site, the competition 
determining a decrease of the affinity. 
 
Determination of drug binding to different biomacromolecules, and particularly 
with specific plasma and tissue proteins, is mandatory in pharmacological and 
toxicological studies for therapeutic drugs. This is in order to predict nonlinear 
pharmacokinetic processes (Gillespie, 1993), stereoselective pharmacokinetics 
(Brocks, 2006), covalent binding of drug metabolites to different molecular 
structures (Nelson, 1982), drug displacement phenomena (MacKichan, 1989, 
Rolan, 1994), or inter-individual binding variability due to different physiological or 
pathological factors (age, disease, genetic aspects, etc.) (Eap and Baumann, 1989, 
Hervé et al., 1993, Zini et al., 1990b, Zini et al., 1990a, Oracová et al., 1996).  
 
Whilst these studies are performed for therapeutic drugs before they enter clinical 
trial, let alone the market, in sharp contrast, this is not the case for complementary 
products. This is an alarming situation as these products are known to cause drug 
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2.2 Albumin  
Human serum albumin (HSA), at a concentration of 40 mg/ml, is the most 
abundant protein in the blood, acting as a transport protein for numerous 
endogenous and exogenous compounds. It is synthesised in the liver and exported 
as a non-glycosylated protein (Peters T Jr, 1996). HSA has 585 amino acids and a 
mass of 66.5 kDa and is composed of three structurally similar -helical domains, I, 
II and III (Thorarensen et al., 2007). 
 
These subdomains are further divided; subdomain A containing 6 -helices and 
subdomain B containing 4 -helices, connected by flexible loops. The main binding 
sites for compounds are Site I, localised within domain II, referred to as the 
warfarin binding site, and Site II localised within domain III and referred to as the 
benzodiazepine binding site (Fournier T et al., 2000).  
 
Figure ‎2-1: The crystal structure of human serum albumin (HSA) at 2.5Å 
resolution. (http://www.rcsb.org/pdb/explore.do?structureId=1AO6) 
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2.2.1 Biological Functions of Human Serum Albumin 
The abundance of HSA and its broad binding capabilities make it a key factor in 
the pharmacokinetic behaviour of many drugs, affecting their efficacy and rate of 
delivery. HSA may act as a reservoir for exogenous or endogenous ligands, or it can 
hold some ligands in a strained orientation, facilitating their metabolic modification 
and rendering potential toxins harmless. 
 
Protein binding can result in an increased solubility in plasma, decreased toxicity 
(as the bound drug cannot cross cell membranes), and/or protection against 
oxidation of the bound ligand. However, binding can also have a significant impact 
on the pharmacokinetics of drugs in other ways. For example, binding to albumin 
can extend the in vivo half-life; bound drugs are unable to cross the renal 
epithelium and therefore are not excreted. 
 
In addition to its binding and transport abilities, HSA also provides most of the 
acid/base buffering action of the plasma, and contributes to osmotic pressure. HSA 
accounts for most of the antioxidant capacity of human serum either directly or by 
binding and carrying radical scavengers or sequestering transitional metal ions with 
pro-oxidant activity. Additionally HSA acts as a depot and carrier for nitric oxide, 
leading to covalent modification of molecules (Fasano et al., 2005). 
 
2.2.2 Binding Properties of Human Serum Albumin 
HSA interacts reversibly with a broad group of compounds, though hydrophobic 
anionic compounds are most strongly bound. The binding capability of HSA is 
diverse; it contains multiple binding sites that vary in structure and polarity. 
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Additionally the binding of ligands may induce conformational changes in the HSA 
molecule, which alter the binding capabilities of the molecules.  
 
Usually drugs bind to one or few high-affinity sites with typical association 
constants in the range of 104-106 M (Kragh-Hansen et al., 2002). At high 
concentrations a single compound may populate multiple sites on albumin, binding 
at a primary site with high affinity and at secondary and tertiary site with lower 
affinity (Day and Myszka, 2002). The binding sites vary in size and polarity and 
allow drugs of differing structure and size to bind simultaneously.  
 
Site I is a complex and large binding site. Evidence for this is shown in the binding 
of bilirubin, a large molecule with a molecular weight of 548 Daltons, and with 
ligands of very different chemical structures binding to the region with high affinity. 
This includes ligands as diverse as warfarin, tolbutamide and indomethacin 
(Yamasaki et al., 1996, Vallner, 1977, Sudlow et al., 1975).  
 
Site I ligands tend to be dicarboxylic acids and/or bulky heterocyclic molecules 
with a negative charge localised in the middle of the molecule (Peters, 1985). 
Conformational changes in HSA post ligand binding have been proposed, changes 
could be anti-cooperative as in the case with warfarin and salicylate (Kragh-
Hansen, 1985) or allosteric as seen with ibuprofen enantiomers and the stereo-
selective binding of 3-acyloxy-1,4-benzodiazepines (Fitos et al., 1999).  
 
Site II ligands are often aromatic carboxylic acids with a negatively charged acidic 
group at one end of the molecule away from a hydrophobic centre (Peters, 1985). 
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Due to the size of the ligands that bind at site II, it is likely that this is a smaller 
binding site than site I. Binding to this site is also highly stereoselective, indicating 
that this region is not as flexible as site I. L-tryptophan which binds with an affinity 
100 times greater than the D-isomer (McMenamy and Oncley, 1958), is an example 
of the highly stereoselective binding. Whilst binding to this site is more restricted 
there are several ligands that bind to site II with high affinity including ibuprofen, 
chlorothiazide and diazepam, (Ferrer et al., 2001, Sudlow et al., 1975, Takamura et 
al., 1994). 
 
2.2.3 Known Interactions Involving Human Serum Albumin 
Competition between two drugs for their binding to plasma protein can strongly 
affect the drug disposition of both drugs, with possible serious outcomes. This is of 
greater importance with compounds that are highly bound to HSA, i.e. over 90% 
(Peters, 1996, Kragh-Hansen et al., 2002).) One well-studied interaction occurs 
between warfarin and phenylbutazone. Warfarin is an anti-coagulant that is over 
90% bound to HSA. Co-administration with phenylbutazone leads to an increased 
bleeding risk in patients as the warfarin is displaced from the albumin, increasing its 
free concentration (Harder and Thürmann, 1996). 
 
2.2.3.1 Known Interaction with Complementary Products 
Several examples of plant and herbal products binding to HSA are known. 
Genistein, a major isoflavone present in soybeans binds at site I (warfarin binding 
site). The binding constant has been determined to be 1.00.2x105 M-1 (Mahesha et 
al., 2006), using equilibrium dialysis (section ‎2.4.1.1).  
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Using micro-dialysis, two components of the traditional Chinese herb Rhizoma 
Chuanxiong: ferulic acid and 3-butylphthalide, were found to bind to HSA with 
36.7 and 30.2% free compound detected, respectively (Guo et al., 2006). 
Fluorescence spectroscopy (section ‎2.4.3.2) was used to investigate the binding of 
Chinese medicinal herbs to HSA and bovine serum albumin (BSA). The 
anthraquinone, emodin, rhein, aloe-emodin and aloin, were all determined to have 
greater binding constants for HSA than BSA; 3.18-2.03x105, 2.20-1.16x105, 
1.14x105-3.84 x 104, and 2.77-3.10 x 104 l mol-1, respectively (Bi et al., 2005).  
 
Both Ginkgo and Ginger were suspected to alter the kinetics of warfarin by protein 
binding interactions but in vivo investigations using healthy human volunteers have 
found no alteration of the kinetics of warfarin when these herbal products are co-
administered with warfarin (Jiang et al., 2005). 
 
One of the potentially more significant examples of Chinese herbs binding to HSA 
is Danshen, a traditional Chinese medicine prepared from the root of Salvia 
miltiorrhiza. Studies have shown that Danshen is 50-70% bound to albumin, and 
can displace salicylate from its binding site (Gupta et al., 2002). Danshen is also of 
concern as it is suggested for patients with ‘stagnation of blood flow’ indicating that 
concurrent use with therapeutic agents such as warfarin are likely.  
 
These studies all indicate that there is a potential for significant protein binding 
with complementary and alternative products and that their potential for 
displacement interactions involving HSA should be investigated.  
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2.2.4 Alpha-1-Acid Glycoprotein 
Alpha-1-acid glycoprotein (AGP); also known as orosomucoid (ORM), was first 
described in 1950 concurrently by Karl Schmid and Richard J Winzler et al. 
(Schmid, 1950, Schmid, 1953, Weimer et al., 1950). It is a 41-43 kDa negatively 
charged (pI = 2.7-3.8), glycosylated acute phase protein that is 183 amino acids in 
length. AGP consists approximately of 45% carbohydrates (Schmid et al., 1977) 
attached in the form of five complex-type N-linked glycans (Yoshima H et al., 
1981), (Figure ‎2-2). The negative charge of AGP is due to the salicylic acid residues 
which may number as many as 16, or 10-14% by weight (Kopecký V et al., 2003).  
 
Five heteropolysaccharide groups are linked via an N-glycosidic bond to 
asparaginyl residues of the protein (Schmid et al., 1973a). AGP has a high -sheet 
content (40%) and consists of eight anti-parallel – strands which form the -barrel 
with a central hydrophobic pocket (Breustedt et al., 2006, Albani, 2006, Kopecký et 
al., 2003). This protein also has an unusually high solubility in water and other 
polar organic solvents. 
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Figure ‎2-2: The crystal structure of human alpha-1 acid glycoprotein at 1.8Å 
resolution. (http://www.rcsb.org/pdb/explore.do?structureId=3BX6). 
 
AGP is a member of the immunocalin family, a lipocalin subfamily. The lipocalin 
proteins are part of a larger group, the acute phase proteins (APPs). These APPs 
can be divided into two major classes depending on their response to cytokines.  
Type 1 APPs, including AGP, complement component 3, serum amyloid A, C-
reactive protein, haptoglobin and hemopexoin, are regulated by interleukin-1, 
interleukin-6 and glucocorticoids. Type 2 APPs including fibrinogen and several 
protease inhibitors are regulated by interleukin-6 type cytokines and glucocorticoids 
(Baumann et al., 1989, Baumann and Gauldie, 1994) 
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AGP is predominantly synthesised in the hepatocytes and parenchymal cells of the 
liver at a rate of 10 mg/kg (of body weight)/day (Lentner C, 1984),  and secreted 
into the plasma at a mean concentration of 0.77 mg/ml with a range of 0.36-1.46 
mg/ml in healthy volunteers (Blain et al., 1985), though the concentration of 1 
mg/ml is most commonly reported (Fournier T et al., 2000, Zsila F, 2007, Schön A 
et al., 2003).  Extra-hepatic synthesis of AGP also occurs in endothelial cells  and 
alveolar type II cell macrophages (Sörensson et al., 1999{Fournier T, 1999 #76)}. 
Protein synthesis and glycosylation of AGP is regulated by cytokines and 
glucocorticoids (MacKiewicz et al., 1987a, van Dijk et al., 1991).  
 
A critically important characteristic of AGP is the change in plasma levels that 
occurs with conditions such as inflammation (e.g. arthritis) and chronic disease 
(e.g. cancer). In these patients, expression is increased 2-5 fold (Fournier et al., 
2000). An increase in AGP also occurs following myocardial infarction (Johansson 
et al., 1972) and surgery (Voulgari et al., 1982), whilst lower levels are seen during 
pregnancy (Perucca E and Crema A, 1982), in thyroid disease (Feely J et al., 1981) 
and in patients with liver cirrhosis (Serbouce-Hougel et al., 1981). Such wild 
fluctuations must be considered when the potential for drug interactions are 
investigated with regards to AGP. 
 
60% of AGP is found in the central compartment; the rest is in the extra-vascular 
space (Koj A, 1974, Lentner C, 1984). AGP is also distributed to other fluids 
including, but not limited to, gastric juice, cerebrospinal fluid, wound exudate, 
pleural and peritoneal effusions and synovial fluid (Lentner C, 1984).  
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This wide distribution gives AGP the potential to be involved in drug interactions 
and protein binding not just within the circulation, but also at the sites of drug 
action. 
 
2.2.5 Structure and Variants of Alpha-1-Acid Glycoprotein 
Each of the five N-glycosylation sites of AGP can express many different glycans. 
Though only 12-20 glycoforms of AGP can be detected in human serum, as site 1 
never carries a tetra-antennary glycan, site 2 never carries glycans with fucose, site 4 
never carries a di-antennary glycan, and only glycosylation sites 4 and 5 carry tetra-
antennary glycans with more than one fucose (Fournier et al., 2000).  
 
Glycosylation has been shown to differ with various inflammatory diseases, this 
micro-heterogeneity of AGP depends on the duration of the inflammatory process 
and not the aetiology (Fassbender et al., 1991). The differentiation between acute 
and chronic inflammatory states can be determined by crossed immuno-affinity 
electrophoresis on the basis of reactivity to concanavalin A (Con A) (Narasimhan et 
al., 1986, Bøg-Hansen, 1973, Hansen et al., 1984b).  
 
A rise in reactivity to Con A has been reported in acute sepsis (Nicollet et al., 1981), 
pancreatitis (Raynes, 1982), and surgical trauma (Hansen et al., 1984a, Hansen et 
al., 1986). By contrast, in rheumatoid arthritis (MacKiewicz et al., 1987b), 
ankylosing spondylitis (MacKiewicz et al., 1989) and Crohn’s disease (Raynes, 
1982, Hansen et al., 1986), a significantly decreased proportion of AGP reacts with 
Con A. Isoform differentiation can also be achieved by capillary electrophoresis 
with time-of-flight mass spectrometry (Ongay and Neusüss, 2010). 
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Polymorphism with AGP is due to a 22 amino acid difference existing between the 
variants. (Eap CB and Baumann P, 1989, Fournier T et al., 2000).  The three genes: 
responsible AGP-A, AGP-B and AGP-B’ are located on chromosome 9. AGP-A 
(also known as ORM1) encodes for the major component of serum AGP, AGP-B 
and AGP-B’ (also known as ORM2) are identical and expressed 100-fold less than 
AGP-A and code for the variant of AGP (Dente et al., 1988).  
 
Due to multiple allelic forms of the genes, there are 70-80 genetic variants of AGP 
in humans (Eap CB and Baumann P, 1989). The three main AGP variants are 
designated F1, S and A; based on their electrophoretic migration. In humans there 
are three main phenotypes, F1S/A, F1/A and S/A with respective frequencies of 
50%, 35% and 15%. Although the majority of AGP ligands are not variant 
selective, some drugs exhibit preferential binding to the ‘A’ (e.g. disopyramide, 
methadone, amitriptyline) or ‘F1/S’ (e.g. warfarin, dipyridamole) variants (Hervé F 
et al., 1998). The relative abundance in commercial pooled AGP is reported to be 
≈40, ≈30, and ≈30% for the F1, S and A variants respectively (Hervé et al., 1998). 
 
2.2.6 Biological Functions of Alpha-1-Acid Glycoprotein 
The pharmacological role of AGP is still under investigation but it has been 
suggested that AGP is probably the only high affinity carrier for basic drugs in the 
serum (Kremer et al., 1988). Additionally, AGP is considered as a natural anti-
inflammatory and immunomodulatory agent (Williams et al., 1997). It also 
stimulates the secretion of tumour necrosis factor (TNF) from mononuclear cells 
and macrophages (Su et al., 1999) and provides protection against the toxic effect of 
TNF (Libert C, 1997).  
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The anti-neutrophil and anti-complement activity that has been reported is 
supported by in vitro and in vivo studies which show that AGP inhibits neutrophil 
activation (Vasson et al., 1994), increases the secretion of interleukin-1 inhibitor  
from macrophages (Bories et al., 1990) and modulates LPS-induced cytokine 
secretion by monocytes-macrophages (Boutten et al., 1992). This 
immunomodulation by AGP has been hypothesised to be a major problem in 
cancer patients because an impaired immune defence against the tumour may result 
in, and predispose to infections, and hinder immunotherapy treatment (Fournier et 
al., 2000, Tamura et al., 1981). 
 
In the endothelial cells, AGP is an important component of the capillary barrier, 
which is essential for capillary charge selectivity (Sörensson et al., 1999). Other 
functions which are more likely to only be important under pathological conditions 
include the ability to bind toxic lectins (Frantz M et al., 2000), endotoxins and 
bacterial lipopolysaccharides (Moore D et al., 1997).  
 
AGP has also been shown to inhibit the attachment of Mycoplasma pneumonia to 
alveolar macrophages (Athamna A et al., 1996), and of human immunodeficiency 
virus type-1 envelope glycoprotein in CD4+ monocytic cells and macrophages 
(Rabehi L et al., 1995). AGP also inhibits rotavirus replication by directly acting on 
the virus due to the negative charge of the AGP (Superti et al., 1993). High levels of 
AGP have been associated with the development of gallstones (Thijs et al., 1999). 
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2.2.7 Binding Properties of Alpha-1-Acid Glycoprotein 
AGP mainly binds basic and neutral compounds. Both from endogenous origins, 
including IgG3, heparin, serotonin (Schmid et al., 1973a), platelet activating factor 
(McNamara et al., 1986), melatonin (Morin et al., 1997) and histamine (ChachajW 
et al., 1980) and exogenous origins, including  tamoxifen (Schmid K et al., 1973, 
Schmid et al., 1973a) and propranolol (Albani et al., 1984). 
 
Disopyramide was the first drug described to bind to AGP (Kopitar and 
Weisenberger, 1971), to date over 300 drugs are known to bind to this protein. For 
some drugs, including cocaine and the protease inhibitors for HIV treatment, AGP 
is the major binding protein (Israili Z and Dayton P, 2001). AGP is also the major 
binding protein for steroids, including synthetic steroids such as RU486 (Grimaldi 
et al., 1989).   
 
It is generally assumed that acidic drugs bind to HSA, but with the increase in AGP 
levels under certain physiological conditions (section ‎2.2.4) and/or when the HSA 
levels decrease (seen with liver failure), phenobarbital, an acidic drug will bind to 
AGP (Schley and Müller-Oerlinghausen, 1983). Additionally warfarin, which 
usually binds to HSA, has been shown to bind to AGP (Hervé et al., 1998). 
  
Many groups have investigated the number and nature of binding sites on AGP. 
Initially it was proposed that AGP possessed one binding site located in the 
hydrophobic area of the protein (Müller, 1989), but seven binding sites with varying 
capacities and affinities have been described.  
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Whilst several binding sites have been characterised, it has been proposed, based on 
fluorescent probe and circular dichroism studies, that the binding sites significantly 
overlap and are influenced by each other (Maruyama et al., 1990), hence AGP is 
often referred to as having one wide and flexible binding area. 
 
The binding of drugs to AGP has been mostly shown to be hydrophobic, though 
electrostatic interactions have also been reported, additionally an increase in the pH 
will increase binding (Ponganis and Stanski, 1985). In the case of basic drugs, 
stereoselective binding is also important.  
 
2.2.8 Known Interactions Involving Alpha-1-Acid Glycoprotein 
A clinically significant drug-interaction can occur with rifampicin which is 80% 
bound to AGP (Johnson and Smith, 2006) and used to treat Mycobacterium 
tuberculosis. If displaced by a competing ligand the metabolism of rifampicin will be 
increased, thus decreasing the therapeutic levels of the antibiotic, leading to 
therapeutic failure.  
 
2.2.8.1 Known Interaction with Complementary Products 
As the levels of AGP are increased in chronic conditions including cancer, HIV and 
chronic inflammation the potential for significant interactions with complementary 
products is also increased. Use of complementary products amongst this patient 
group is extremely high with over 60% of cancer patients using herbal products 
(Richardson et al., 2000).  
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This potential for interactions is significant as chemotherapeutic drugs including 
tamoxifen (Paterson et al., 2003) and vinblastine (Steele et al., 1982) and the HIV 
anti-protease drugs saquinavir, indinavir, ritonavir and nelfinavir  (Schön et al., 
2003) all bind predominantly to AGP. 
 
To date there are only very limited studies with complementary products and their 
ability to bind to AGP. The need for rapid and reliable testing for the potential of 
complementary products to bind and displace previously bound drugs from AGP is 
demonstrated by the increased risk of concurrent use with important therapeutic 
agents that bind to AGP, in particular those with a narrow therapeutic index. 
 
2.3 Clinical Relevance of Displacement Interactions 
Plasma protein binding and its impact on the in vivo efficacy of a drug is an 
ongoing area of research in pharmacokinetics. Many of the techniques that 
determine protein binding do so in an attempt to measure the amount of free drug. 
This is because of the accepted dogma that it is the free drug concentration in the 
plasma is responsible for the pharmacological activity. This is because it is the free 
drug that is available to passively partition into the site of action and interact with a 
molecular target. This concept is reflected by the pair of equilibrium equations 
given below: 
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Where D is the free drug, PP are plasma proteins, DPP is drug bound to plasma 
proteins, R is the molecular target at the site of action, and DR is the drug bound to 
the target. 
 
The concept of determining the free drug concentration has been proposed as 
misleading as it is the amount of free drug at the therapeutic target that determines 
the in vivo efficacy not the free drug in plasma (Smith et al., 2010). But generally 
concentrations in plasma and target sites are assumed to be in equilibrium. 
 
The first adverse clinical outcomes attributed to protein-binding displacement 
interactions was the observation of an increase in prothrombin time in patients who 
were concurrently taking phenylbutazone and warfarin (Rowland and Tozer, 2010, 
Eisen, 1964). The hypoglycaemia observed in patients who were concurrently using 
sulphonamides and tolbutamide has also been attributed to displacement 
interactions (Christensen et al., 1963). 
 
Whilst there are clearly clinically significant displacement interactions, it has been 
suggested that the role of displacement interactions have been overstated and a 
flowchart proposed to help determine which drugs are more likely to cause adverse 
reactions (Figure ‎2-3) (Rolan, 1994).  
D   +     R
D    +    PP DPP (in blood)
DR (at the site of action)
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Figure ‎2-3: Flowchart for determining the clinical significance of potential protein 
binding displacement interactions (Rolan, 1994). 
 
The flowchart allows for the various scenarios that may arise when two drugs (A 
and B) are concurrently administered. For example, if drug A, is displaced by drug 
B, an increase in the free concentration of drug A results, but this increase in free 
drug A may not correlate with an increase in drug A at the receptor site because it 
will also be available for redistribution to the rest of the body, any increase in free A 
following redistribution will also be available for elimination. For low clearance 
drugs, where intrinsic clearance of free drug is the only determinant of mean 
steady-state free drug concentration, free concentration for A will return to the pre-
B level.  
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Thus any increase in the pharmacological effect of A will be transient and cannot 
be sustained. This flowchart also indicates that the interaction may become 
significant if the transient increase in the free drug is for a drug with a narrow 
therapeutic index. 
 
Predicting if a clinically significant interaction will arise from in vitro data is further 
complicated by the potential for drug metabolites to bind to plasma proteins and 
potentially displace previous bound compounds. Binding of drug intermediates has 
been shown for several drugs including zomepirac (Smith et al., 1990) and tolmetin 
(Hyneck et al., 1988). These studies indicate that the parent compounds and the 
intermediates may be the cause of an adverse interaction and both require 
investigation.  
 
2.4 Determination of Protein Binding 
Protein binding is increasingly becoming important in the early stages of drug 
development. Whilst there are many methods to study the binding of drugs to 
proteins, each technique will depend on one of the following (Klotz, 1973):  
 Separation of free and protein-bound fraction of ligand; 
 Detection of a change in the physicochemical property of the complexed 
ligand; 
 Detection of a change in a physicochemical behaviour of the binding 
protein.  
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The techniques used to determine protein binding can be generally divided into 
three main types: classical, chromatographic and spectrophotometric. Several of 
these techniques are discussed in more detail below and summarised in Table ‎2-1. 
 
When investigating protein binding, purified proteins or samples of serum and 
plasma can be utilised. With the complex and undefined nature of complementary 
products, utilising purified proteins allows for a more targeted investigation of the 
key transport proteins (HSA and AGP) and specific study of the underlying cause 
of a pharmacokinetic interaction. Studies with whole serum can be employed and 
may provide additional information of binding to minor and variable proteins such 
as gelatin-binding protein, insulin-like growth factor binding protein and retinol-
binding protein.  
 
Assays with whole plasma often employ classical methods for the analysis of the 
free or bound drug (section ‎2.4.1) which require the ability to measure the test 
compound, a task which is often not possible with the unknown and variable 
composition of complementary products.  
 
2.4.1 Classical Methods 
Classical methods including equilibrium dialysis, ultrafiltration and gel separation, 
all involve the determination of the free or bound drug using a separation step. 
These techniques are all based on the separation of the free drug from the bound 
after equilibrium is reached. Therefore the common limitation of these techniques 
occurs when the drug is tightly bound to the protein. The concentration of the free 
drug should be, in these cases, very low, and therefore difficult to detect.  
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Additionally the results obtained differ for each of these methods, and whilst 
experimental factors may be the cause of these differing results the technique may 
be responsible. For example equilibrium dialysis indicated 23% plasma protein 
binding for fleroxacin but 47% by ultra-filtration (Zlotos et al., 1998). This same 
study also highlighted inter-laboratory variation with 20-40% for ciprofloxacin, 8-
30% for ofloxacin, norfloxacin, and 30-50% for enoxacin.  
 
Whilst these classical methods may provide information relating to a compounds 
ability to bind to albumin, they do not provide information relating to the specific 
binding site, which in the case of drug-drug interactions is key. With regards to 
complementary products these classical methods are limited in their use as these 
complex mixtures are often unknown in their composition with multiple 
components, therefore monitoring for “free drug” is not possible.  
 
2.4.1.1 Equilibrium Dialysis 
Equilibrium dialysis is based on the establishment of an equilibrium state between a 
protein compartment and buffer compartment separated by a membrane, which is 
permeable only for low-molecular weight ligands i.e., free or unbound drug. 
Equilibrium dialysis is the preferred method to determine the free drug fraction and 
is often the reference method where nonspecific binding of drug to the filtration 
membrane and other surfaces causes experimental artefact (Lin et al., 1987). 
Equilibrium dialysis is also amenable to high throughput screening (Kariv et al., 
2001). 
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The major advantage of this technique is that the drug binding to plasma proteins is 
analysed at equilibrium, thus eliminating the effect of nonspecific binding. The 
disadvantage is the volume shift between the matrix and the buffer can disturb the 
equilibrium, though the addition of high molecular weight dextran can eliminate 
the difference in osmotic pressure (Lima et al., 1983).  
 
Equilibrium dialysis has many disadvantages including the time required for the 
system to reach equilibrium (Kurz et al., 1977, Oracová et al., 1996, Bowers et al., 
1984), volume shifts (Huang, 1983), Donnan effects (which hinder the passage of 
free ligand (Mapleson, 1987), nonspecific adsorption to dialysis apparatus (which is 
more problematic for highly lipophilic drugs i.e. cyclosporine (Henricsson, 1987, 
Fois and Ashley, 1991b, Fois and Ashley, 1991a), and difficulty in the control of 
experimental parameters i.e. pH of the medium (Henry et al., 1981, Brørs et al., 




Ultrafiltration with semi-permeable membranes produces a separation of the free 
drug from macromolecules by employing a pressure gradient, which forces small 
molecules through the membrane. The advantages of this technique include that 
when compared to equilibrium dialysis the analysis time is shortened, and there is a 
lack of dilution effects and volume shifts.  
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When ultrafiltration is combined with Raman difference spectroscopy this allows 
for the label free detection and quantitation of protein-ligand binding, which yields 
both thermodynamic and structural information and requires low amounts of 
protein, approximately 10-100 μg (Xie et al., 2008). 
 
Ultrafiltration, whilst quicker than dialysis, still requires the use of a labelled drug 
and/or additional analysis steps to determine the actual level of free drug by 
techniques such as immunoassay, gas chromatography or high-performance liquid 
chromatography. With the unknown composition of complementary products, 
ultrafiltration is not a suitable method to investigate protein binding.  
 
2.4.1.3 Ultracentrifugation 
This technique eliminates the problems associated with membrane effects seen in 
equilibrium dialysis and ultrafiltration and enables the separation of the free and 
protein bound fraction. Although there are discrepancies between the results 
obtained for ultracentrifugation from equilibrium dialysis and ultrafiltration.  
These discrepancies are most likely due to factors including sedimentation, 
viscosity and floating lipoprotein fractions (Kurz et al., 1977, Külpmann et al., 
1984, Verbeeck and Cardinal, 1985, Barré et al., 1985). 
 
2.4.1.4 Gel Filtration 
Gel filtration is effective when separating bound drugs from unbound drugs when 
the molecular mass of the complex is considerably larger than the free drug. The 
technique was first used to measure the binding of bilirubin in neonates sera (Schiff 
et al., 1972).  
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Gel filtration columns are selected so that the protein of interest and the protein-
ligand complex is in the mobile phase and the free ligand remains in the stationary 
phase. This technique is time consuming and complex so it is not commonly 
employed in laboratories. 
 
However, gel filtration has been combined with radio ligand-binding assays to 
allow for a 96-well plate method (Liu et al., 2002). This method can be used to 
process a large number of samples but as it requires radiolabeling of the drug can 
alter the binding data. 
 
2.4.2 Chromatographic techniques 
Chromatographic techniques in general are more sensitive and reproducible than 
conventional techniques and are able to detect small differences in binding affinity 
(Oracová et al., 1996). The major advantage of these techniques is that the ligand in 
questions does not require labelling with fluorescent tags or radioactive material 
and does not involve separation steps. 
 
2.4.2.1 Affinity chromatography 
Affinity chromatography combined with a protein stationary phase has many 
advantages including precision and reproducibility, this method also allows for 
enantioselective studies. Affinity chromatography is also useful in the investigation 
of drug interactions involving protein binding. Zonal elution with a known 
displacer at various concentrations can provide information on the ligand binding, 
including if the binding is co-operative, anti-cooperative or non-cooperative (Ascoli 
et al., 2006, Hage et al., 2009). 
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Unlike with HSA, binding studies with AGP are not reliable using affinity 
chromatography. Experiments have shown no correlation between the retention of 
compounds known to binds to AGP (Jewell et al., 1989) and the potential to 
displace (S)-propranolol which is a high affinity binding marker. It has been 
proposed that the high level of salicylic acid (section 2.2.4) is the reason for the lack 
of correlation (Schill et al., 1986). 
 
2.4.2.2 Capillary electrophoresis 
Capillary electrophoresis including affinity capillary electrophoresis and capillary 
affinity gel electrophoresis, have all been utilized for binding studies. Affinity 
capillary electrophoresis can be used as a rapid screening method of ligand-protein 
interaction and the evaluation of ligand-ligand interactions at the various binding 
sites (Birnbaum and Nilsson, 1992, Chu et al., 1993, Li and Lloyd, 1993).  
 
The major disadvantage of capillary electrophoresis in the low sensitivity, with 
therapeutic concentration of drugs not being easily detected. Recent advances in 
coupling capillary electrophoresis with micro-fluidics has shown promise in 
particular with the detection of the binding of bilirubin to albumin in neonates (Sun 
et al., 2010) but at this stage this technology is not scaled to a high through put 
screening method.  
 
2.4.3 Spectrophotometric Methods 
Spectroscopic techniques have been used to study the interaction of drugs with 
macromolecules (Chignell, 1973, Chignell, 1969).  
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These techniques, including nuclear magnetic and electron spin resonance, optical 
rotary dispersion, circular dichroism and fluorescence all have the advantage over 
classical methods (see section ‎2.4.1) as they do not require separation, Instead they 
measure a change in the physical property of the drug and/or protein upon binding. 
 
2.4.3.1 Circular dichroism 
Circular dichroism (CD) spectroscopy measures the difference in absorbance of 
right- and left-circularly polarized light producing characteristic bands- the Cotton 
effect. CD is often employed to investigate the secondary and tertiary structure of 
proteins but it can also be used in study of ligand-protein binding for both HSA and 
AGP as binding of a ligand to the protein will alter the Cotton effect. The spectral 
position, sign, shape, number and amplitude of the bands are used to determine the 
nature of the binding site and the mechanism of binding (Zsila et al., 2002, 
Beuckmann et al., 1999, Zsila et al., 2003). 
 
Spectral data obtained from CD studies can be used to determine the binding 
stoichiometry and the association constant as demonstrated with bilirubin (Siligardi 
and Hussain, 1998, Knudsen et al., 1986). Competitive binding studies using CD 
can only be conducted providing that the ligand being investigated has little or no 
measurable CD absorption in the wavelength region of the induced CD spectrum.  
 
The major limitation of CD for investigating protein binding is that UV inactive 
compounds cannot be investigated directly by this method and that not all ligand   
molecules with suitable chromophores give a measurable Cotton effect following 
interactions with proteins (Zsila et al., 2004).  
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2.4.3.2 Fluorescent Probes 
HSA has two fluorophores, tryptophan (Trp-214) and tyrosine (Tyr) (He and 
Carter, 1992), whilst AGP has three (Trp-160, Trp-122 and Trp-25) (Schmid et al., 
1973b, Hof et al., 1986, Schmid et al., 1973a). These residues can act as intrinsic 
fluorescence probes. If a ligand binds to the protein, there is a measurable decrease 
in the intrinsic fluorescence, known as quenching.  
 
Fluorescence was first used to study the binding of warfarin to HSA, using 
enhancement of the warfarin fluorescence and the quenching of protein 
fluorescence as measure of bound drug (Chignell, 1970). Whilst fluorescence 
quenching is a rapid technique there are limitations that make this technique best 
for early stage screening and not for the detection of drug interactions.  
 
The information from these studies does not indicate the specific site of ligand 
binding, only that binding occurs. As the binding site and the affinity are key in the 
probability for a drug interaction, quenching studies are limited in their application 
in drug binding and displacement studies. Additionally, interference from the 
compound is also problematic as compounds that absorb light at the excitation 
wavelength cause absorptive screening and if their absorption wavelengths are 
towards the red spectrum (>300nm) they quench the intrinsic tryptophan 
fluorescence (Epps et al., 1999). 
 
By employing fluorescent probes as non-covalent competitive ligands for specific 
binding sites on HSA and AGP, information regarding the environment, number 
and affinity for each of the binding sites for a particular ligand can be determined. 
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Fluorescent probes may respond in nearly identical ways to a number of unrelated 
phenomena (Chance and Radda, 1971). A decrease in probe fluorescence may 
result from competitive displacement of the probe. Alternatively there may be non-
competitive displacement of the probe or a decrease in the quantum yield of the 
bound probe as a result of ligand-induced conformational change in the protein.  
 
Various fluorescent probes can be used in these displacement studies, for HSA: 
dansyl amide for site I and, dansyl sarcosine and dansyl glycine for site II (Muller et 
al., 1994) and coumarin derivatives (Goya et al., 1982). For AGP, auramine-O 
(Sugiyama et al., 1985), 7,chloro-2-(p-diethylaminophenyl)-2H-benzotriazolyl-5-
amine (Narita et al., 1989) and 1-anilino-8-napthalene sulfonate (Johansen et al., 
1992), have all been successfully used. 
 
The main disadvantage for fluorescence studies is that coloured and concentrated 
protein solutions may cause difficulties. With probe displacement the main 
disadvantage is that several experiments need to run in order to investigate the 
ligand and its affinity for each of the binding sites, though this can be overcome 







Table ‎2-1: The key advantages and disadvantages of the common techniques to determine protein binding. 
Classification Method Advantages Disadvantages 
    Classical 
 Equilibrium dialysis Amenable to high throughput screening.  
Drug binding to plasma proteins is analysed at equilibrium, 
eliminating the effect of nonspecific binding. 
The volume shift between the matrix and the buffer can disturb the 
equilibrium. 
The system can take time to reach equilibrium and is affected by 
volume shifts, Donnan effects, nonspecific adsorption to dialysis 
apparatus.  
Difficulty in the control of experimental parameters i.e. pH of the 
medium. 
Radio-labelling of the drug will also add potential impurities to the 
experimental set-up. 
 Ultrafiltration Shorter analysis time than equilibrium dialysis and lack of 
dilution effects and volume shifts. 
When combined with Raman difference spectroscopy allows for 
the label free detection and quantitation of binding. 
Usually requires the use of a labeled drug and/or additional analysis 
steps to determine the actual level of free drug.  
 
 Ultracentrifugation Eliminates problems associated with membrane effects of other 
classical methods. 
Discrepancies in data with other methods.  
 Gel filtration When combined with radio ligand-binding assay a 96-well plate 
method can be utilised. 
 
 
Time consuming and complex.  












Precise and reproducible method that allows for enantioselective 
studies. 
Can indicate if the binding is co-operative, anti-cooperative or 
non-cooperative.  
Cannot be used to investigate AGP. 
 Capillary 
electrophoresis 
Can be used as a rapid screening method. 
Can be coupled with micro-fluidics to increase sensitivity. 
Low sensitivity. 
Spectroscopy 
 Circular dichroism Can be used to determine the binding stoichiometry and the 
association constant.  
Cannot be used with ligands that have little or no measurable CD 
absorption in the wavelength region of the induced CD spectrum of 
the protein.  
UV inactive compounds cannot be investigated directly.  
 Fluorescence Fluorescence quenching is a rapid technique.  
Probe displacement can provide information on the environment, 
number and affinity for each of the binding sites for a particular 
ligand.  
Probe displacement is amenable to high-throughput screening. 
 
The main disadvantage for fluorescence studies is that coloured and 
concentrated protein solutions cannot be used.  
Fluorescence quenching does not indicate the specific site of ligand 
binding; only that binding occurs.  
Interference from the ligand is often problematic due to absorptive 
screening.  
With probe displacement several experiments need to run in order 
to investigate the ligand and its affinity for each of the binding sites. 
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2.5 Aims of this project 
The general aim of this study was to determine the potential for complementary 
products to bind to albumin and alpha-1-acid glycoprotein, and determine the 
potential for these products to displace previously bound drugs from the proteins. 
Additionally the aim of this work was to use a rapid fluorometric method that can 
be easily adapted to high-throughput screening. The specific aims included: 
 Establishing a standard extraction method that is easily reproducible.  
 Determination of the disassociation constants from albumin (binding site I 
and II) for selected complementary products. 
 Determination of the disassociation constants from alpha-1-acid 
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2.6 Materials and Methods 
2.6.1 Chemicals 
Albumin from human serum (HSA), dansyl amide (DA), dansyl sarcosine (DS), 
phenylbutazone, ibuprofen, alpha-1-acid glycoprotein (AGP), quinaldine red (QR) 
imipramine and chlorpromazine were all purchased from Sigma and were of the 
highest quality available. Phosphate buffered saline (PBS) was prepared in house 
and maintained at a pH of 7.4. Water was freshly prepared in-house with Milli-Q 
equipment and was ultra-pure grade (18.2M). All other chemicals were from 
Sigma Chemical Co. (St Louis, MO, USA) and were of the highest purity available.  
 
2.6.2 Herbal Samples 
Danshen was a generous gift from Assoc. Prof. Chun Guang Li, Chinese Medicine 
Department, RMIT University, Melbourne, Australia. All other herbal products 
were purchased from local suppliers in Victoria, Australia and were all of 
commercial quality (Table ‎2-2). The methanolic and aqueous extraction method 
was modified from Unger et al., (Unger and Frank, 2004). 
 
In brief, tablets were crushed, the contents of capsules emptied, extractions were 
either water or 80% methanol to allow for the aqueous and distinctly lipophilic 
components to be separated. Solvent volumes were adjusted so that standardised 
extracts at 100 mg of product/ml were obtained. This was based on the 
manufacturers’ stated concentration of the active or principal agent. The extracts 
were agitated in a shaking water bath at 37°C for 30 minutes then centrifuged at 
2500 g for 10 minutes.  
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Standard extracts were diluted to final nominal concentrations of 0.1, 1 and 10 
mg/ml. Methanol was evaporated to dryness under vacuum, the final volume of 
methanol did not exceed 1% (v:v). Extracts were kept in the dark and the shelf life 
set at 2 weeks.  
 
2.6.3 Human Serum Albumin 
2.6.3.1 Control Experiments 
Stock solutions of human serum albumin (HSA) were prepared fresh on the day of 
use in PBS. Stock solutions of dansyl amide (DA) and dansyl sarcosine (DS) were 
prepared in methanol and PBS respectively. Immediately before use, stock solutions 
were dissolved in PBS. To determine the dissociation constant (Kd) of dansyl amide 
(DA) and dansyl sarcosine (DS) under our experimental conditions, the probes 
were titrated against known concentrations of HSA and the fluorescence recorded 
with a Perkin-Elmer Multi-label fluorometer with an excitation wavelength of 
370nm and an emission wavelength of 475nm for DA and 350nm and 450nm for 
DS. All experiments were conducted in 96-well plates maintained at 37°C. Kd 
values were calculated using non-linear regression with one site hyperbolic binding.  
 
Positive controls were run with each experiment, phenylbutazone and ibuprofen 
were used as controls for sites I and II respectively. Stock solutions of 
phenylbutazone and ibuprofen were prepared in DMSO and immediately before 
use were diluted with PBS. The Kd was determined for both binding sites with both 
controls. HSA was kept constant at 5 M and the fluorescence recorded with 
increasing concentrations of the controls (0-1000 M).   
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The fluorescence was recorded with a Perkin-Elmer Multi-label fluorometer with an 
excitation wavelength of 370nm and an excitation of 475nm for DA and 350 and 
450nm for DS. All experiments were conducted using 96-well plates maintained at 
37°C. Kd values were calculated using non-linear regression with one site hyperbolic 
binding.  
 
2.6.3.2 Displacement Studies 
To ensure that the extracts did not cause significant changes in fluorescence in the 
absence of protein, each extract was assayed with the buffer and probes without the 
addition of HSA. 
 
Displacement of the fluorescent probes dansyl amide (DA) and dansyl sarcosine 
(DS) from site I and II respectively was determined for each of the extracts. The 
final concentration of the fluorescent probes and the HSA was kept constant at 5 
μM. The extract being investigated was added at various concentrations (0-2.5 
mg/ml). Stock solutions were diluted with PBS to the required concentration.  
 
Fluorescence was recorded with a Perkin-Elmer Multi-label fluorometer with an 
excitation wavelength of 370nm and an excitation of 475nm for DA and 350nm 
and 450nm for DS. All experiments were conducted using 96-well plates 
maintained at 37°C. Kd values were calculated using non-linear regression with one 
site hyperbolic binding. 
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2.6.4 Alpha 1-acid Glycoprotein Studies 
2.6.4.1 Control Experiments 
Stock solutions of alpha-1-acid glycoprotein (AGP) were prepared fresh on the day 
of use in PBS. Stock solutions of quinaldine red (QR) were prepared in methanol 
and immediately before use were diluted with PBS. To determine the dissociation 
constant (Kd) for QR under our experimental conditions, the probe was titrated 
against known concentrations of AGP and the fluorescence recorded with a Perkin-
Elmer Multi-label fluorometer with an excitation wavelength of 520nm and an 
emission wavelength of 610nm. All experiments were conducted using 96-well 
plates maintained at 37°C. Kd values were calculated using non-linear regression 
with one site hyperbolic binding. 
 
Imipramine and chlorpromazine were used as positive controls to investigate the 
basic and acidic drug binding to AGP, though these binding pockets are known to 
overlap (section ‎2.2.7). Stock solutions of imipramine and chlorpromazine were 
prepared in methanol and immediately before use were diluted with PBS. AGP was 
kept constant at 1 M and the fluorescence recorded with increasing concentrations 
of the controls (0-1000 M).  The fluorescence was recorded with a Perkin-Elmer 
Multi-label fluorometer with an excitation wavelength of 520nm and an emission 
wavelength of 610nm. All experiments were conducted using 96-well plates 
maintained at 37°C. Kd values were determined using non-linear regression with 
one site hyperbolic binding. 
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2.6.4.2 Displacement Studies 
To ensure that the extracts did not cause significant changes in fluorescence in the 
absence of protein, each extract was assayed with the buffer and probes without the 
addition of AGP. 
 
Displacement of the fluorescent probe quinaldine red (QR) was determined for each 
of the extracts. The concentration of the AGP was kept at 1 M and the 
concentration of QR was kept at 20 M. The extract being investigated was added 
at various concentrations (0-2.5 mg/ml). Stock solutions were diluted with PBS to 
the required concentration. 
 
Fluorescence was recorded with a Perkin-Elmer Multi-label fluorometer with an 
excitation wavelength of 520nm and emission wavelength 610nm. All experiments 
were conducted using 96-well plates maintained at 37°C. Kd values were calculated 
using non-linear regression with one site hyperbolic binding. 
 
2.6.5 Data Analysis 
All assays were conducted in triplicate on five separate occasions. Analysis was 
conducted with Prism version 5.0. The dissociation constant (Kd) was determined 
by non-linear regression using one site binding. All Kd vales reported are the 





Table ‎2-2: Complementary products used to screen for their potential to cause displacement interactions with human serum 









Human serum albumin studies 
Co-Enzyme 
Q10 
Ubidecarenone 50mg Heron 57122 Reduces heart damage caused by free radicals and 
improves energy, stamina and endurance. 
Danshen Tanshinone IIA 80mg * N/A Invigorates the blood to improve circulation. Treatment of 
liver disease including cirrhosis and hepatitis. 
Dong Quai Angelica polymorpha 520mg Nature’s 
Sunshine 
01240714 Enrich the blood to promote circulation, regulate 
menstruation, calm nerves and sooth intestines. 
Ginkgo Biloba Ginkgo flavonglycosides 
Ginkgolides and Bilobalide 
10.7mg 
2.4mg 
Herron 58751 Improve mental clarity and concentration. May also relieve 
the symptoms of vertigo and tinnitus. 




01220333 Assist in the treatment of respiratory infections. 
Alpha 1-acid glycoprotein studies 
Astragalus Astragalus membranaceus 450mg Nature’s 
Sunshine 
0128172 Helps to support the body’s immune system and in used as 
a “rejuvenating tonic” 
Echinacea Echinacea purpurea 410mg Nature’s 
Sunshine 
0124471 Supports the immune defenses. 
Ginkgo Biloba Ginkgo flavonglycosides 
Ginkgolides and Bilobalide 
10.7mg 
2.4mg 
Herron 56311 Helps to improve mental clarity and concentration and 
improves long and short term working memory. May also 
relieve the symptoms of vertigo and tinnitus. 
Gotu Kola Centella asiatica 395mg Nature’s 
Sunshine 
01223293 Eases anxiety and mood disorders.  
Valerian Valeriana officinalis 2250mg Bio-Organics 301338 Antispasmodic and muscle relaxant. Relieve nervous 
tension, insomnia and anxiety. 
*Product provided by the Chinese Medicine Research Group- RMIT University. Composition determined using HPLC (Li, Sheng et al. 2009).   
  N/A- not applicable 
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2.7 Results 
2.7.1 Human Serum Albumin 
2.7.1.1 Dissociation of Site Specific Probes 
To determine the dissociation constant (Kd) of the site I and site II probes dansyl 
amide (DA) and dansyl sarcosine (DS) under our experimental conditions, probes 
were titrated against 5 µM of human serum albumin (HSA) and the fluorescence 
recorded (Figure ‎2-4). Kd values were calculated using nonlinear regression with 
one site hyperbolic binding (Table ‎2-3). 
 
Figure ‎2-4: The relative fluorescence of human serum albumin (HSA) when bound 
with the site specific probes dansyl amide (DA), site I and dansyl sarcosine (DS), 
site II. Fluoresce recorded with an excitation wavelength of 370nm and an 
excitation of 475nm for DA and 350nm and 450nm for DS. Each point represents 
the mean of triplicate incubations for 5 replicate runs.  
■ Dansyl amide ▲ Dansyl sarcosine 
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Table ‎2-3: Dissociation constant (Kd) µM determined for dansyl amide (DA) and 
dansyl sarcosine (DS) binding to sites I and II on human serum albumin (HSA). Kd 
values were calculated using non-linear regression with one site hyperbolic binding 
(n = 5). 
 Dansyl amide (DA) Dansyl sarcosine (DS) 
Site I 6.84 ±0.42 µM 159.22 ±8.2 µM 
Site II 136.91 ±11.36 µM 6.04 ±0.92 µM 
 
2.7.1.2 Disassociation of Site Specific Controls 
Phenylbutazone and ibuprofen were used as positive controls for sites I and II 
respectively. HSA (5 μM) was titrated against the controls (0-1000 μM) 
(Figure ‎2-5). Kd values were determined using nonlinear regression with one site 
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Figure ‎2-5: % Dansyl amide (DA) and dansyl sarcosine (DS) displaced by 
phenylbutazone and ibuprofen from human serum albumin (HSA). DA is a specific 
probe for site I and DS for site II. Fluoresce recorded with an excitation wavelength 
of 370nm and an emission wavelength of 475nm for DA and 350nm and 450nm for 
DS. Each point represents the mean of triplicate incubations for 5 replicate runs ± 
SEM. 
■ DA and Phenylbutazone ▲ DS and Phenylbutazone   
 DA and Ibuprofen ◆ DS and Ibuprofen  
 
Table ‎2-4: Dissociation constant (Kd) µM determined for sites I and II on human 
serum albumin for phenylbutazone and ibuprofen. Kd values were calculated using 
non-linear regression with one site hyperbolic binding (n = 5). 
 Phenylbutazone (µM) Ibuprofen (µM) 
Site I 6.06 ±0.36 1222 ±96.2 
Site II 102.5 ±11.36 8.35 ±0.41 
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2.7.1.3 Displacement Studies with Complementary Products 
Displacement of the site-specific probes was investigated in the presence of the 
complementary product extracts. The total displacement of the probes is shown in 
Figure ‎2-6 and Figure ‎2-7. The Kd was determined for each of the investigated 
products and is shown in Table ‎2-5.  
 
No changes in fluorescence were seen when the extracts were incubated with the 
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Figure ‎2-6: Displacement of the site I probe dansyl amide (DA) from human serum 
albumin (HSA) for each of the products (a) the aqueous extracts, and (b) the 
methanolic extracts. Fluoresce recorded with an excitation wavelength of 370nm 
and an emission wavelength of 475nm. Data points represent the mean of triplicate 
incubations for 5 replicate runs ± SEM. 
■ CoEnzyme Q10 ▲ Danshen  Dong Quai ◆ Ginkgo Biloba ● Goldenseal 
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Figure ‎2-7: Displacement of the site II probe dansyl sarcosine (DS) from human 
serum albumin (HSA) for each of the products (a) the aqueous extracts, and (b) the 
methanolic extracts. Fluoresce recorded with an excitation wavelength of 350nm 
and an emission wavelength of 450nm Data points represent the mean of triplicate 
incubations for 5 replicate runs ± SEM. 
■ CoEnzyme Q10 ▲ Danshen  Dong Quai ◆ Ginkgo Biloba ● Goldenseal 
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Table ‎2-5: Kd in mg/ml for each of the products investigated as determined by non-
linear regression for site I and II on human serum albumin (HSA). Kd values were 
calculated using non-linear regression with one site hyperbolic binding from the 
mean of 5 independent experiments ± SEM. 
 Site I Site II 
 Aq Meth Aq Meth 
CoEnzyme Q10 * 4.4 ±0.30# 0.76 ±0.04 0.08 ±0.01 
Danshen 1.73 ±0.06 7.39 ±0.42 3.15 ±0.30# 0.28 ±0.02 
Dong Quai 21.27 ±2.56# 1.02 ±0.08 33.41 ±4.50# 13.36 ±1.09# 
Ginkgo Biloba 14.43 ±1.37# * 1.07 ±0.03 0.35 ±0.02 
Goldenseal 5.78 ±0.25# 0.60 ±0.06 1.69 ±0.06 0.31 ±0.02 
Aq- Aqueous extract.  
Meth- Methanolic extract.  
# Kd determined was greater than the concentrations investigated.  
* Kd not determined. 
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2.7.2 Alpha-1-Acid Glycoprotein 
2.7.2.1 Disassociation of Site Specific Probe 
To determine the dissociation constant (Kd) of the probe quinaldine red (QR) under 
our experimental conditions, QR was titrated against 1µM of alpha-1-acid 
glycoprotein (AGP) and the fluorescence recorded (Figure ‎2-8).  The Kd value was 
calculated using nonlinear regression with one site hyperbolic binding and 
determined to be 3.3 ±0.43 µM. 
 
Figure ‎2-8: The relative fluorescence (RFU) of alpha-1-acid glycoprotein (AGP) 
when bound with the probe quinaldine red (QR). Fluorescence recorded with an 
excitation wavelength of 520nm and an emission wavelength of 610nm. Data 
points represent the mean of triplicate incubations for 5 replicate runs ± SEM. 
 
2.7.2.2 Disassociation of Site Specific Control 
Imipramine and chlorpromazine were used as positive controls to investigate the 
basic and acidic drug binding to AGP. AGP (1 μM) was titrated against the 
controls (0-1000 μM). Kd values were determined using nonlinear regression with 
one site hyperbolic binding.  
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Under our experimental conditions the Kd for imipramine and chlorpromazine was 
determined to be 10.22 ± 0.78 and 2.7 ± 0.35 µM, respectively. Each incubation 
was run in triplicate on 5 separate occasions.  
 
Figure ‎2-9: % Quinaldine red (QR) displaced by imipramine and chlorpromazine 
from alpha-1-acid glycoprotein (AGP). Fluorescence recorded with an excitation 
wavelength of 520nm and an emission wavelength of 610nm. Data points represent 
the mean of triplicate incubations for 5 replicate runs ± SEM. 
■ Imipramine ▲ Chlorpromazine   
 
2.7.2.3 Displacement Studies with CAMs 
Displacement of the probe (QR) was investigated in the presence of the 
complementary product extracts. The total displacement of the probes is shown in 
Figure ‎2-10. The Kd was determined for each of the investigated products and is 
shown in Table ‎2-6.  
 
No changes in fluorescence were seen when the extracts were incubated with the 
buffer and probe in the absence of AGP. 





Figure ‎2-10: Displacement of the probe quinaldine red (QR) bound to alpha-1-acid 
glycoprotein (AGP) for (a) the aqueous extracts, and  (b) the methanolic extracts. 
Fluorescence recorded with an excitation wavelength of 520nm and an emission 
wavelength of 610nm. Data points represent the mean of triplicate incubations for 5 
replicate runs ± SEM. 
■ Astragalus ◆ Echinacea  Ginkgo Biloba ▲ Gotu Kola ● Valerian 
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Table ‎2-6: Kd in mg/ml for each of the products investigated for alpha-1-acid 
glycoprotein as determined by non-linear regression. Kd values were calculated 
using non-linear regression with one site hyperbolic binding from the mean of 5 
independent experiments ± SEM. 
 Aq Meth 
Astragalus 1904  ±671.4# 116.6 ±15.62# 
Echinacea 16.92 ±1.2# 1.007 ±0.14 
Ginkgo Biloba 12.09 ±0.6# 2.043 ±0.17 
Gotu Kola 50.14 ±3.97# 19.22 ±0.72# 
Valerian  7.69 ±0.2# 1.35 ±0.21 
 
Aq- Aqueous extract.  
Meth- Methanolic extract.  
# Kd determined was greater than the concentrations investigated.  
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2.8 Discussion 
2.8.1 Product Selection 
The products selected for these investigations were based on the potential for 
concurrent use with therapeutic agents that are known to bind to albumin or alpha-
1-acid glycoprotein, based on the traditional claimed therapeutic benefit. 
 
In addition to the therapeutic claims overlapping with the conventional medicine, 
products were selected if the scientific literature indicated that there may be an 
interaction, i.e. Dong Quai, which has been suspected of interacting with the highly 
protein bound warfarin (Table ‎2-2). 
 
2.8.2 Selection of Method to Screen CAMs 
Each method for determining protein binding has its own advantages and 
disadvantages (Table ‎2-1). With so many products on the market and very little 
information regarding these products there is a need for a rapid and reproducible 
method to screen for protein binding and potential drug interactions due to 
displacement of previously bound drugs. As the composition of complementary 
products is often unknown and widely variable traditional methods such as 
equilibrium dialysis, are not suitable. 
 
Probe displacement studies can provide information for the key binding sites on 
both HSA and AGP and can be scaled to a high-throughput method. These studies 
are also rapid and cost efficient.  
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The potential for interference by the products at the excitation and emission 
wavelengths must be taken into consideration but can be determined by assaying 
the products with the buffer and probes without the addition of the protein. 
 
Spectroscopy techniques have been shown to have good correlation with separation 
methods (Sugiyama et al., 1985, Baumann and Eap, 1988, Rahman et al., 1993), 
though this is mainly for high-affinity binding sites; with low affinity interactions 
the sensitivity decreases. Whilst there is a risk that low affinity reactions may not be 
identified in these studies, it is far more likely that high affinity binding will be 
involved in adverse interactions and therefore are the important to identify 
(Figure ‎2-3).  
 
2.8.3 General Discussion 
Previous investigations into the ability for complementary products to displace 
bound drugs from human serum albumin (HSA) and alpha-1-acid glycoprotein 
(AGP) are very limited. This study utilises a rapid fluorometric method to 
investigate the potential for these products to bind to plasma proteins and 
potentially displace previously bound drugs. 
 
Investigations into protein binding should be conducted with human protein as 
species differences in binding properties are known (Benke et al., 2009, Brown et 
al., 1979, Son et al., 1998). Parameters including temperature and pH need to be 
controlled as small changes can alter protein binding, increasing the free-fraction of 
drugs (Christensen, 1989, Kodama et al., 2001).  
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The concentration of the protein used may alter the results obtained in these 
studies, in order to relate the in vitro data more closely to the in vivo situation the 
concentration of protein was set at physiological levels, 5μM for HSA and 1μM for 
AGP. 
 
Studying complementary products provides many challenges including the variable 
composition and effect of the extraction method selected. Our choice was made on 
the basis of the relevance of the extract to the patient use of the product. As these 
products are generally administered as tablets or infusions (‘teas’), aqueous and 
alcohol (methanol) extracts were prepared for these studies. Methanol was selected 
to extract the distinctly more lipid soluble components. 
 
2.8.4 Displacement Studies- Human Serum Albumin 
2.8.4.1 Site Specific Probe Binding 
To confirm that the probes, dansyl amide (DA) and dansyl sarcosine (DS) were site 
specific they were titrated with HSA under our experimental conditions. Kd values 
were determined using non-linear regression with one site hyperbolic binding. For 
site I the Kd for DA and DS was 6.84 ± 0.42 and 159.22 ± 8.2 µM respectively, and 
for site II 136.91 ± 11.36 and 6.04 ± 0.92 µM respectively (Table ‎2-3).  
 
This data is in line with previous studies. The Kd for DA at site I was previously 
determined to be 5.6-7.5 µM and 6-6.06 µM for DS at site II (Sudlow et al., 1975, 
Epps et al., 1995). The specificity of the probe binding is confirmed by the high Kd 
for DA at site II (136.91 ±11.36 µM and for DS at site I (159.22 ±8.2 µM).  
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2.8.4.2 Site Specific Positive Controls 
Phenylbutazone and ibuprofen were used as positive controls for sites I and II 
respectively (Figure ‎2-5). Kd values were determined using non-linear regression 
with one site hyperbolic binding. Kd values were determined to be 6.06 ±0.36 µM 
and 8.35 ±0.41 µM, for phenylbutazone and ibuprofen respectively (Table ‎2-4). The 
values are in line with previously reported data. 
 
Previous studies of phenylbutazone for site I have reported Kd values of 1.9±0.3 µM 
(Epps et al., 1995) and 8.4 ±1.7 µM (Parikh et al., 2000). For ibuprofen the Kd has 
been previously determined as 2.7 ±1.2 µM (Epps et al., 1995) and 11.6 µM 
(Wanwimolruk et al., 1983). The specificity of the probes is confirmed with the 
high Kd values for phenylbutazone at site II and ibuprofen at site I, 102.5 ±11.36 
and 1222 ±96.2 µM respectively. 
 
2.8.5 Displacement Studies with Complementary Products  
Whilst site I is referred to as the more flexible binding site on HSA, in general, 
displacement from site II was more significant in our experiments. For 6 of the 
extracts a Kd < 1mg/ml for site II was determined. Whilst only one extract (the 
methanolic extract of Goldenseal) had a Kd <1 mg/ml for site I (Table ‎2-5). The 
lowest Kd was for the methanolic extract of CoEnzyme Q10 at site II with a value 
of 0.08 ±0.01 mg/ml.  
 
It is known that alkaloids bind to site II (Zhang et al., 2011) and that many plant 
and herbal products contain alkaloids, which may account for the more significant 
binding at this site.  
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In general the methanolic extracts caused more displacement of the bound probes 
than the aqueous extracts. The alkaloids that are the most likely cause of the 
binding would be present in the methanolic rather than the aqueous extracts.  
 
2.8.5.1 CoEnzyme Q10 
CoEnzyme Q10, also known as ubiquinone, is proposed as treatment for heart 
failure and to lower blood pressure. CoEnzyme Q10 is the only lipid soluble 
antioxidant synthesised endogenously and is present in all cellular membranes. It 
plays a role in cellular metabolism, acting as an electron carrier and also protects 
membranes and lipoproteins from protein oxidation and lipid peroxidation (Villalba 
et al., 2010, Crane, 2001, Stocker et al., 1991). 
 
Plasma CoEnzyme Q10 levels range from 0.40-1.91 µmol/L (Bhagavan and 
Chopra, 2006). It is estimated that the daily dietary intake is 3-5 mg per day, and 
that diet supplementation does not increase tissue levels above this point of 
saturation (Crane, 2001, Beal, 1999, Weber et al., 1997). Despite this, concern for 
drug interactions involving CoEnzyme Q10 exist as this product is often consumed 
by patients diagnosed with conditions including Parkinson’s and cardiovascular 
disease. Entacapone and clofibrate (and other fibrates) used in the treatment of 
Parkinson’s and high cholesterol respectively are bound to HSA. Entacapone is 
>98% bound to human serum albumin (Casarett et al., 2008) and the fibrates are 
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Previous in vivo studies have shown no interaction between CoEnzyme Q10 and 
warfarin (Gage and Milligan, 2005), whilst binding to site I of albumin (the binding 
site of warfarin) was determined, the Kd was high, 4.4 ±0.30 mg/ml, and therefore 
not clinically likely to occur. This highlights the importance of correct extrapolation 
of in vitro data to the in vivo situation when the potential for drug interactions are 
being investigated.  
 
In vitro studies using human blood have shown that quercetin a flavonol found in 
Coenzyme Q10 binds to albumin (Kaldas et al., 2005). This binding is thought to be 
most likely at site II. These experiments determined, binding to site II was more 
significant for the methanolic extract (Kd 0.08 ±0.01 mg/ml) than the aqueous 
extract (Kd 0.76 ±0.04) (Table ‎2-5). This data supports the conclusion that the 
flavonols including quercetin are responsible for the binding seen as the flavonols 
are best extracted in the methanolic solvent.  
 
2.8.5.2 Danshen 
Danshen (Salvia miltiorrhzia) is of concern with regards to herb-drug interactions as 
it is used traditionally as a ‘blood thinning’ herb and therefore the potential for 
concurrent use of this product with anti-coagulant therapy such as warfarin (a 
coumarin derivative that is bound to site I on albumin) is significant, additionally 
Danshen is known to be 50-70% bound to albumin (Liu et al., 2008).  
 
Dialysis studies into components of Danshen have demonstrated binding to 
albumin, though this work was conducted with bovine albumin which has only a 
76% sequenced identity with human albumin (Peters, 1985). 
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Using dialysis sampling coupled with high-performance liquid chromatography, 
danshensu (a component of Danshen) was shown to have a strong association with 
bovine albumin (9.68 ±1.23*103 K/L mol-1) (Wang et al., 2011). 
 
Previous studies have shown that the interaction between Danshen and warfarin is 
due to tanshonine II sulfonate, a component of Danshen, displacing warfarin from 
its binding site on albumin (Liu et al., 2008). Danshen is also known to displace 
salicylate from HSA (Gupta et al., 2002). In this study, the displacement of 
salicylate by Danshen was increased at the higher concentrations of salicylate. 
Whilst salicylates bind to site I, at the higher concentrations investigated in this 
study salicylate would be bound to site I and II on albumin. This displacement of 
salicylate being more significant at the higher concentrations can be explained by 
the binding of Danshen to site II.  
 
These experiments concluded that Danshen is able to bind to both sites I and II on 
albumin, though there was more significant displacement with the site II probe. In 
particular the methanolic extract produced significant displacement with a Kd of 
0.28 ±0.02 mg/ml. Displacement of dansyl amide, the probe for site I did occur in 
our studies with Danshen (Figure ‎2-7) but the Kd values were high, 1.73 ±0.06 and 
7.39 ±0.42 mg/ml for the aqueous and methanolic extracts respectively.  
 
2.8.5.3 Dong Quai 
Dong Quai (Angelica sinensis) is reported to be beneficial in the treatment of 
menopause, in particular in easing the symptoms of hot flushes.  
 Chapter 2- Protein Binding 70 
It is known to contain coumarin (Zhao et al., 2003) and has been suspected of being 
involved in adverse interactions based on pharmacodynamics with warfarin (Hu et 
al., 2005). 
 
The methanolic extract of Dong Quai bound to site I on albumin with a Kd of 1.02 
±0.08 mg/ml, whilst this is the most significant Kd determined for Dong Quai in 
our studies, it may not be at a level to be clinically significant. As can be seen in 
Figure ‎2-6, at the highest investigated concentration of the methanolic extract of 
Dong Quai, 65% of the probe was displaced from its binding site, at 1mg/ml 50% 
of the probe was still bound to site I. 
 
As with Danshen and Ginkgo Biloba the pharmacodynamic interaction between  
Dong Quai and warfarin may be of greater clinical significance than the 
pharmacokinetic interaction. That is the coumarins potentiate the effect of the 
warfarin.  
 
2.8.5.4 Ginkgo Biloba 
Ginkgo Biloba is known to contain flavonoids, glycosides and terpenoids 
(ginkgolides, bilobaldides). It has been suspected of clinical interactions with 
warfarin due to its anti-platelet activity (Diamond et al., 2000). However, a 
randomized, single-dose crossover study found no significant alteration of the 
pharmacokinetic or pharmacodynamic profile of ticlopidine (an antiplatelet agent) 
with a single administration of Ginkgo Biloba (Kim et al., 2010). 
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The Kd determined for the binding at site I for the aqueous extract was above the 
range investigated and could not be determined for the methanolic extract. The 
displacement that occurred with the site II probe is not likely to cause a clinically 
significant interaction. Ginkgo Biloba is claimed to have a therapeutic benefit in the 
treatment of dementia and Alzheimer’s disease and as such it may be taken 
concurrently with medications for these conditions including galantamine and 
rivastigmine which are both alkaloids likely to bind to site II on albumin, but the 
binding of these agents to albumin is relatively low therefore reducing the 
likelihood of a clinically significant interaction. 
 
2.8.5.5 Goldenseal 
Goldenseal (Hydrastis canadensis) contains several isoquinalone alkaloids including 
berberine and hydrastine (Douglas et al., 2010). Isoquinalone alkaloids are known 
to bind to site II of albumin (Khan et al., 2012, Cheng et al., 2009). Both the 
aqueous and methanolic extracts were able to displace dansyl sarcosine, the site II 
probe with Kd values of 1.07 ±0.03 and 0.35±0.02 mg/ml respectively (Table ‎2-5). 
 
Goldenseal is claimed to be useful in the treatment of respiratory infections. A 
potential interaction can arise with the concurrent use of penicillin’s, which also 
bind to site II. This interaction would increase the plasma concentration of the 
penicillin potentially increasing the occurrence and severity of adverse effects 
including hypersensitivity, nausea and neurotoxicity in patients susceptible to these 
side effects. However, clinically inhibition of renal extraction of penicillin is more 
likely to be the cause of adverse drug interactions.  
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2.9 Displacement Studies- Alpha-1-Acid Glycoprotein 
2.9.1 Site Specific Probe Binding 
Quinaldine red (QR) is known to bind to AGP, under our experimental conditions 
the Kd, determined using non-linear regression with one site hyperbolic binding, 
was 3.3 ±0.43 µM (Figure ‎2-8).  Previous studies have demonstrated variability in 
the Kd for QR with AGP with figures ranging from 1.3 µM (Imamura et al., 1994) 
to 40 µM (Hazai et al., 2006). The differences in these values can be explained by 
the experimental conditions. All experiments were conducted in this study were at 
37°C, whilst the other studies were conducted at 23°C and room temperature 
respectively, temperature is known to alter the binding properties of proteins 
(Kodama et al., 2001, Christensen, 1989).  
 
2.9.2 Site Specific Positive Controls 
Imipramine and chlorpromazine were used as positive controls. Imipramine is a 
basic tricyclic drug that is known to bind to AGP (Kremer et al., 1988) but with 
lower affinity to the F1/S variant (Hervé et al., 1993) whilst chlorpromazine has a 
preference for the A variant (Hervé et al., 1996). 
 
In line with previous reported data, Kd for imipramine and chlorpromazine was 
determined to be 10.22 ±0.78 and 2.7 ±0.35 µM, respectively, under our 
experimental conditions. Imipramine has been reported to have a Kd of 2.23 - 11.4 
µM (Zsila and Iwao, 2007, van der Sluijs and Meijer, 1985) and chlorpromazine a 
Kd of  2.32, 2.6 and 2.8 µM (Fitos et al., 2010, Berry et al., 2009, Matsumoto et al., 
2002). 
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2.10 Displacement Studies with Complementary Products 
Investigations into the displacement of previously bound drugs from alpha-1-acid 
glycoprotein (AGP) are very limited, even more limited are published reports 
involving the interaction between complementary products with AGP. This is the 
first study to combine dye displacement method with AGP interactions for 
complementary products.  
 
As with the investigations into displacement by complementary products from 
albumin, more significant displacement was seen with the methanolic extracts than 
the aqueous extracts (Table ‎2-6).  
 
2.10.1 Astragalus 
Astragalus (Astragalus membranaceus) is native to the temperate regions of the 
Northern Hemisphere. Previous studies with Astragalus have focused on the 
potential for treatment of type II diabetes and its cardio-protective effects. 
Astragaloside IV, a saponin isolated from the Astragalus membranaceus plant is 
proposed to improve the sarcoplasmic reticulum Ca2+ pump function in myocardial 
injury (Xu et al., 2007). Pharmacokinetic studies using rat and dog plasma 
demonstrated that astragaloside IV is 83% bound to plasma protein (Zhang et al., 
2006), though the specific plasma protein was not identified.  
 
The experiments conducted have shown no significant binding to AGP for the 
aqueous or methanolic extract of Astragalus (Figure ‎2-10). Therefore the binding to 
plasma protein by astragaloside IV is most likely to a different plasma protein, 
potentially albumin.  
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Though it should be noted that the study that determined binding to protein did so 
in animal models and not human. 
 
2.10.2  Echinacea 
Echinacea (Echinacea purpurea) is a genus of flowering plants belonging to the 
Asteraceae family. There are nine members of the species, all endemic to North 
America but Echinacea purpurea is most commonly used in complementary and 
alternative products. Echinacea has gained popularity as it is report to support and 
boost the immune system. This is of concern as several antibiotics and drugs used 
in the treatment of HIV/AIDS also bind to AGP including rifampicin (Johnson 
and Smith, 2006) and the protease inhibitors (Schön et al., 2003). Additionally 
levels of AGP increase in patients with tuberculosis (Ebersole and Cappelli, 2000) 
and HIV/AIDS (Kremer et al., 1988). 
 
Most significantly, interactions with HIV/AIDS medication via displacement of the 
bound drug to AGP can reduce the therapeutic efficacy of the treatment, 
contributing to the emergence of drug resistant viral strains (Finzi et al., 1997, 
Williams and Sinko, 1999).  
 
The most significant displacement of QR for the investigated extracts occurred with 
the methanolic extract of Echinacea (Kd = 1.01 ±0.14 mg/ml). The aqueous extract 
did not cause significant displacement (Kd = 16.92 ±1.18 mg/ml) (Figure ‎2-10). 
This displacement highlights the need to prioritise further investigations into 
Echinacea in the context of drug interactions. 
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2.10.3 Ginkgo Biloba 
As Ginkgo Biloba is used to aid in the treatment of memory loss it has gained 
popularity and is now one of the most commonly used herbal products (Xue et al., 
2007, Eisenberg et al., 1998). Ginkgo has predominantly been investigated for its 
interaction with the cytochrome P450 enzymes and for its increased anti-coagulant 
effect, most likely due to the coumarin in the product, when combined with 
warfarin (Izzo, 2004, Matthews, 1998). 
 
The experiments conducted did not show significant displacement of QR with the 
aqueous extract (Kd 12.09 ±0.56 mg/ml) or the methanolic extract (Kd 2.04 ±0.17 
mg/ml). Whilst this is the first study to investigate the binding of Ginkgo Biloba to 
AGP, Chen et al., determined the binding of ginkgolide B (a major component of 
Ginkgo Biloba) to human plasma to be 17.99-21.49% using equilibrium dialysis 
(Chen et al., 2007). These limited studies suggest that protein binding is not likely 
to be a cause of adverse interactions with Ginkgo Biloba.  
 
2.10.4 Gotu Kola 
Gotu Kola (Centella asiatica) is a small plant native to several countries including 
India, Sri Lanka, Indonesia and Iran. It is recommended in the treatment of 
bacteria and viral infections and also for any inflammatory conditions. As with 
Echinacea, there is an increased risk of concurrent use with antibiotics and antiviral 
drugs that are known to bind to AGP. 
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No significant displacement of QR was detected with the aqueous (Kd = 50.14 
±3.97 mg/ml) or methanolic (Kd = 19.22 ±2.73 mg/ml) extracts, therefore these 
studies indicate that displacement of drugs bound to AGP is not likely to occur with 
Gotu Kola. This negative finding is important as Gotu Kola is used in the treatment 
of anxiety and depression and therefore may be concurrently used with anti-anxiety 
medication that is known to bind with high affinity to AGP including 




(Verbeeck and Cardinal, 1985, Piafsky et al., 1978, Wright et al., 1988) and 
diazepam (60% bound with affinity constants (Ka) of 4*10
4-2.5*105) (Schley and 
Müller-Oerlinghausen, 1983, Muruyama et al., 1992). 
 
2.10.5 Valerian 
Valerian (Valeriana officinalis) is native to Europe and Asia, and is used as a muscle 
relaxant and in the treatment of anxiety and insomnia. Valerenic acid and 
valerenol, components of Valerian, are known to bind to GABA(A) receptors 
(Benke et al., 2009). Valerian binding to plasma proteins to date has not been 
reported but the increased use of this product highlights the need for investigations 
such as these.  
 
The methanolic extract was determined to have a Kd of 1.35 ±0.20 mg/ml; this was 
the second greatest displacement of all the extracts investigated with AGP. The 
potential for adverse interactions whilst not significant may warrant further 
investigations or caution in patients concurrently taking Valerian and therapeutic 
agents with a narrow therapeutic index such as phenobarbital, which is bound to 
AGP (Lai et al., 1995). 
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2.11 Conclusions 
The binding of complementary and alternative products was more significant with 
human serum albumin than with alpha-1-acid glycoprotein. Six of the investigated 
extracts were determined to have a Kd <1mg/ml with albumin whilst none of the 
extracts produced a Kd <1mg/ml with alpha-1-acid glycoprotein.  
 
Specifically with regards to albumin binding, the displacement of the site II bound 
probe (dansyl sarcosine) was more significant than the site I probe (dansyl amide). 
Site II is known to be the binding site for carboxylic acids which are present in high 
levels in complementary and herbal products (Fournier et al., 2000). 
 
The lowest Kd was for the methanolic extract of CoEnzyme Q10 (0.08 ±0.01 
mg/ml). The displacement of dansyl amide, the site I probe by Dong Quai is 
potentially the most significant interaction as it suggests that there is a 
pharmacokinetic interaction between this product and warfarin, which is also 
bound to site I. 
 
With alpha-1-acid glycoprotein, the most significant binding was seen with the 
methanolic extract of Echinacea (Kd = 1.01 ±0.14 mg/ml). Importantly the plasma 
concentration of alpha-1-acid glycoprotein can vary dramatically, up to 2-5 fold 
(Huang et al., 2010). This variation may contribute to adverse interactions, and 
must be considered when in vitro data is extrapolated to in vivo.  
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The displacement of previously bound compounds from proteins in the serum can 
be significant in the context of drug interactions, though caution should be used 
when placing significance on these interactions (Rolan, 1994). As highlighted in 
section 2.3, binding to protein is only one criterion to consider. In these studies not 
only does the binding of components to the protein have to be significant but also 
there has to be a risk of displacing another significantly bound compound, for 
which displacement would cause therapeutic failure or toxicity. The interactions 
observed in these experiments are of greatest significance for products that could 
potentially displace warfarin due to the narrow therapeutic index and likely 
concurrent use of complementary products. 
 
Interactions with protein binding can alter the kinetic profile of a drug which can 
lead to adverse interactions or a decrease in the therapeutic effect. We have 
proposed a rapid screening method that will allow for the potential displacement 
interactions to be identified from both HSA and AGP.  
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Chapter 3 - P-glycoprotein: 
Inhibition of the transmembrane transporter P-glycoprotein 
 
 
3.1 Overview of Drug Transporters 
Transporters are membrane proteins that facilitate the flux of molecules into and 
out of cells. They control the intake and efflux of endogenous substrates including 
amino acids, sugars and inorganic ions. Many foreign compounds including 
complementary products are also recognised by transporters, and as a consequence, 
transporters play a role in determining the bioavailability, elimination, and 
therapeutic efficacy of many endogenous and exogenous compounds.  
 
Transporters can be induced or inhibited by a wide variety of compounds; 
additionally transporters can alter the transport of endogenous substrates by altering 
homeostasis. The pharmacokinetic behaviour of drugs that are substrates for 
transporters can be influenced by concurrently administered compounds including 
conventional medicines, foods and complementary products, that function as 
inhibitors or inducers of transporter function.  
 
Advances in the identification of carrier-mediated transport systems for drugs have 
been made in recent years. In total, it is estimated that at least 5% of all human 
genes are transporter related, indicative of the importance of the transport function 
in normal biological and toxicological outcomes (Hediger et al., 2004).  
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Transporters can be divided into two categories; passive transporters which allow 
molecules to move across cell membranes down their electrochemical gradients, 
and facilitated transporters which typically move molecules against their 
electrochemical gradients, requiring energy. 
 
Transporters are classified based on their molecular structure or their mechanism of 
action, as either members of the adenosine triphosphate (ATP) binding cassette 
(ABC) family or the solute carrier (SLC) transporter family. ABC transporters are a 
family of membrane transport proteins that require ATP hydrolysis for moving the 
substrates across membranes.  Therefore, ABC transporters are primarily active 
transporters. SLC transporters utilize the electrochemical potential difference in the 
substance transported and are therefore classified as facilitated transporters. Most 
drug transporters belong to the SLC family. 
 
3.2 ABC Transporter Family 
The ABC (ATP-binding cassette) proteins form one of the largest protein families, 
with members found in all living organisms from microbes to plants and mammals. 
The widespread presence of these proteins with a relatively conserved structure and 
function suggests a fundamental role. Members of the ABC superfamily are 
responsible for the active transport of compounds across biological membranes, 
including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, 
organic anions, bile acids, drugs and xenobiotics (Klein I et al., 1999).  
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ABC transporters bind ATP and use the energy from ATP hydrolysis to transport 
various compounds across cell membranes as well as intracellular membranes of 
the endoplasmic reticulum, peroxisome and mitochondria (Higgins C, 1992). The 
functional protein contains two ATP-binding domains or nuclear binding folds 
(NBF) and two transmembrane  (TM) domains.  
 
ABC genes are organized as either full transporters containing two TM and two 
NBF or as half transporters containing one of each domain (Hyde et al., 1990). The 
half transporters can form functional transporters by combining as either 
heterodimers or homodimers. 
 
In humans, 48 ABC transporters have been identified to date, and classified on the 
basis of phylogenetic analysis into 7 subfamilies (A-G) (Dean M and Allikmets R, 
2001, Klein I et al., 1999). ABCA (12 members; previously ABC1), ABCB (11 
members; previously MDR/TAP), ABCC (12 members; previously MRP/CFTR). 
ABCD (4 members; previously ALD), ABCE (1 member; previously OABP), 
ABCF (3 members; previously GCN20) and ABCG (5 members; previously White) 
(Dean M et al., 2001). The subfamily designation is not based on functionality; 
genes in different subfamilies may have more similarity in substrate recognition 
than genes in the same subfamily. 
 
Members of three ABC subfamilies have been recognised to play a key role in drug 
efflux from cells: the MDR1 P-glycoprotein (ABCB1) of the ABCB subfamily, the 
breast cancer resistance protein (BCRP, ABCG2) of the ABCG subfamily and the 
multidrug resistance proteins (MRPs) of the ABCC subfamily.  
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3.3 P-Glycoprotein 
Permeability glycoprotein (P-gp) is a 170-180 kDa transmembrane glycoprotein first 
described in 1976 (Juliano RL and Ling V, 1976). It is composed of two 
homologous and symmetrical cassettes; each contains six transmembrane domains 
that are separated by an intracellular flexible linker-polypeptide loop with an ATP 
binding motif (Higgins C, 1992, Juliano RL and Ling V, 1976). 
 
P-gp is expressed at low levels in most tissues but is found in higher levels in 
epithelial cells with excretory roles. The location of P-gp is tissue-specific, it is 
localized on the canalicular surface of hepatocytes, the apical surface of renal 
tubular epithelial cells, the apical surface of epithelial cells in the intestine and 
placenta and the luminal surface of the capillary endothelial cells in the brain 
(Theibaut F et al., 1987, Cordon-Cardo C et al., 1990). P-gp is synthesised in the 
endoplasmic reticulum and subsequently modified in the Golgi apparatus (Loo and 
Clarke, 1999). 
 
Whilst the physiological function of P-gp is still not fully understood, it is known to 
extrude a wide variety of structurally and chemically unrelated compounds out of 
cells. Due to its localization on tissues, P-gp is thought to have a protective effect 
for organs such as the testes and brain (Fromm M, 2004a). This is because P-gp 
extrudes toxic drugs and metabolites. Other functional roles include the secretion of 
metabolites into bile, urine and the lumen of the gastrointestinal tract (Leung and 
Bendayan, 1999a, Fromm M, 2004b, Kullak-Ublick and Becker, 2003, Leung and 
Bendayan, 1999b) and also the transport of hormones from the adrenal gland (van 
Kalken et al., 1993) and uterine epithelium (Axiotis et al., 1991). 
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Surprisingly when the broad range of substrates and diverse roles of P-gp are 
considered, P-gp may not be essential to life. This is demonstrated by transgenic 
knockout mice being fertile, viable and phenotypically indistinguishable from wild 
type mice (Schinkel et al., 1994). Though to date no human null alleles have been 
reported (You G and Morris M, 2007). 
 
3.3.1 P-glycoprotein Isoforms 
P-gp is the product of several genes. Two members of the P-gp gene family (MDR1 
and MDR3) occur in humans, whilst three members of this family (mdr1a, mdr1b 
and mdr2) are found in mice (Gottesman and Pastan, 1993). The P-gp encoded by 
human MDR1 and mouse mdr1a/1b genes function as a drug efflux transporter, 
whilst human MDR3 and mouse mdr2 encoded P-gp are believed to transport 
phospholipids (van Helvoort et al., 1996, Ruetz and Gros, 1994). The isoforms 
have a 70% sequence homology. 
 
3.3.2 P-Glycoprotein Structure 
P-gp consists of two tandem repeats of approximately 1280 amino acids joined by a 
linker region of approximately 60 amino acids (Chen et al., 1986). Each repeat 
consists of an NH2-transmembrane (TM) domain (TMD) containing six potential 
TM segments, followed by a hydrophilic region containing a nucleotide biding 









Figure ‎3-1: Schematic representation of the primary structure of P-gp as embedded 
in the membrane. The molecule contains 1280 amino acids spanning 28 exons 
(each exon sequence shown in a different color). Black dots show the location of 
some of the identified SNPs. Modified from Ambudkar et al. (Ambudkar et al., 
2003). 
 
The secondary structure of P-gp has been established using Fourier transform 
attenuated reflective infrared spectroscopy and circular dichroism. P-gp 
approximately consists of 2-43% -helix, 16-26% -sheet, 15-29% -turn and 13-
26% unordered structure (Sonveaux et al., 1996{Dong M, 1998 #259)}. What is 
known is that the nucleotide-binding domains are not required for interaction with 
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The binding pocket of P-gp has been extensively studied but to date there is no 
high-resolution crystal structure. Radio-ligand binding and functional transport 
studies indicate that there are anywhere from two (van Veen et al., 1998, Homolya 
et al., 1993, Loo and Clark, 1999, Shapiro et al., 1999) to at least four (Martin et al., 
2000) substrate-binding sites, These sites fall into two categories:  
 Transport: at which translocation of drug across the membrane can occur, 
and, 
 Regulatory sites: which modify P-gp function.  
 
Multiple substrates can bind with P-gp. Using cysteine-scanning mutagenesis of the 
TM segments, P-gp was demonstrated to have overlapping binding for colchicine 
and calcein, but not verapamil (Loo et al., 2003). Other data indicates that 
substrate-binding sites may overlap or be allosterically coupled (Dey et al., 1997, 
Ayesh et al., 1996), leading to the possibility that there is only a single common 
binding site (Borgnia et al., 1996).  
 
3.3.3 Regulation of Expression of P-Glycoprotein 
The human MDR1 promoter region is atypical as it does not contain a TATA 
promoter sequence, but it does have multiple response elements (Hennessy and 
Spiers, 2007). P-gp is constitutively expressed in a cell and tissue-specific manner 
(section ‎3.3.5), but can be induced by heat shock, cytokines, chemotherapeutic 
agents, UV radiation, oxygen free radicals and tumour suppression genes (Miyazaki 
et al., 1992a, Chaudhary and Roninson, 1993, Hu et al., 2000, Wartenberg et al., 
2005). 
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In many cells lines, P-gp expression is increased through the up-regulation of 
MDR1 mRNA levels (Thorgeirsson et al., 1987, Abolhoda et al., 1999, van Kalken 
et al., 1992). The tumour suppressor protein p53 can either positively or negatively 
regulate MDR1 transcription. The p53 gene modulates the expression activity of 
MDR1 gene promoter in a promoter-CAT system (Li et al., 1997). The up-
regulation of MDR1 expression has been shown to be a two-step process: mRNA 
stabilization and translational initiation (Yague et al., 2003). Post-transcriptional 
regulation occurs with heat shock factor 1 (Tchénio et al., 2006).  
 
3.3.4 Genetic Variability of P-Glycoprotein 
The MDR1 gene is located on chromosome 7 and consists of 28 exons. Evidence of 
structural variability in the MDR1 locus was first described in 1998 (Mickley et al., 
1998) and to date more than 100 mutations have been identified. 15 single 
nucleotide polymorphisms (SNPs) were identified when the 28 exons were 
investigated (Hoffmeyer et al., 2000). Nine mutations alter the amino acid sequence 
of P-gp. Complete P-gp deficiency has not been reported for any of these 
polymorphisms, though the SNP at position C3435 in exon 26 does influence the 
expression level of intestinal P-gp (Lin J, 2003, Hoffmeyer et al., 2000).  
 
3.3.4.1 Genetic Variability and Drug Disposition 
Several other polymorphisms are known to influence drug disposition, including 
the disposition of digoxin (Hoffmeyer et al., 2000, Cascorbi et al., 2001, Sakaeda et 
al., 2001), phenytoin (Kerb et al., 2001) and cyclosporine (von Ahsen et al., 2001).  
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3.3.5 Tissue distribution of P-glycoprotein 
P-gp is expressed in tumour cells and in cells of many normal tissues. The cellular 
localization differs for each tissue. Thus transporter activity changes in any location 
can modify drug disposition in the body leading to an increased exposure and 
inducing specific tissue toxicity issues. This information is summarised, Table ‎3-1. 
 
3.3.5.1 Gastrointestinal Tract 
P-gp is expressed at the apical surface of the epithelial cells lining the intestine 
(Thiebaut et al., 1987, Maliepaard et al., 2001), with levels increasing from the 
duodenum to the colon (Dietrich et al., 2003). The role of P-gp in the 
gastrointestinal tract is to prevent and/or modulate the passage of certain 
xenobiotics or their metabolites from the gut intro circulation. Murine studies have 
indicated a second potential role, the prevention of accumulation of inflammation-
inducing bacteria and bacterial products (Panwala et al., 1998). 
 
3.3.5.2 Lung  
P-gp is localized on the apical surface of bronchus and bronchiolar epithelium and 
at the plasma membrane of alveolar macrophages, it has been suggested that it 
removes environmental compounds to the lung lumen (Scheffer et al., 2002). 
Though this protective role has not yet been demonstrated in vivo.  
 
3.3.5.3 Central Nervous System 
High levels of P-gp are found in the brain, on the apical side of capillary endothelial 
cells, taking part in the blood-brain barrier (Cordon-Cardo et al., 1989, Thiebaut et 
al., 1987, Thiebaut et al., 1989).  
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In the brain P-gp is expressed in many cell types including choroid plexus, 
astrocytes, microglia and capillary endothelium. P-gp is also located on the luminal 
plasma membrane of the capillary endothelium, where it prevents the passage of 
drugs and toxins (Fricker and Miller, 2004). 
 
3.3.5.4 Testis 
The structure of the blood-testes barrier is similar to the blood-brain barrier and 
likewise it provides a protective function. Immunohistochemical studies have 
shown that P-gp is observed at the luminal side of the capillary endothelial cells 
(Thiebaut et al., 1989, Cordon-Cardo C et al., 1990). 
 
3.3.5.5 Placenta 
P-gp is expressed at relatively high levels in the syncytiotrophoblast cells (Atkinson 
et al., 2003), the role of this is to protect the foetus (Lankas et al., 1997). 
 
3.3.5.6 Liver  
In the liver, several ABC and other transporters are important for the elimination of 
drugs and toxins across the canalicular or sinusoidal hepatocyte membrane into bile 
or systemic circulation (Leslie E et al., 2005).  
 
3.3.5.7 Kidney 
P-gp is found on the apical surface of the epithelial cells of the proximal tubules 
(Schaub et al., 1999, Thiebaut et al., 1987).  The role of P-gp in the kidney is to 
mediate the export of certain drugs (including uncharged and cationic drugs) from, 
blood into urine (Fricker et al., 1999, Gutmann et al., 2000, Schaub et al., 1999). 
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Table ‎3-1: The cellular localisation of P-glycoprotein in tissues and the effect on 
drug disposition. Material from various resources (Fromm, 2002, Cordon-Cardo C 
et al., 1990, Thiebaut et al., 1987). 
 
Tissue Localization Function 
Gastrointestinal tract Apical membrane of epithelial cells Secretion of drugs into gut lumen 
Lung Apical surface of bronchial and 
bronchiolar epithelium 
Remove environmental compounds/ 
particulates to the lung lumen 
Central nervous 
system 
Apical side of capillary endothelial 
cell 
Prevents the passage of drugs and 
toxins 
Testis Luminal side of the capillary 
endothelial cells 
Protective function, blood-testis barrier 
Placenta Trophobalsts Protection of the foetus from 
xenobiotics 
Kidney Apical membrane of epithelial cells 
of proximal tubules 
Secretion of drugs into tubules lumen 
Liver Canalicular membrane of 
hepatocytes 
Secretion of drugs into bile 
 
 
3.4 P-glycoprotein Binding and Efflux 
Two to three molecules of ATP are hydrolysed per molecule of substrate 
transported (Eytan et al., 1996, Ambudkar et al., 1997, Shapiro A and Ling V, 
1998, Delannoy et al., 2005). In the absence of a substrate, both NBDs are occupied 
with either ATP or ADP (Qu et al., 2003). Two potential models have been 
proposed in order to explain the sequence of events on the efflux cycle (Figure ‎3-2): 
 An ATP-switch driven pump system (Higgins and Linton, 2004, Linton and 
Higgins, 2007).  
 An ATP hydrolysis driven efflux pump (Ambudkar et al., 2006). 
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b) 
 
Figure ‎3-2: Summary of the two models proposed for the translocation process for 
P-gp. a) The nucleotide switch model in which dimerization of the nucleotide-
binding domains drives the pump. b) Model in which ATP hydrolysis drives the 
pump. Both models encompass four distinct stages: (i) Loading of P-gp with drug 
and nucleotide. (ii) Reorientation of the drug-binding sites from high to low affinity. 
(iii) Nucleotide hydrolysis. (iv) Resetting phase. Modified from (Hennessy M and 
Spiers JP, 2007, Callaghan et al., 2006, Hennessy and Spiers, 2007).  
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In general, transport by P-gp is saturable, osmotically sensitive, requires ATP 
hydrolysis, and generates a drug concentration gradient (Sharom, 1997). P-gp 
exhibits a high level of basal ATPase activity in the absence of a substrate (Shapiro 
and Ling, 1994, Sharom et al., 1995, Hennessy M and Spiers JP, 2007, Hennessy 
and Spiers, 2007). Upon substrate binding the level of ATPase activity in increased 
3-4 fold (Senior et al., 1995, Martin et al., 1997), though increases of 20-fold have 
also been reported (Ambudkar et al., 1992). 
 
3.5 P-Glycoprotein Substrates and Inhibitors 
P-gp is a highly promiscuous transporter, able to recognize and transport an 
amazing number of diverse substrates that differ in chemical structure and 
pharmacological action, this includes many clinically important drugs, for example, 
doxorubicin, vinblastine, cortisol, indinavir, colchicine and rifampicin (Hennessy 
and Spiers, 2007).  A typical substrate is large (Mr >400), hydrophobic, 
amphipathic, with a planar ring system, and often carries a positive charge at 
physiological pH (Pearce et al., 1989), though this is not always true.  
 
Dissociation constant (Kd) values for P-gp substrates cover a 1000-fold range, 
indicating that P-gp is able to discriminate between substrates (Sharom, 1997). Key 
physico-chemical properties for substrates and inhibitors have been identified, 
including lipid solubility, cationic charge and molecular refractivity, additionally 
hydrogen bonding potential, presence of an amine group, molecular weight, size, 
surface area and the presence of aromatic ring structures (Wang et al., 2003, 
Zamora et al., 1988, Ueda et al., 1997b, Stouch and Gudmundsson, 2002, Ueda et 
al., 1997a). 
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The presence of a hydrogen bond acceptor (or electron donor) moiety with a 
defined spatial separation is key (Seelig, 1998, Seelig et al., 2000). This spatial 
separation pattern is defined as type I, with two electron donor groups separated by 
2.5 ± 0.3Å, or type II, with two electron donor groups separated by 4.6 ±0.6Å. A 
prerequisite for substrate binding is either a type I or II pattern (Seelig et al., 2000).  
 
3.6 P-Glycoprotein Induction 
The mechanism of transcription of the MDR1 gene is complex and not yet fully 
understood. Induction of P-gp/MDR1 expression does not occur via direct drug 
binding to P-gp, it is regulated by nuclear factors at the transcriptional level 
(Kuwano et al., 2004). As described in section ‎3.3.5, P-gp is constitutively 
expressed in a cell and tissue-specific manner, but it may be induced by 
environmental factors such as heat shock, cytokines, chemotherapeutics agents, UV 
radiation, oxygen free radicals and tumour suppressor genes (Chin et al., 1990a, 
Miyazaki et al., 1992b, Chaudhary and Roninson, 1993, Hu et al., 2000, 
Thottassery et al., 1997, Wartenberg et al., 2005, Chin et al., 1990b).  
 
Nuclear receptors (NR) relevant for the expression of the ABC transporters are liver 
X receptor (LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR), and 
peroxisome proliferator-activated receptors  and  (PPAR and PPAR) (Borst 
and Elferink, 2002). The NRs are also known to be involved in the induction of the 
cytochrome P450 enzymes (section 4.7).  
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The up-regulation of MDR1 mRNA levels, may involve several transcription 
factors including GC, HSF1, Sp1, AP-1, NF-Il6, NF-Y, EGR1, YB-1 and MED-1 
(Chaudhary and Roninson, 1993, Thorgeirsson et al., 1987, van Kalken et al., 
1992). The tumour suppressor protein p53 can either positively or negatively 
regulate the MDR1 transcription (Thottassery et al., 1997, Li et al., 1997). 
 
3.7 Methods for studying P-Glycoprotein 
Transporter interactions can be assessed by several methods. These assays can 
classify compounds as inhibitors and/or substrates of P-gp (Sharom, 1997, Seelig, 
1998). Combinatorial chemistry and advances in synthetic chemistry have led to the 
development of many new compounds in the area of drug discovery and this has 
driven the development of screening assays for permeability. Ideally screening 
assays will have high efficiency, reproducibility, time, cost and space effectiveness 
and capability for high throughput. 
 
3.7.1 In vitro Assays 
There are many in vitro assays available to investigate the interaction of a test 
compound with P-gp, each with advantages and disadvantages. 
 
3.7.1.1 Transcellular Transport  
Transport studies can identify P-gp substrates, modulators or inhibitors. With 
monolayer efflux assays, where the ratio or basolateral-to-apical (BA) 
permeability versus apical-to-basolateral (AB) permeability is regarded as the 
standard for identifying P-gp substrates as it measures the efflux of drugs in the 
most direct manner (Polli. J et al., 2001a, Rautio et al., 2006).  
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The major disadvantage of these assays is they are labour intensive due to cell 
culture and analytical techniques, limiting throughput. 
 
In brief, cells are seeded on a membrane surface and the test compound is added to 
the apical and/or basolateral compartment. At pre-determined time points the 
concentration of the compound is determined in each compartment. In the case of 
P-gp which is apically located, the basolateral to apical flux will dominate (Szakács 
et al., 2001). As this technique requires identification of the compound, it is not 
suitable for complementary products as the composition is often unknown and is 
highly variable.  
 
In these studies different cell types may be employed including human colonic 
adenocarcinoma (Caco-2), Madin-Darby canine kidney (MDCK) and porcine 
kidney epithelial (LLC-PK1) cells. Caco-2 cells resemble intestinal epithelium, and 
are the most extensively characterized model for examining the permeability of 
drugs (Balimane et al., 2006, Elsby et al., 2008b, Elsby et al., 2008a).  
 
Membranes isolated from the cells mentioned above, can be isolated. They contain 
high levels of transporters suitable for the characterization. Membrane-based assays 
characterization of the transporter may follow (i) the catalytic activity, (ii) the 
binding of the compound to the transporter, (iii) the actual substrate transport. An 
assay based on inside-out membrane vesicles is a clinically relevant method 
(Kharasch et al., 2005).  
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3.7.1.2 ATPase Expression 
As P-gp is ATP dependent (see section 3.3), monitoring ATPase activity is a useful 
tool to determine P-gp interactions. In the absence of a test compound, P-gp will 
express a basal ATPase activity level. If a test compound binds to P-gp then an 
increase in ATPase activity will be detected. Whilst monitoring ATPase activity 
can be scaled to a high-throughput assay (Garrigues et al., 2002), these studies can 
not determine if the test compound is acting as an inhibitor, inducer or substrate for 
the transporter.  
 
One important advantage of ATPase assays that is key when working with 
unknown tests compounds such as complementary products is that these assays do 
not require analytical techniques to identify the product. ATPase assays have been 
developed for a variety of systems including enriched and crude plasma membranes 
(Kokubu et al., 1997, Garrigues A et al., 2002, Garrigues et al., 2002), and enriched 
microsomal membranes (Litman et al., 1997). Purified P-gp can also be used 
(Ambudkar et al., 1997, Lu et al., 2001). 
 
3.7.1.3 Cellular Accumulation  
The accumulation of fluorescent dyes within the cell can be used to identify 
inhibition of P-gp. These assays are easily adapted for high-throughput screening, 
though identification of inhibitor or substrates can be difficult as there are multiple 
binding sites on P-gp (Schwab D et al., 2003a). 
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Measurement of the cellular accumulation of these dyes in the presence of a test 
compound may be done via flow cytometry, as in the case of Rhodamine 123 (a 
cationic dye) or by standard fluorometric measurements as with Calcein. Calcein 
AM is a non-fluorescent, highly lipid soluble dye that rapidly penetrates the plasma 
membrane of cells. In addition to this, Calcein AM is a good substrate for the efflux 
carriers for both P-gp and multidrug resistance protein (MRP).  When Calcein AM 
enters the cells it is metabolized by the cytosolic esterase’s into calcein, which is 
highly hydrophilic and fluorescent  (Figure ‎3-3). 
 
a)      b) 
 
 
Figure ‎3-3: Schematic representation of the calcein AM extrusion assay. a) The 
lipid soluble calcein AM is able to cross the cell membrane. b) In the presence of 
esterase’s the calcein AM is hydrolyses to the fluorescent calcein which is also 
hydrophilic. If inhibition of the P-gp pump occurs then calcein cannot be extruded 
and the fluorescence is recorded. 
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3.7.2 In Vivo Assays  
In vivo mouse models can be used to evaluate the interaction of compounds with P-
gp. The use of mdr1 knockout mice is useful in the identification of the role of P-gp 
in drug absorption and disposition (Bain and LeBlanc, 1996, Schinkel et al., 1994), 
though these mice have two members of drug-transporting P-gp (mdr1a (brain and 
intestine) and mdr1b (liver and kidney) expressed in a tissue specific manner  
(Croop et al., 1989).  
 
The double knockout mdr1a/b mice have more recently been developed and can be 
used to study P-gp interactions (Schinkel et al., 1997). These mice display a 100-
fold increase in the sensitivity to the centrally acting neurotoxic pesticide 
ivermectin, and to the carcinostatic drug vinblastine (3-fold). In addition to P-gp 
alterations, both single and double knockout mice display an increased expression 
of hepatic CYP2B and CYP3A proteins (Schinkel et al., 1997), which must be 
taken into consideration when pharmacokinetic studies are conducted using these 
animals. 
 
3.7.3 In Silico 
In silico studies have been utilised to predict the potential interaction of a drug with 
P-gp. One such study was used to predict the ability of drugs to form H-bonds, 
which as shown in section ‎3.5 are key for an interaction with the receptor to occur  
(Seelig and Landwojtowicz, 2000), lipophilicity and molecular weight have also 
been correlated with binding (Bain et al., 1997). A multi-tier approach has been 
utilised to classify compounds into three classes, substrates, inhibitors or non-
interaction, with 82, 72 and 89% accuracy (Bain and LeBlanc, 1996). 
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With complementary products, the composition is often unknown and complex; 
this limits the use of in silico techniques with these products. In the future, in silico 
modelling may have a role in predicting the fate of these products when more 
information is available and potentially classes or family of products are found to 
behave in a similar pattern. At this stage the technology cannot provide predictions 
on the metabolic outcomes and kinetic behaviour of these products. 
 
Table ‎3-2: The major advantages and disadvantages of the systems used in the 
investigation of P-glycoprotein interactions. 
System Advantages Disadvantages 
Transcellular 
transport 
Can identify substrates, modulators 
and inhibitors. 
Labour intensive with limited through-
put.  
ATPase activity Rapid and amenable to high 
throughput. Can identify substrates, 
modulators and inhibitors. 
Cannot distinguish between substrates 
modulators and inhibitors.  
Cellular 
accumulation 
Rapid and cost efficient. Indicate inhibition of P-gp, not 
induction. 
In vivo Knockout mice are available. Not rapid or cost efficient for 
screening studies. 
In silico No reagents or drug required.  Molecular and structural knowledge of 




3.8 Interactions Caused by Herbal Products 
To date several complementary and alternative products have been identified as 
substrates, inhibitors and/or inducers of P-gp. One of the most clinically significant 
examples is St. John’s Wort (Hypericum perforatum), which is commonly used to 
treat mild depression. 
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Studies have indicated that St. John’s Wort induces intestinal P-gp in vitro and in 
vivo (Hennessy et al., 2002, Perloff et al., 2001). These finding have been consistent 
in healthy volunteers who consumed the product for 14 days, with a subsequent 
1.4-1.5 fold increase in their expression of P-gp (Dürr et al., 2000). 
 
Silymarin, a component of the herb Milk Thistle has been studied due to concerns 
of adverse interactions between this herb and indinavir which is a known substrate 
for P-gp used in the treatment of AIDS. In healthy volunteers, treatment with Milk 
Thistle (175mg) for 3-weeks caused a 9-36% reduction in the AUC of indinavir. 
 
3.9 Aims of the Present Study 
The general aim of this study was to investigate complementary products that have 
the potential to alter the kinetic behaviour of therapeutic agents via the inhibition of 
P-glycoprotein. The specific goals included: 
 Establishing a standard extraction method that is easily reproducible.  
 To determine the potential for two assay types, the ATPase activity and 
cellular accumulation assay can be used in the context of complex mixtures 
such as complementary products. 
 To determine if these methods produce comparable results when using 
complex mixtures.  
 To determine if these methods can be used as high throughput screening 
assays for investigating the interaction of complementary and alternative 
products with P-glycoprotein. 
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3.10 Materials and Methods 
3.10.1 Chemicals 
Verapamil, calcein, Hank’s balanced salt solution (HBSS), MgATP, peroxidase-
conjugated goat anti-mouse IgG and anti-mouse β-actin antibody were purchased 
from Sigma-Aldrich, Australia. Sodium orthovanadate was purchased from Merck. 
Advanced RPMI-1640 media from Gibco Technologies. K562 and K562-MDR 
cells were a generous donation from Dr Dodie Pouniotis, Cancer and Tissue Repair 
Research Group, RMIT University. Human p-glycoprotein membranes were 
purchased from BD Gentest. (US). Nitrocellulose membrane (Geneworks, SA, 
Australia) and 0.2-μm pore size Clear Blot Membrane-P (Atto Corp., Tokyo, 
Japan). Anti-P Glycoprotein antibody (JSB-1) was purchased from Abcam Ltd. 
UK.  
 
Water was freshly prepared in-house with Simplicity 185 (Millipore S.A., 
Molsheim, France) water purification system and was ultra pure grade (18.2M). 
All other chemicals were from Sigma Chemical Co. (St Louis, MO, USA) and were 
of the highest purity available. 
 
3.10.2 Preparation of Herbal Samples  
Herbal products were purchased from local suppliers in Victoria, Australia and 
were all of commercial quality (Table ‎3-3). The methanolic and aqueous extraction 
method was modified from that previously described (Unger and Frank, 2004). 
Tablets were crushed and the contents of capsules emptied, extractions were either 
water or 80% methanol to allow for the aqueous and distinctly lipophilic 
components to be separated.  
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Solvent volumes were adjusted so that standardised extracts at 100 mg of 
product/ml were obtained. This was based on the manufacturers’ stated 
concentration of the active or principle component.  
 
Extracts were agitated in a shaking water bath at 37C for 30 minutes then 
centrifuged at 2500 g for 10 minutes. Standard extracts were diluted to final 
nominal concentrations of 10, 100 and 1000 g/ml. Methanol was evaporated to 
dryness under vacuum and the final volume of methanol did not exceed 1% (v:v). 
Extracts were kept in the dark and shelf life set at 2 weeks.  
 
3.10.3 Cell culture 
The human erythromyeloblastoid leukaemia cell line K562 and its over expressing 
variant K562-MDR cells were maintained in Advanced RPMI 1640 supplemented 
with 10% (v:v) heat-inactivated foetal bovine serum, 2mM L-glutamine, 100 μg/ml 







Table ‎3-3: Complementary products screened for their potential to interact with P-glycoprotein. 
Product Active or Principle 
Component 
[Active or principle 
component] in each 
tablet/capsule 
Manufacturer Batch Number Reported benefit/Use 
Cordyceps Cordyceps sinensis 530mg Nature’s Sunshine 0170794 For general wellbeing and aphrodisiac. Assist in 
the treatment of inflammatory conditions and 
fatigue. 
 
Echinacea Echinacea purpurea 410mg Nature’s Sunshine 0124471 Supports the body’s own immune defences. 
Milk Thistle Silybum marianum  84mg Nature’s Own 302090 Assist the liver in detoxification. 
Slippery Elm Ulmus rubra 400mg Nature’s Own 314087 Sooth digestive disturbance and enhance overall 
digestive health.  
Valerian Valeriana officinalis 2250mg Bio-Organics 301338 Antispasmodic and muscle relaxant. Relieve 
nervous tension and anxiety. 
 
 Chapter 3 – P-glycoprotein Inhibition 104 
3.10.4 Immunoblotting Analysis 
Immunoblotting analysis for P-gp was undertaken as previously described with 
minor modifications (Auora et al., 2005). K562 and K562-MDR cells were 
centrifuged, and suspended in lysis buffer containing 2 mM EDTA, 25 mM Tris-
phosphate, pH 7.8, 1% Triton X-100, and 10% protease inhibitor cocktail. Protein 
concentration was determined using the method of Bradford (Bradford, 1976).  
 
Equal amounts of protein lysates were separated on SDS/7% (w/v)-polyacrylamide 
gels and then transferred to nitrocellulose in glycine transfer buffer. The blots were 
blocked overnight with 3% non-fat dry milk and probed with anti P-glycoprotein 
antibody (JSB-1) (0.5 μg/ml). Immunoblots were detected by horseradish 
peroxidase-conjugate anti-mouse IgG using chromogen 3,3’-diaminobenzidine 
tetrahydrochloride (dilution 1:1500).  Anti mouse β-actin antibody was used at a 
1:10,000 dilution as an internal load control. Immunoblots were scanned and band 
intensities quantitatively measure using Metamorph version 4.01 imaging software 
(Universal Imaging Corporation, USA). 
 
3.10.5 Calcein AM Assay 
Calcein AM assay was modified from previously described (Liminga G et al., 1994, 
Polli. J et al., 2001b, Polli. J et al., 2001a). Calcein AM was dissolved in dimethyl 
sulfoxide (DMSO) to a stock solution of 1 mg/ml and kept at -20°C until use. 
Accumulation of the calcein AM dye in K562-MDR cells was determined using a 
Perkin-Elmer Multi-label fluorometer, with an excitation of 485nm and an emission 
of 538nm. 1 x 105 cells were seeded in 100 μl Hank’s balanced salt solution (HBSS), 
pH 7.4, in 96-well black plates with clear bottoms.  
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3.10.5.1 Control Experiments 
Increasing concentrations of verapamil, a known P-gp inhibitor was incubated with 
K562-MDR cells for 15 minutes before the addition of calcein AM at a final 
concentration of 250 nM. Fluorescence intensities were recorded for 10 minutes at 
30-second intervals, with an excitation of 485nm and an emission of 538nm in a 
Perkin-Elmer Multi-label fluorometer. Experiments were run in triplicate on three 
separate occasions. 
 
3.10.5.2 Inhibition Studies 
The aqueous and methanolic extracts of the complementary products were added 
to cells seeded at a density of 1 x 105 cells HBSS, pH 7.4 and pre-incubated at 37°C 
for 15 minutes. Calcein was added at a final concentration of 250 nM. Fluorescence 
intensities were recorded for 10 minutes at 30-second intervals with an excitation of 
485nm and an emission of 538nm in a Perkin-Elmer Multi-label fluorometer. 
Positive control measurements to determine 100% inhibition were carried out in the 




From the time dependent increase of cellular fluorescence the initial rate of 
fluorescence generation (IRF) was determined. Quantification of P-gp inhibition 
was determined with the following equation: 
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Where IRF (control) was the average of three reading with verapamil 50 μM used 
as the positive control, and IRF (background) was the IRF in the absence of test 
compound. A compound was determined to inhibit P-gp when an inhibition ≥50% 
was reached. 
 
The IC50 values for the extracts (concentration causing 50% reduction of control 
activity) were determined from the mean of the triplicate incubations run on three 
separate occasions by non-linear regression analysis (GraphPad Prism, v5.0). 
 
3.10.6 ATPase Assay 
The ATPase activity of human P-gp membranes was determined by measuring the 
inorganic phosphate released from ATP. The ATPase activity measured in the 
presence of 100 μM sodium orthovanadate represents non P-gp ATPase activity 
and was subtracted from the activity generated without sodium orthovanadate to 
determine basal ATPase activity.  
 
All incubations were carried out in reaction buffer containing 50 mM MES, 2 mM 
EGTA, 2 mM dithiothreitol, 50 mM potassium chloride, 5 mM sodium azide (pH 
adjusted to 6.8 with Tris) and 1000 μM ATP magnesium salt. Incubations were 
conducted at 37°C for 20 minutes and stopped by the addition of 0.03 ml of 10% 
SDS.  
 
At the end of the incubation, detection reagent (7 mM ammonium molybdate, 3 
mM zinc acetate, and 16% ascorbic acid, pH 5.0) was added to each well. The 
colour reaction was incubated for 20 minutes at 37°C.  
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The plate was read immediately for endpoint absorbance at 850 nm using a Perkin-
Elmer Multi-label spectrophotometer. A potassium phosphate standard curve was 
used to extrapolate nanomoles of phosphate from the absorbance readings.  
 
3.10.6.1 Control Experiments 
P-gp membranes (25 μg) were incubated at 37°C for 20 minutes in the presence of 
increasing concentrations of verapamil as a positive control, DMSO (1%) was used 
as a negative control. Assays were run in 96-wells in triplicate on three separate 
occasions. 
 
3.10.6.2 Complementary Products 
Aqueous and methanolic extracts of the complementary products were incubated at 
increasing concentrations (0-500 μg/ml) with P-gp membranes (25 μg) at 37°C for 
20 minutes in the presence of verapamil. Assays were run in 96-wells in triplicate 
on three separate occasions. 
 
3.10.6.3 Calculations 
The drug stimulated ATPase activity (nmol/min/mg of protein) was determined as 
the difference between the amount of inorganic phosphate released from ATP in 
the absence and presence of sodium orthovanadate for each of the extracts. 
Phosphate standards were prepared in each plate and verapamil was used as a 
positive control. The ATPase activity in verapamil stimulated cells was determined 
as a % of the control (50 μM verapamil). The results are expressed as the mean 
±SEM of triplicate replications run on three separate occasions.  
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The IC50 values for the extracts (concentration causing 50% reduction of control 
activity) were determined from the mean of the triplicate incubations run on three 
separate occasions by non-linear regression analysis (GraphPad Prism, v5.0). 
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3.11 Results 
3.11.1 Immunoblotting Analysis 
K562 and K562-MDR cells were subjected to immunoblotting to confirm the 
presence of P-gp. Anti P-glycoprotein antibody (JSB-1) is specific for the MDR1 
isoform of P-gp and does not cross-react with MDR3.  K562-MDR but not K562 
cells were shown to express P-gp (Figure ‎3-4). 
 
a)     b) 
 
 
Figure ‎3-4: P-glycoprotein levels determined with immunoblot analysis. a) K562 
and K652-MDR cells were probed with anti P-glycoprotein monoclonal antibody 
C219 anti-mdr1. Immunoblots were detected by horseradish peroxidase-conjugate 
anti-mouse IgG using chromogen 3,3’-diaminobenzidine tetrahydrochloride 
(dilution 1:1500). b) Bands were quantitatively measured by scanning densitometry 
and the density compared to the loading control anti mouse β-actin antibody. Data 
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3.11.2 Calcein AM 
Calcein AM is a non-fluorescent highly lipid soluble dye that rapidly penetrates the 
plasma membrane of cells. It is a substrate for P-gp and multiple resistance protein 
(MRP) (Essodaïgui M et al., 1998). Inside the cell, calcein AM is hydrolysed by the 
cytosolic esterases into the hydrophilic and fluorescent calcein. In the presence of a 
P-gp inhibitor, the fluorescent calcein molecules remain in the cell. 
 
3.11.2.1 Positive Control Experiments 
Verapamil, a known inhibitor of P-gp was used as a positive control. Under our 
experimental conditions maximum inhibition of P-gp was seen at 50 μM of 
verapamil (Figure ‎3-5).  
 
Figure ‎3-5: Inhibition of calcein AM extrusion from K562-MDR cells in the 
presence of increasing concentrations of verapamil. Cells were pre-incubated with 
verapamil for 15 minutes prior to the addition of 250 nM calcein. Fluorescence was 
recorded for 10 minutes at 485nm excitation and 538nm emission. Data points 
represent the mean % inhibition ± SEM for 3 independent assays each ran in 
triplicate. 
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3.11.2.2 Inhibition of Calcein Extrusion by Complementary Products 
K562-MDR cells were incubated with increasing concentrations of the aqueous and 
methanolic extracts of the complementary product extracts for 15 minutes. Calcein 
AM (250 nM) was added to the incubation and the fluorescence recorded. The % 
inhibition of P-gp calcein retention was determined for each of the tested extracts 

























Figure ‎3-6: Inhibition of calcein AM extrusion in the presence of (a) aqueous and 
(b) methanolic extracts of complementary products, in K562-MDR cells. Cells were 
incubated with the extracts for 15 minutes prior to the addition of 250 nM of 
calcein. Fluorescence was recorded for 10 minutes at 485nm excitation and 538nm 
emission. Data points represent the mean % inhibition ± SEM for 5 independent 
assays ran in triplicate. 
■ Cordyceps ▲ Echinacea  Milk Thistle ◆ Slippery Elm ● Valerian 
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The IC50 for P-gp inhibition was determined from the mean of triplicate 
experiments ran on 3 separate occasions by nonlinear regression analysis as per the 
method previously described (section 3.1.12).  
 
Table ‎3-4: The IC50 (μg/ml) for products with the Calcein AM assay (n = 3).  
Product Extract IC50 μg/ml 
Cordyceps Aq 90.58 ±10.1 
Cordyceps Meth # 
Echinacea Aq # 
Echinacea Meth # 
Milk Thistle Aq # 
Milk Thistle Meth 96.93 ±13.7 
Slippery Elm Aq 69.95 ±8.44 
Slippery Elm Meth 45.71 ±5.04 
Valerian Aq # 
Valerian Meth 353.1 ±27.4 
#IC50 was greater than the concentration investigated and could not be determined. 
Aq = Aqueous extract 
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3.11.3 ATPase Assay 
ATPase activity is increased above the basal level when compounds bind to P-gp. 
Basal ATPase activity is determined by measuring the ATPase activity in the 
presence of orthovanadate, this represents non P-gp ATPase activity and can be 
subtracted from the activity generated without orthovanadate to yield vanadate-
sensitive ATPase activity. 
 
3.11.3.1 Control Experiments 
Verapamil was incubated at increasing concentration with P-gp membranes (25 μg) 
(Figure ‎3-7). The biphasic response seen with verapamil in the assay which is 
consistent with previous reports (Sharom et al., 1995, Borgnia et al., 1996). As 
DMSO is known to stimulate ATPase activity (Lehotský et al., 1992), increasing 
concentrations were added to ensure that the 1% used in the assays did not affect 
the incubation. At the 1% level used there is no affect of the DMSO on ATPase 
activity (Figure ‎3-8). For each control experiment, ATPase activity measured in the 
presence of sodium orthovanadate was subtracted from the activity generated 
without sodium orthovanadate. Reactions were stopped by the addition of SDS 
(3%) and were run in triplicate on three separate occasions. 
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Figure ‎3-7: Concentration dependent stimulation of ATPase activity in K562-
MDR cells by verapamil. Each point represents the mean of three incubations 





Figure ‎3-8: Concentration dependent stimulation of ATPase activity in K562-
MDR cells by DMSO. Each point represents the mean of three incubations ±SEM 
ran in triplicate. 
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3.11.3.2 ATPase Activity with Complementary Products 
To determine the potential for the complementary products to inhibit the verapamil 
stimulated ATPase activity of P-gp, human P-gp membranes (25 μg) were 
incubated at 37°C for 20 minutes in the presence of 50 μM verapamil. The ATPase 
activity in the presence of verapamil was shown to increase 2 fold above the basal 
level at this concentration (Figure ‎3-7). Increasing concentrations of extracts of the 
complementary products (0-500 μg/ml) were added to the incubation and the 

























Figure ‎3-9: Inhibition of verapamil stimulated ATPase activity in K562-MDR cells 
by a) aqueous and b) methanolic extracts of complementary products. ATPase 
activity determined in the presence and absence of sodium orthovanadate, 
fluorescence recorded at 850nm. Data expressed as the mean ±SEM of three 
independent experiments ran in triplicate.  
■ Cordyceps ▲ Echinacea  Milk Thistle ◆ Slippery Elm ● Valerian 
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The IC50 for inhibition of the ATPase activity was determined from the mean of 
triplicate experiments ran on 3 separate occasions by nonlinear regression analysis 
as per the method previously described (section ‎3.10.6.3).  
 
Table ‎3-5: The IC50 (μg/ml) for products in the verapamil stimulated ATPase assay 
with K563-MDR cells (n = 3). 
Product Extract IC50 μg/ml 
Cordyceps Aq 138.5 ±14.42 
Cordyceps Meth # 
Echinacea Aq # 
Echinacea Meth # 
Milk Thistle Aq # 
Milk Thistle Meth 135.55 ±15.13 
Slippery Elm Aq 51.17 ±11.81 
Slippery Elm Meth 28.48 ±4.55 
Valerian Aq # 
Valerian Meth 467.1 ±17.31 
#IC50 was greater than the concentration investigated and could not be determined. 
Aq = Aqueous extract 
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3.12 Discussion 
3.12.1 Product Selection 
Products were selected for investigation based on the risk of concurrent use with 
therapeutic agents that are known to inhibit P-gp (Table ‎3-3). As many 
conventional medications are substrates, inducers and/or inhibitors of P-gp, the 
focus in this project was on products that have a broad therapeutic claim with 
particular focus on those that would likely to be concurrently consumed by patients 
also taking drugs for which failure would be a critical out come i.e.: the protease 
inhibitors for HIV/AIDS treatment. 
 
3.12.2 Method Selection 
The inhibition of P-gp can be determined by several assays (Table ‎3-2). Calcein AM 
was selected as this assay is amenable to high-throughput screening and can provide 
information relating specifically to the inhibition of P-gp. The ATPase assays have 
been used extensively and like the calcein AM assay can be relatively high-
throughout.  
 
The major advantage with these assays in the context of complementary products is 
that neither requires the identification of the product for the analysis, both have an 
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3.12.3 Immunoblotting Assays 
To confirm the expression of P-gp, K562-MDR cells were stained with the specific 
MDR1 anti P-glycoprotein antibody (JSB-1). K562 cells, which do not express P-
gp, were used as a negative control. Immunoblotting confirmed the presence of P-
gp on the K562-MDR cells but not the K562 cells (Figure ‎3-4).  This data confirms 
that the K562-MDR cells were a viable cell line to use in these studies. 
 
3.12.4 Calcein AM Assay 
Calcein AM is a non-fluorescent, highly lipid soluble dye that rapidly penetrates the 
plasma membrane of cells. In addition to this, Calcein AM is a good substrate for 
the efflux carriers for both P-gp and multidrug resistance protein (MRP).  When 
Calcein AM enters the cells it is metabolized by the cytosolic esterases into calcein, 
which is highly hydrophilic and fluorescent product. 
 
In our study 5 of the 10 tested extracts produced and IC50 <100 μg/ml (Table ‎3-4), 
with the methanolic extract of Slippery elm being the most significant (45.71 ±5.04 
μg/ml).  
 
3.12.5 ATPase Assay 
ATPase activity is increased above the basal level when compounds interact with P-
gp, though these studies cannot determine if the test compound is acting as an 
inhibitor, inducer or substrate for the transporter.  By investigating the ATPase 
activity in the presence of verapamil-stimulated cells, the data indicates which of 
the extracts is more likely to be acting as an inhibitor.  
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Of the 10 extracts investigated, the 5 that were positive in the calcein AM assay 
(IC50 <100 μg/ml) also inhibited the release of ATPase from the K5632-MDR 
verapamil stimulated cells.  
 
3.12.6 Comparison of the Assays 
As shown in Table ‎3-6, the IC50s determined are comparable between the two 
methods. For some of the extracts the Calcein AM assay was more sensitive (the 
aqueous extract of Cordyceps and the methanolic extract of Milk Thistle) for the 
remaining extracts, the ATPase assay was more sensitive. Significantly no extract 
was positive in one assay and not the other.  
 
Table ‎3-6: IC50 (μg/ml) for the extracts that showed inhibition in the Calcein AM 
and ATPase assays (n = 3). 
Product Extract Calcein AM Assay ATPase Assay 
Cordyceps Aq 90.58 ±10.1 138.5 ±14.42 
Milk thistle Meth 96.93 ±13.7 135.55 ±15.13 
Slippery elm Aq  69.95 ±8.44 51.17 ±11.81 
Slippery elm Meth 45.71 ±5.04 28.48 ±4.55 
Valerian Meth 353.1 ±27.4 467.1 ±17.31 
Aq = Aqueous extract 
Meth = Methanolic extract 
 
Several other studies have concluded that multiple assays should be utilised to 
determined interactions of compounds with P-gp including those used in these 
studies and additional assays such as transcellular transport assays (Schwab D et 
al., 2003b, Seelig et al., 2000). 
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3.12.7 Herbal Products 
3.12.7.1 Cordyceps 
Cordyceps (Cordyseps sinensis) is from the genus of ascomycete fungi that originates 
in Tibet. Traditional use in Tibetan and Chinese medicine is as an aphrodisiac and 
as treatment for fatigue, inflammatory conditions, ageing, anti-viral, anti-fungal, 
cancer and to enhance well being (Nogueira Neto et al., 2011). Research to date has 
focused on isolating the many active components of this mushroom including, 
cordycepin (3'-de-oxyadenosine), ergosterol and peptides including alpha-
aminoisobutyric acid, which have been proposed to be responsible for the 
therapeutic claims (Ng and Wang, 2005). This is the first report of investigations 
into extracts of Cordyceps and the potential for inhibition of P-gp.  
 
Inhibition of P-gp was determined with the calcein AM assay for the aqueous 
extract (IC50 90.58 ±10.1 μg/ml). The ATPase assay also confirmed that the 
aqueous but not the methanolic extract of Cordyceps can inhibit P-gp (IC50 138.5 
±14.42). This inhibition is of note as Cordyceps is a product with a very broad 
therapeutic claim.  
 
Concurrent use of this product with conventional medicines used in the treatment 
of infections and chronic inflammatory conditions such as several of the macrolide 
antibiotics including clarithromycin and roxithromycin which are also known to 
inhibit P-gp (Hughes and Crowe, 2010), could result in a significant inhibition of P-
gp. Protease inhibitors used in the treatment of HIV, including nelfinavir and 
ritonavir are also inhibitors of P-gp. With the reported benefits of Cordyceps there 
is a likelihood of concurrent use with the protease inhibitors.  
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3.12.7.2 Echinacea 
Echinacea (Echinacea species) is a genus of herbaceous plants that belongs to the 
Asteraceae family, endemic to eastern and central North America. Medicinal 
species of the Echinacea genus includes E. purpurea, E. angustifolia, and E. pallida, 
which vary in their chemical composition (Greene et al., 2007). This is of concern 
as products labelled as Echinacea may contain a wide variety of components. These 
studies utilised E. purpurea. This product is commonly taken as an immune system 
boost, for colds and flu, and to increase immune function. For this reason it is 
commonly consumed by patients diagnosed with HIV/AIDS and those receiving 
chemotherapeutic treatment.  
 
With the high risk of concurrent use of Echinacea with anti-viral and/or 
chemotherapeutic treatment, Echinacea is an important product to study in regards 
to its interaction with P-gp. As substrates for P-gp include the protease inhibitors 
indinavir and nelfinavir (Kim et al., 1998), and the chemotherapeutics doxorubicin 
and vinblastine (Zhou S et al., 2008).  
 
In our experiments, no significant inhibition was detected with any of the assays 
conducted. These findings are consistent with previous studies indicating that the 
assays used in our experiments do not overestimate the inhibition of P-gp. Studies 
with Caco-2 cells and the transcellular transport of radiolabelled digoxin (a known 
substrate for P-gp) also determined that there was no inhibition of P-gp with 
ethanol extracts of E. purpurea (Hellum and Nilsen, 2008).  
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This in vitro study is supported further by a human in vivo trial. Echinacea (267mg) 
was administered three times a day for two weeks to healthy volunteers, this 
supplementation did not alter the pharmacokinetics of digoxin (Gurley B et al., 
2008). 
 
3.12.7.3 Milk Thistle 
Milk Thistle (Silybum marianum) is a flowering plant that is native to the 
Mediterranean regions of Europe, North Africa and the Middle East. It is 
commonly used as a liver tonic.  
 
The aqueous extract showed no inhibition in either assay. This is consistent with a 
previous study that determined no interaction with P-gp with the aqueous extract in 
the Caco-2 cell transport assay (Budzinski et al., 2007). The methanolic extract 
showed inhibition in both assays with an IC50 of 96.93 ± 13.7 μg/ml in the Calcein 
assay and 135.55 ± 15.13 μg/ml in the ATPase assay.  
 
In agreement with the experimental data (Table ‎3-6), studies using 50 μM silymarin 
(a lipid soluble component of Milk Thistle) produced a significant accumulation of 
digoxin in transport assay with Caco-2 cells (Zhang and Morris, 2003). This 
inhibition was most significant for the apical to basal transport, mean transport 
ratio Papp B-A/Papp A-B 1.62 and 4.48, respectively. Indicating that silymarin is a 
substrate for P-gp and can inhibit the P-gp mediated efflux. As silymarin is lipid 
soluble it is possible that this compound is responsible for the inhibition seen. 
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In vivo studies with healthy human volunteers determined no statistically 
significant effect on digoxin pharmacokinetics with Milk Thistle (900mg a day) 
(Gurley et al., 2006a). This lack of correlation may be explained as the in vitro 
studies conducted by Zhang and Morris (Zhang and Morris, 2003) did not include 
investigations with known P-gp inhibitors. As other transporters including MRP2 
and BCRP are also present in Caco-2 cells, the more significant transport seen in 
this bi-directional assay may have been due to transporters other than P-gp. 
Conducting these studies in the presence of selecting P-gp inhibitors can confirm 
that the results are due to P-gp based efflux transport. 
 
3.12.7.4 Slippery Elm 
Slippery Elm (Ulmus rubra) is native to eastern North America, the bark is 
traditionally used to neutralize stomach acids, sooth digestive inflammation and 
alleviate digestive pain. To date limited studies have been conducted into slippery 
elm, several have investigated its use in the treatment of irritable bowel syndrome 
(Zhou S et al., 2004), but to date there are no reports relating to the 
pharmacokinetic characteristics of the herb. 
 
With the proposed use of Slippery Elm as aiding in digestive disturbances there is 
an increased risk of concurrent use of this product with patients receiving treatment 
for cancer and HIV/AIDS as these treatments are known to cause digestive 
disturbances and nausea. Slippery elm has also been investigated for its use in the 
treatment of neoplasia (Mazzio and Soliman, 2009). 
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This is of concern as P-gp is an important measurement in determining the dose 
and type of chemotherapy prescribed (Gasparini et al., 1993) and any alteration in 
the measurement of P-gp activity may lead to incorrect dosage of chemotherapeutic 
agents. 
 
These studies demonstrated that both the aqueous and methanolic extracts of 
Slippery Elm are inhibitors of P-gp. The methanolic extract of Slippery Elm was a 
more potent inhibitor (IC50 45.71 ±5.04 and 28.48 ±4.55 μg/ml in the calcein and 
ATPase assay respectively). Though the levels of inhibition by the aqueous extracts 
is also significant (IC50 69.95 ±8.44 and 51.17 ±11.81 μg/ml in the calcein and 
ATPase assay respectively). This IC50 is comparable to the known inhibitor 
fluoxetine (IC50 64.0 ± 16.8 μg/ml) (Weiss et al., 2003), and therefore should be 
considered significant and investigated further. 
 
3.12.7.5 Valerian 
Valerian (Valeriana officinalis) is a flowering plant that is native to Europe and Asia 
and is used in the treatment of insomnia. The use of Valerian is increasing and 
therefore the risk of interactions is increasing. 
 
The methanolic extract acted as a weak P-gp inhibitor (IC50 353.1 ±27.4 and 467.1 
±17.31 μg/ml in the calcein and ATPase assay respectively). In a previous study 
the IC50 could not be determined in the Caco-2 cell transport assay, but the IC25 was 
shown to be 1777 μg/ml (Hellum and Nilsen, 2008). The discrepancy in this data 
may not only be due to the different assays used but also the extraction technique 
for the herbal products.  
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In the studies conducted by Hellum and Nilsen (Hellum and Nilsen, 2008), 
ethanol was used as the extraction solvent, this would extract different components 
than the methanol used in these experiments.  
 
3.13 Conclusions 
These studies have shown that several products can act as inhibitors of P-
glycoprotein and that this inhibition may be significant for several of the extracts 
tested. Significant inhibition (IC50 <100 μg/ml) was determined for the aqueous and 
methanolic extracts of Cordyceps and Milk Thistle respectively and all the extracts 
of Slippery Elm. The methanolic extract of Slippery Elm was responsible for the 
most significant inhibition of P-glycoprotein with an IC50 of 45.71 ±5.04 μg/ml 
with the calcein AM assay and 28.48 ±4.55 μg/ml with the ATPase assay. 
 
We have also demonstrated that the data between the two assay methods utilised- 
the fluorescent based calcein AM assay and the enzyme based ATPase assay are 
comparable when being used with this limited number of complementary products. 
Previous studies have shown that these assays are often comparable (Schwab D et 
al., 2003), though difference are known to occur. Compounds that have high 
esterase activity are known to cause false positives in the calcein assay and several 
known sub stares for P-gp do not stimulate ATPase activity (colchicine, vincristine 
and methotrexate) (Litman et al., 1997). The potential for false positives or false 
negatives at the early screening stage is a risk that can be avoided by employing 
both the ATPase and the calcein AM assay simultaneously. 
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Chapter 4  - Cytochrome P450: 
Inhibition of Human Cytochrome P450 Enzymes by 
Complementary Products 
 
4.1 Introduction - Mixed Function Oxidases 
The mixed function oxidases (MFOs) were initially characterised in 1955 
concurrently by two groups (Hayaishi et al., 1955, Mason et al., 1955), and require 
both an oxidant and a reductant. Reactions catalysed by the MFOs cause one atom 
of molecular oxygen to be reduced to water whilst the other is incorporated into an 
enzyme substrate. 
  
4.2 Cytochrome P450 Monooxygenases 
The cytochrome P450 (CYP) system is comprised of a family of haeme-containing 
(haemoprotein) enzymes with closely related isoforms, belonging to the MFOs. 
This enzymatic system is found in almost all organisms, including mammals, 
bacteria and plants; being crucial for the oxidative, per-oxidative, and reductive 
metabolism of exogenous and endogenous compounds. More than >11,000 CYPs 
have been identified, and new CYPS are continuously being added (Nelson, 2009).  
 
The most common reaction catalysed by the CYP system is a monooxygenase 
reaction, shown in the equation below:  
 
where RH represents an oxidisable drug substrate and ROH the hydroxylated 
metabolite, NADPH-nicotinamide adenine dinucleotide phosphate.  
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CYPs are composed of approximately 500 amino acids and have an iron 
protoporphyrin IX as the prosthetic group, shown in Figure ‎4-1. 
 
  
Figure ‎4-1: Structure of iron protoporphyrin IX, the prosthetic group of 
cytochrome P450 (Gibson and Skett, 2001). 
 
Evidence for the existence of CYPs first emerged in the 1950s; studies revealed an 
enzyme system in liver that converted drugs and aromatic compounds into more 
polar metabolites and required NADPH (Axelrod, 1955, Brodie et al., 1955). An 
understanding of the biochemical nature of CYPs was gained from work initially 
involving liver pigments. It was observed in liver microsomes that a red-brown 
pigment when reduced by NADPH could be detected complexed with carbon 
monoxide due to its characteristic absorption peak at 450 nm (Garfinkel, 1958, 
Klingenberg, 1958).  
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This peak, from which CYPs gain their name, is due to the iron contained in the 
haeme prosthetic group, which is normally in the oxidized state, this absorbs light 
at a maximum wavelength of 418 nm but when reduced produces the peak at 450 
nm. With the use of detergent solubilisation of microsomes, and interaction studies 
with isocyanide ligands, this pigment was ultimately characterized by Omura and 
Sato (Omura and Sato, 1964a, Omura and Sato, 1964b). It was shown that the 
pigment was a cytochrome with typical a, b and Soret absorption bands, Figure ‎4-2. 
 
 
Figure ‎4-2: Typical absorption spectra for cytochrome P450. Carbon monoxide 
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4.3 Cytochrome P450 Superfamily 
4.3.1 CYP Families 
The CYP enzymes have been subdivided into families and subfamilies based on 
similarities in their amino acid sequence. Isoenzymes with 40% similarity are 
grouped in families denoted by a number i.e. CYP1 or CYP2. Isoenzymes within a 
family that have greater than 55% sequence similarity are grouped in a subfamily 
designated by a capital letter i.e. groups of family CYP2 are known as CYP2C, 
CYP2D, CYP2E. Individual isoenzymes that have been specifically identified are 
given a further number i.e. CYP2E1. 
 
To date there have been 107 genes identified encoding for CYPs in humans, with 
18 families and 45 subfamilies. Of the genes identified, 57 have been isolated, 
identified and characterised, most appear to be expressed primarily in the 
endoplasmic reticulum. Table ‎4-1 summarises information for the known human 






Table ‎4-1: Human cytochrome P450 genes. The 57 CYPs isolated in humans are shaded based on catalytic activities. Information collated 
from various sources: Number of amino acids, substrates, inducers and inhibitors (Cytochrome P450 Knowledgebase, 2006), tissue sites, 
subcellular location and typical reactions (Guengerich, 2005), with additional typical reactions from (Weizmann Institute of Science, 2009) and 
the classification (Klaassen, 2008). 
CYP Amino 
acids 
Tissue sites Subcellular 
locationa 
Classification Typical reactionb Substrates Inhibitors Inducers 
1A1 512 Lung, extra-hepatic sites. 
Peripheral blood cells. 
ER Xenobiotics Benzo[]pyrene 3-hydroxylation 141 96 100 
1A2 515 Liver ER Xenobiotics Caffeine N3-demethylation 246 208 48 
1A8 379        
1B1 543 Extra-hepatic sites, lung, 
kidney 
ER Xenobiotics 17-oestradiol 4-hydroxylation 78 47 35 
2A6 494 Liver, lung, extra-hepatic 
sites 
ER Xenobiotics Coumarin 7-hydroxylation 120 93 9 
2A7 494  ER Unknown  2   
2A13 494 Nasal tissue ER Xenobiotics Activation of 4-(methylnitrosamino)-1-(3- 
pyridyl)-1-butanone (NNK) 
15 1  
2A18         
2B6 491 Liver, lung ER Xenobiotics (S)-Mephenytoin N-demethylation 136 58 27 
2B7 377        
2C8 490 Liver ER Xenobioticsc Taxol 6-hydroxylation 110 64 11 
2C9 490 Liver ER Xenobioticsc Tolbutamide methyl–hydroxylation 215 214 30 
2C10 485     9 7  
2C17 468        
2C18 490 Liver ER Xenobiotics  37 1  
2C19 490 Liver ER Xenobiotics (S)-Mephenytoin 4’-hydroxylation 187 137 15 
2C56 70        








Tissue sites Subcellular 
locationa 
Classification Typical reactionb Substrates Inhibitors Inducers 
2C58 96        
2C59 114        
2C60 56        
2C61 59        
2C62 183        
2C63 56        
2C64 73        
2D6 500 Liver ERd Xenobiotics Debrisoquine 4-hydroxylation 302 253 8 
2D7         
2D8         
2D31 43        
2E1 493 Liver, lung, other tissues ER Xenobiotics Chlorzoxazone 6-hydroxylation 161 102 28 
2F1 491 Lung ER Xenobiotics 3-Methylindole activation 6 1  
2G1 44        
2G2 501        
2J2 502 Lung ER Xenobioticsc Arachidonic acid oxidations 6 2  
2R1 506  ER Vitamin D Vitamin D hydroxylation    
2S1 504 Lung ER Unknown Benzo[a]pyrene-trans-7,8-dihydrodiol  
hydroxylation 
   
2T2 468        
2T3 344        
2U1 539  ER Unknown Fatty acids hydroxylation. 4   
2W1 495  ER Unknown  3   
3A3 503     13 2 9 
3A4 503 Liver, small intestine ER Xenobioticsc Testosterone 6-hydroxylatione 636 384 129 
3A5 502 Liver, lung ER Xenobiotics Testosterone 6-hydroxylation 59 12 15 
3A7 503 Foetal liver  ER Xenobiotics Testosterone 6-hydroxylation 34 8 8 
3A43 524 mRNA in gonads (ER) Unknown Testosterone hydroxylation# 3 2  
3A51         








Tissue sites Subcellular 
locationa 
Classification Typical reactionb Substrates Inhibitors Inducers 
3A53         
3A54 32        
3A55 39        
4A11 521 Liver ER Fatty acids/ 
Eicosanoids 
Fatty acid -hydroxylation 9 3 10 
4A20 504        
4A22 519  ER Unknown Fatty acid -hydroxylation#    
4A26         
4A27         
4B1 511 Lung ER Fatty acids/ 
Eicosanoids 
Lauric acid -hydroxylation 12 2  
4F2 520 Liver ER Fatty acids/ 
Eicosanoids 
Leukotriene B4 -hydroxylation 14 1 5 
4F3 520 Neutrophils ER Xenobioticsc Leukotriene B4 -hydroxylation 14 1 1 
4F8 520 Seminal vesicles ER Fatty acids/ 
Eicosanoids 
Prostaglandin -2 hydroxylation 6   
4F10 125        
4F11 523 Liver ER Unknown Arachidonic acid -, -2 hydroxylation 5   
4F12 458 Liver ER Fatty acids/ 
Eicosanoids 
Arachidonic acid -, -2 hydroxylation (?)# 8   
4F22    Unknown 12(R)-lipoxygenase pathway. (?)#    
4F24 473        
4F25 109        
4F26 101        
4F27 109        
4F29 156        
4F30 78        
4F31         
4F32 152        
4F33 76        








Tissue sites Subcellular 
locationa 
Classification Typical reactionb Substrates Inhibitors Inducers 
4F35 77        
4F36 61        
4V2 539   Unknown Fatty acid -hydroxylation#    
4X1 506   Unknown    2 
4Z1 503   Unknown     
4Z2 505        
5A1 533 Platelets ER Fatty acids/ 
Eicosanoidsf 
Thromboxane A2 synthase reaction 4 8 2 
7A1 504 Liver ER Bile acid Cholesterol 7-hydroxylation 6 12 4 
7B1 506 Brain ER Bile acid Dehydroepiandrosterone 7-hydroxylation 6 3  
8A1 500 Aorta, others ER Fatty acids/ 
Eicosanoidsf 
Prostacyclin synthase reactiong 3 2  
8B1 462 Liver ER Bile acid 7-hydroxyprogesterone 12-hydroxylation (?) 1 6  
11A1 521 Adrenals, steroidogenic 
tissues 
Mit Steroidogenic Cholesterol side chain cleavage 4 4  
11B1 503 Adrenals Mit Steroidogenic 11-Deoxycortisol 11-hydroxylation 5 13 1 
11B2 503 Adrenals Mit Steroidogenic Corticosterone 18-hydroxylation 7 6  
17A1 508 Steroidogenic tissues ER Steroidogenic Steroid 17-hydroxylation    
19A1 502 Steroidogenic tissues,  
adipose, brain 
ER Steroidogenic Androgen aromatization 3 11  
20A1 145   Unknown     
21A1 495      3   
21A2 494 Steroidogenic tissues ER Steroidogenic 17-Hydroxyprogesterone 21-hydroxylation 1   
21B0 495     1   
24A1 513 Kidney Mit Vitamin D 25-Hydroxyvitamin D3 24-hydroxylation 8 3 1 
26A1 497 Several ER Retinoic acid Retinoic acid 4-hydroxylation 4 1 2 
26B1 512 Brain ER Retinoic acid Retinoic acid 4-hydroxylation 2 1  
26C1 199  (ER?) Vitamin D Retinoic acid 4-hydroxylation# 3 1 1 
27A1 531 Liver Mit Bile acidi Sterol 27-hydroxylation 13 4 6 
27B1 508 Kidney Mit Vitamin D Vitamin D3 1-hydroxylation 4 1 1 








Tissue sites Subcellular 
locationa 
Classification Typical reactionb Substrates Inhibitors Inducers 
39A1 582 Liver (?) ER Bile acid 24-Hydroxycholesterol 7-hydroxylase 2   
46A1 516 Brain ER Bile acid Cholesterol 24-hydroxylation (?) 8   
46A4 101        
51A1 509 Liver, testes ER Bile acidj Lanosterol 14-demethylation 5 4 2 
51P1 513        
51P2 516        
51P3 514        
 
aER- endoplasmic reticulum (microsomal), Mit = mitochondria 
bIf known 
cAlso involved in fatty acid and eicosanoid metabolism 
dMainly endoplasmic reticulum, some detected in the mitochondria 
eAlso involved in bile acid synthesis 
fThromboxane A synthase (TBXAS1) 
gProstaglandin I2 (prostacyclin) synthase (PTGIS) 
hAlso involved in retinoic acid metabolism 
iAlso involved in vitamin D metabolism 
jAlso involved in cholesterol biosynthesis 
#Information from (Weizmann Institute of Science, 2009). 
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4.4 Function of CYPs 
Of the CYPs with known catalytic activities, 14 are involved in steroidogenesis, 4 in 
aspects of metabolism of vitamins, 5 in eicosanoid metabolism, 4 have fatty acids as 
their substrates and 15 catalyse transformation of xenobiotic chemicals (Table ‎4-1). 
Those classified as xenobiotic transforming are mainly in the families 1-3 and 
discussed in greater detail (section ‎4.9, ‎4.10 and ‎4.11 respectively).  
 
The CYP catalytic cycle leading to substrate oxidation is complex and may not 
necessarily take place in the linear fashion shown in Figure ‎4-3. Substrate binding, 
which is shown (in this figure) to occur prior to the reduction of the haeme iron 












Figure ‎4-3: The catalytic cycle, adapted from Gibson and Skett (Gibson and Skett, 2001). Where RH represents the drug substrate and ROH 
the corresponding hydroxylated metabolite.   
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4.4.1 Drug Metabolism 
It has been shown that 75% of all drugs can be metabolised by 3 CYPs (CYP3A4, 
CYP2D6 and CYP2C9) (Rendic, 2002), and a set of 6-7 CYPs (CYP1A1, 
CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 
CYP2E1 and CYP3A4) will account for 90-95% of all drug metabolism (Evans and 
Relling, 1999) (Figure ‎4-4). CYPs are involved in the metabolism of 78% of the 200 
top selling prescription medications in the United States (Zanger et al., 2008, Evans 
and Relling, 1999). 
 
The relative contributions of these xenobiotic-metabolising CYPs are, to some 
extent, a function of the relative abundance, although there are some important 
exceptions. The patterns reported for human liver do not necessarily apply in other 
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Figure ‎4-4: Estimated contribution of individual human cytochrome P450 isoforms 
to the metabolism of the 200 top selling drugs. Adapted from Evans and Relling 















 Chapter 4- Cytochrome P450 Inhibition   141 
4.5 Regulation of CYPs 
The regulation of CYP enzymes is controlled by several factors including age, 
hormones (sex steroids, growth hormones, thyroid hormones), diet, nutritional and 
disease status.   
 
4.5.1 Factors that Regulate CYPs 
4.5.1.1 Age 
Microsomal protein content changes with age, neonates have an average of 26 
mg/g liver (Hines, 2008), the average for a 30 year old is 40 mg/g liver with a 
decline by the age of 60 to an average of 31 mg/g liver (Barter et al., 2007b).  
 
4.5.1.2 Hormonal Factors  
The hormones of the pituitary, adrenal, testes and ovaries are predominantly 
involved in the developmental control and sexual dimorphism of the CYPs. The 
differing patterns of growth hormones are known to cause the induction 
(section ‎4.7) or repression of some CYP isoenzymes.  
 
For example continuous low levels of growth hormone in women causes a 
reduction in CYP2C1 and an increase in CYP2C12 by altering gene transcription 
(Gibson and Skett, 2001).  As pregnancy alters the hormone status, in particular the 
increase in progesterone (and its metabolites) in the mother’s circulation and the 
breast milk may inhibit drug metabolism. During pregnancy, elimination of drugs 
metabolised by CYP2A6, CYP3A4, CYP2D6 and CYP2C9 is increased, whilst 
elimination of CYP1A2 and CYP2C19 substrates is decreased (Dempsey et al., 
2002, Anderson, 2005, Hodge and Tracy, 2007). 
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4.5.1.3 Diseases  
As the liver contains the greatest concentration of CYPs, diseases affecting the liver 
including cirrhosis, alcoholic liver disease, hepatitis and hepatocarcinoma all alter 
the level and activities of the CYPs and therefore drug metabolism. CYP activity 
may also be decreased due to altered hepatic blood flow and hypoalbuminaemia.  
Infection and/or inflammation can alter the activity and expression levels of CYPs 
in the liver as well as extra-hepatic tissues such as the kidney and brain (Renton, 
2005). Known agents that can alter CYP levels include viruses (Hepatitis A, 
Influenza A and B), bacteria (Helicobacter pylori, Listeria monocytogenes) and 
inflammatory agents (vaccines and tissue injury) (Devchand et al., 1996). 
 
Generally this infection/inflammation results in an inhibition of activity 
(section ‎4.8) but in some circumstances may lead to induction (section ‎4.7). The 
latter is particularly seen with the CYP4A family. Under inflammatory conditions 
this enzyme family which is predominantly involved in fatty acid hydroxylation 
(Table 4-1), is induced, it has been proposed that this is an important step in the 
termination of the inflammatory eicosanoids (Morgan, 1997). 
 
4.5.1.4 Diet and Nutrition 
The CYPs are highly responsive to nutrient (protein, carbohydrates, fat, vitamins 
and minerals), and non-nutrient factors (phytochemicals, antioxidants, flavours and 
agents including tobacco smoke and pesticides) present in the diet (Gibson and 
Skett, 2001, Parke and Ioannides, 1994). 
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In rodents, the activities of hepatic MFOs are known to increase up to 30% when 
the dietary protein content is increased (Kato et al., 1980), conversely rats fed a 
low-protein diet are known to have decreased drug metabolism capability (Gibson 
and Skett, 2001). Vitamin A and its metabolites are known to affect drug 
metabolism, ligands that bind to the retinoid X receptor stimulate CYP2B1, 
CYP2C11, CYP3A and CYP4A, but ligands for the retinoic acid receptor decrease 
CYP1A2 (Howell et al., 1998, Gibson and Skett, 2001).  
 
4.5.1.5 Environmental Factors 
Lead has been shown to decrease CYP1A1 activity in isolated human hepatocytes 
(Vakharia et al., 2001a), and mercury is a known potent inhibitor of CYP1A2 
(Vakharia et al., 2001b). Inhibition of CYP1A1 by heavy metal contamination 
either from diet, environmental exposure and even as components of 
complementary products may therefore cause adverse drug interactions with 
therapeutic agents that are metabolised by the CYP1 family including the anti-
cancer agents 5-fluorouracil (Yoshisue et al., 2001), and the anti-malarial drug 
quinidine and quinine (Granvil et al., 2002). As heavy metals can accumulate over 
time, cumulative exposure becomes important to consider. 
 
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) a polycyclic herbicide is known to 
affect both phase I and II metabolism, it causes induction of the metabolism of 
polycyclic hydrocarbons and the enzymes UDP-glucuronsyltransferase and 
glutathione-S-transferase (GST) (Gibson and Skett, 2001). TCDD is known to 
induce CYP1A1 via activation of the aryl-hydrocarbon receptor (Nebert et al., 
2000).  
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4.6 Genetic Polymorphism 
Genetic polymorphism is a common phenomenon in the CYP superfamily, and is a 
major cause of inter-individual and ethnic differences in the rates (which can vary 
by more than 100-fold) at which individuals metabolise drugs. The occurrence of 
different gene variants translates into four major phenotypes: 
 Poor metabolisers (PMs): Carrying two defect alleles and therefore completely 
lacking in enzyme activity. 
 Intermediate metabolisers (IMs): Heterozygous for a defect allele or carrying 
two alleles resulting in enzyme with decreased activity. 
 Extensive metabolisers (EMs): Carrying two functioning alleles. 
 Ultrarapid metabolisers (UMs): Carrying more than 2 active gene copies.  
 
To date alleles have been described for the CYP1A1, CYP1A2, CYP1B1, CYP2A6, 
CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2W1, CYP3A4, CYP3A5, CYP3A7, 
CYP3A43, CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP5A1, CYP8A1, 
CYP19A1, CYP21A2, and CYP26A1 genes (http://www.cypalleles.ki.se). The 
different polymorphic variants are designated by the addition of an asterisk 
followed by a number for example, CYP2D6*1. 
 
Toxicity can arise depending on the phenotype. With PMs, a xenobiotic may 
accumulate, or in the case of a pro-drug, therapeutic efficacy may be compromised 
due to a lack of activation. Alternatively toxicity may arise in the UMs due to the 
accumulation of an active or reactive metabolite or therapeutic efficacy may be 
decreased due to the rapid clearance of a xenobiotic.  
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The number of alleles varies for each CYPs and is shown in Figure ‎4-5. CYP2D6 
and 21A2 have the greatest level of polymorphism. 
 
 
Figure ‎4-5: Frequency of alleles identified for human cytochrome P450s. The 
number of alleles includes haplotypes, normal variants, gene deletions, pseudo 
gene-derived mutations, combinations of pseudo-derived mutations and rare 
mutations and combinations. Additionally many single nucleotide polymorphisms 
(SNPs) have been identified for which the haplotype has yet to be identified. 
Information is based on the homepage of the human cytochrome P450 (CYP) allele 
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4.7 Induction 
The ability for foreign chemicals to induce CYPs was first described in 1954 (Brown 
et al., 1954). Subsequent work demonstrated that PAHs and barbiturates increase 
enzyme activity by inducing the synthesis of enzyme protein (Conney et al., 1957, 
Conney et al., 1961). Many CYPs in humans are susceptible to induction including 
CYP1A, CYP2A, CYP2B, CYP2C, CYP2E and CYP3A. To date induction of 
CYP2D6 has not been identified.  
 
The induction of CYPs can have a major impact on drug metabolism, 
pharmacokinetic properties, and drug-drug interactions, on the toxicity and 
carcinogenicity of foreign chemicals, and on the activity and disposition of 
endogenous hormones (Conney, 1982). It is now known that a wide range of 
chemicals are capable of causing induction including therapeutic agents, pesticides, 
food additives, industrial chemicals, diet, natural products and environmental 
pollutants (Pelkonen et al., 2008).  
 
Induction can arise as a consequence of increased synthesis, decreased degradation, 
activation of pre-existing components or a combination of these processes. 
Induction is said to occur when there is an increase in the amount and activity of 
enzyme. The time for induction is not only dependent on the half-life of the 
inducing agent but also the time course for enzyme degradation production. The 
two main mechanisms by which CYP induction occurs are: 
1) Nuclear receptor-mediated induction. Transcriptional gene activation is the 
most common mechanism for CYP induction (section ‎4.7.1.1).  
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2) Stabilization of the mRNA or enzyme. For example, troleandomycin 
induces rat CYP3A by decreasing the rate of CYP3A protein degradation 
with no increase in the rate of protein synthesis (Watkins et al., 1986). 
 
Though induction of CYPs is highly conserved, species differences are known 
(Dickins, 2004, Hewitt et al., 2007). The transcription factors encoded for by the 
nuclear receptors are the molecular basis of species differences.  
 
4.7.1 Nuclear-Receptor Family 
The nuclear receptor (NR) superfamily codes for transcription factors that 
transform extra-cellular and intra-cellular signals into cellular responses by 
triggering the transcription of target genes, including the expression of phase I and 
II enzymes and transporters. 
 
The NR super-family consists of a large group of transcription factors, including the 
aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR, NR1l3), 
pregnane X receptor (PXR or the human orthologue SXR; NR1l2), bile-activated 
farnesoid X receptor (FXR, NR1H4), peroxisome proliferator-activated receptor 
(PPAR), cholesterol-sensing liver X receptor (LXR, NR1H2/3), thyroid hormone 
receptors (TR), the retinoic acid receptors (RAR), hepatic nuclear factor (HNF) 
family members, glucocorticoid receptor (GR), and  the CCAAT/enhancer-binding 
proteins (C/EBPs) (Tompkins and Wallace, 2007, Pelkonen et al., 2008, 
Honkakoski and Negishi, 2000).  
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CYP genes are able to respond to both endogenous and exogenous signals by 
changes in CYP gene expression, and also to modulate the strength and duration of 
these signals and even to form new signalling molecules through CYP-mediated 
metabolism. These signalling molecules may then exert their function via the 
ligand-dependent NRs. (Honkakoski and Negishi, 2000). Not all of the NRs listed 
above are involved in CYP induction. AhR, PXR/ SXR, and CAR have been 
identified as the xenosensors; the others are not primarily activated by xenobiotics. 
 
4.7.1.1 Nuclear-Receptor Mediated Induction 
The NRs, AhR and CAR are localized in the cytoplasm of hepatocytes and once 
activated are translocated to the nucleus, whilst PXR has been identified in the 
cytoplasm but is mainly located in the nucleus (Richter et al., 2001, Kawana et al., 
2003, Squires et al., 2004, Amacher, 2010). In the absence of a ligand, the NRs are 
associated with co-repressor complexes, conferring a basal level of transcription 
(Figure ‎4-6).  
 
With ligand binding to the ligand-binding domain of the NRs, conformational 
changes occur leading to the release of co-repressors and recruitment of co-
activators. Recruitment of co-activators and a dimerization partner (retinoid X 
receptor, RXR, for CAR/PXR and the AhR nuclear translocator, ARNT, for AhR) 
leads to chromatin remodelling and subsequent transcriptional activation. 
Regulation of gene transcription is achieved through binding of the nuclear receptor 
DNA binding domain to respective DNA response elements present in the 
promoter region of the target CYP gene (Amacher, 2010). 
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Figure ‎4-6: Receptor-mediated mechanism of CYP enzyme induction. Adapted 
from Hewitt (Hewitt et al., 2007). AhR- aryl hydrocarbon receptor, Arnt- AhR 
nuclear translocator, CAR- constitutive androstane receptor, PXR- pregnane X 
receptor, RXR- retinoid X receptor, X- xenobiotic/chemical inducer. 
 
4.7.1.2 AhR  
The aryl hydrocarbon receptor (AhR) is a basic helix-loop-helix protein that belongs 
to the family of PAS (PER- Drosophila period clock protein, ARNT-AhR nuclear 
translocator, SIM- Drosophila single-minded protein) domain transcription factors 
which binds dioxins and aromatic hydrocarbons (Gu et al., 2000, Poland and 
Glover, 1976).  
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The AhR and the AhR nuclear translocator, both present in high levels in placental 
tissue, (Hakkola et al., 1997, Manchester et al., 1987), control expression and 
activity of the isoenzymes belonging to the CYP1 family.  
 
4.7.1.3 CAR 
The constitutive active/androstane receptor (CAR) is located in the cytosol and 
when activated by phenobarbital induces CYP2B. It is now known that activated 
CAR induces many enzymes and transporters, including those that encode for the 
expression of CYP2B, 2C, 3A, NADPH-cytochrome P450 reductase, 
sulfotransferases, glucoronsyltransferases and glutathione-S-transferase, and 




The pregnane X receptor (PXR) also known as PAR, SXR and NR1I2 activates 
CYP3A genes in response to diverse chemicals including natural and synthetic 
steroids (Zhou et al., 2009a, Lehmann et al., 1998, LeCluyse, 2001, Istrate et al., 
2010). Unlike the other nuclear receptors, PXR has more divergence across the 
species with the ligand binding domain having only 70-80% homology (LeCluyse, 
2001, Lehmann et al., 1998) which accounts for the species differences seen, for 
example rifampicin is an inducer of CYP3A in humans and rabbits but not rodents 
(Waxman, 1999). 
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4.7.2 Post-Transcriptional Induction 
Post-transcriptional regulation is known to occur, with CYP2E1 being mainly 
regulated at this level. Xenobiotics responsible for the regulation of CYP2E1 
include ethanol, acetone and isoniazid. It has been proposed that these agents work 
by enzyme stabilization and therefore prevention of the degradation of the CYP2E1 
enzyme (Song et al., 1989, Carroccio et al., 1994).  
 
4.8 Inhibition 
Inhibition of metabolism may in general mean an acute decrease of metabolism of a 
particular substrate by another simultaneous present chemical (concurrent 
administration) or a time-dependent decrease in the amount of drug metabolizing 
enzyme by several factors such as chemical injury or a disease process. Specifically, 
inhibition of CYPs can occur at several stages of the catalytic cycle (Figure ‎4-3), 
this may be at the point of substrate binding; the reduction of the ferrous form by 
NADPH-cytochrome P450 reductase; the binding of molecular oxygen; the point of 
substrate oxidation; interference with the electron supply (from P450 reductase 
and/or cytochrome b5); the point of product release.  
 
The inhibition of any CYP isoenzyme may be clinically significant; the degree of 
significance and the potential for significance is determined by several factors: 
 Therapeutic index (TI) of the drug/xenobiotic.  
o Drugs with a narrow TI have an increased risk of adverse reactions.  
 Proportion of metabolism of the drug conducted by the inhibited pathway.  
o Many drugs are capable of being metabolised by an alternate and/or 
secondary pathway(s). 
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 Affinity constant (Ki) of the inhibitor relative to the affinity constant (Km) of 
the drug.  
o An inhibitor may have a much greater affinity for a CYP catalytic site than 
the drug/xenobiotic of interest.  
 Whether or not the drug is metabolised to a pharmacologically active or toxic 
metabolite by the inhibited enzyme.  
 Liver damage. 
o Whilst this is not truly an inhibition of CYP enzymes, destruction of hepatic 
tissue causes a decrease in CYP enzymes available. 
 
As CYPs have broad substrate specificity, competition between substrates for the 
same enzyme occurs. Such competition depends on their relative affinities and 
inhibitory potencies. Additionally inhibition is dose related; at low concentrations 
the inhibitor may be relatively selective for a single CYP, whilst at high 
concentrations, the inhibitor may be relatively non-selective and several CYP 
enzymes may be inhibited. The inhibition of CYPs can be broadly divided into two 
categories; irreversible and reversible. The distinction between these two groups is 
relative and can be difficult to determine if the inhibitor binds tightly to the enzyme 
and is slowly released (Wienkers and Heath, 2005).  
 
4.8.1 Irreversible Inhibition 
Irreversible inhibition occurs with competitive/non-competitive co-substrates. 
There are two basic processes that lead to irreversible inhibition:  
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 Autocatalytic inactivation- (or suicide inhibition) occurs when a reactive 
drug metabolite binds to CYP and alters the structure of the CYP 
irreversibly. The inhibition of CYP1A2 by furafylline is a classical 
autocatalytic inactivation reaction. (Ortiz de Montellano et al., 1979, Yin et 
al., 2000, Kunze and Trager, 1993). Additionally drugs that contain terminal 
olefinic or acetylinic substituent’s are likely to be suicide substrates of CYPs 
(Hasler et al., 1999). 
 Complexation of reactive intermediates occurs when drug metabolites are 
formed that bind tightly to the CYP haeme moiety. After formation, the 
complex between the CYP and the metabolite intermediate is quite stable. 
The insecticide piperonyl butoxide is a classic example of this (Hasler et al., 
1999, Murray and Reidy, 1990). The most significant class of drugs that 
form metabolite-intermediates is the alkylamines (Hasler et al., 1999). 
 
The major distinction between autocatalytic inactivation and complexation of 
metabolic intermediate, is that in the latter case the haemeprotein is rendered 
catalytically inert, but not destroyed. As the CYP must be reactivated or re-
synthesized to restore activity, irreversible inhibition is said to be long lasting 
(Pelkonen et al., 2008, Halpert, 1995, Kent et al., 2001). 
 
4.8.2 Reversible Inhibition 
Reversible inhibitors (or direct inhibitors) differ from irreversible inhibitors in that 
they act fast and do not permanently destroy the enzyme (Lin and Lu, 1998, 
Hollenberg, 2002, Pelkonen et al., 2008).  
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They bind to the active site with varying affinities and compete with substrates 
(Pelkonen et al., 2008). This includes agents that bind to the hydrophobic regions of 
the active site, or coordinate to the haeme iron atom or, enter into specific 
hydrogen bonding or ionic interactions with active-site-residues (Correia and Ortiz 
de Montellano, 2005, Lewis and Ito, 2010, Murray and Reidy, 1990).  
 
Reversible inhibition can be further subdivided into the following categories: 
 Competitive inhibition 
- competition between a substrate and the inhibitor to bind to the same 
position on the active site of the enzyme. 
 Non-competitive inhibition 
- the active binding site of the substrate and inhibitor is different from 
each other. 
 Uncompetitive inhibition 
- the inhibitor binds to the enzyme-substrate complex, but not to the 
free enzyme entity.  
 Mixed type inhibition 
- both competitive and non-competitive inhibition is observed. This is 
the most frequently observed type of inhibition (Madan et al., 2002). 
 
4.9 CYP1 Family 
This family has been identified in 41 species and in humans contains 2 subfamilies 
(CYP1A and 1B) and is encoded by 4 genes (Cytochrome P450 Knowledgebase, 
2006, Nelson, 2009). The human CYP1 family consists of three enzymes, CYP1A1, 
CYP1A2 and CYP1B1, although all three enzymes are not expressed in all tissues.   
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All mammalian species possess two inducible CYP1A enzymes, CYP1A1 and 
CYP1A2, which share approximately 70% amino acid sequence identity. CYP1A1 
is readily detectable in the lung (Shimada et al., 1992), intestine and skin (Shimada 
et al., 1996), lymphocytes (Vanden Heuvel et al., 1993) and placenta (Fujino et al., 
1984), particularly from cigarette smokers.  It is also expressed in foetal liver 
(Kitada et al., 1991) but not adult liver. It can be induced in primary human 
hepatocyte cultures (Liu et al., 2006).  
 
4.9.1 CYP1A2 
CYP1A2 accounts for approximately 5-10% of drug metabolism, (Figure ‎4-4), and 
10-15% of total CYP content, with individual levels varying approximately 40 fold 
(Guengerich, 2005). Variation in the elimination of drugs metabolised by CYP1A2 
has been attributed to both genetic and environmental factors. 
 
4.9.1.1 Sites of Expression 
CYP1A2 is almost exclusively expressed at low levels in the liver. CYP1A2 is not 
expressed in extra-hepatic tissues; therefore, in humans, CYP1A2 and CYP1A1 can 
be considered hepatic and extra-hepatic enzymes, respectively.  
 
4.9.1.2 Regulation and Polymorphism 
The gene for CYP1A2 is located on chromosome 15 at location 15q24.1 and 36 
allelic variants are known (Figure ‎4-5). CYP1A2 is induced through AhR-mediated 
transactivation following ligand binding and nuclear translocation, and is induced 
by PAHs and TCDD (Nebert et al., 2000). Consumption of charcoal- broiled meat 
for 7 days can induce CYP1A2 (Fontana et al., 1999). 
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In human liver microsomes, a large (10- to 80-fold) inter-individual variability in 
the activity of CYP1A2 has been observed using various probes (Gunes and Dahl, 
2008). These findings may reflect a genetically determined difference in constitutive 
and/or inducible CYP1A2 gene expression. Of the polymorphic alleles showing 
variability in the promoter region, only CYP1A2*1K has been associated with 
altered enzyme activity, with 40% lower inducibility (Aklillu et al., 2003).  
 
4.9.1.3 Substrates and Reactions 
Model substrates and their reactions include caffeine (caffeine N3-demethylation), 
theophylline (theophylline N-demethylation) and phenacetin (phenacetin O-
deethylation). The CYP1 family is important in the catalysis of carcinogen 
bioactivation reactions, such as PAH epoxidation and aromatic/heterocyclic amine 
N-hydroxylation (Nebert et al., 2004). Importantly, all members of the CYP1 
family are active in the metabolism of PAHs to intermediates that can bind to 
DNA, if the damage is unrepaired, this may produce mutations involved in 
neoplasmic transformation (Baird et al., 2005). 
 
4.9.1.4 Inhibitors 
Several CYP1A2 inhibitors are known from clinical work, including furafylline 
(Ortiz de Montellano et al., 1979, Kunze and Trager, 1993) and isoniazid (Wen et 
al., 2002). -Naphthoflavone is a strong inhibitor as are several of the polycyclic 
acetylenes (Shimada et al., 1998). 
 
 Chapter 4- Cytochrome P450 Inhibition   157 
4.9.1.5 Clinical Issues 
Drug interactions involving CYP1A2 have been reported. High levels of CYP1A2 
activity have been associated with failure of theophylline therapy in the treatment 
of asthma (Kappas et al., 1978). Clinical studies have shown that smoking can 
increase the clearance and reduce the plasma concentrations of many therapeutic 
drugs including, theophylline, melatonin, clozapine, riluzole, lidocaine, verapamil, 
erlotinib, fluvoxamine, and ropivacaine (Zhou et al., 2010). 
 
Since CYP1A2 (and CYP1A1) catalyses the metabolic activation of PAHs and 
heterocyclic aromatic amines/amides to ultimate carcinogens, it is expected that 
induction of the enzyme is detrimental in humans exposed to high levels of PAHs 
and heterocyclic aromatic amines/amides such as by cigarette smoking.  
 
4.10 CYP2 Family 
This family has been identified in 41 species and in humans contains 13 subfamilies 
and is encoded by 36 genes (Cytochrome P450 Knowledgebase, 2006, Nelson, 
2009).  It is the largest family in terms of the numbers of isoenzymes; and is 




CYP2A6 represents less than 1% of the total enzyme in the liver (Figure ‎4-4) but 
accounts for approximately 5% of drug metabolism. It was first purified as 
coumarin 7-hydroylase and is the major enzyme responsible for the metabolism of 
nicotine (Yun et al., 1991, Nakajima et al., 1996).  
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4.10.1.1 Sites of Expression 
CYP2A6 is expressed primarily in the liver, but has also been detected in the nasal 
mucosa, trachea, lung (Ding and Kaminsky, 2003) and oesophageal mucosa 
(Lechevrel et al., 1999). 
 
4.10.1.2 Regulation and Polymorphism 
The CYP2A6 gene spans a region of approximately 6kb pairs consisting of 9 exons 
and has been mapped to the long arm of chromosome 19 (between 19q12 and 
19q13.2). CYP2A6 is subject to genetic polymorphism, with four allelic variants 
having been described and 1% of the population having an inactive variant 
(Brockmöller et al., 2000). Polymorphisms are the major factor contributing to the 
inter-individual differences in activity and expression, but dietary or environmental 
factors as well as endogenous factors such as steroid hormones are also involved. 
Studies have suggested that this variation in activity affects smoking behaviour and 
cancer susceptibility (Kamataki et al., 2005).  
 
CYP2A6 is regulated by PXR, oestrogen receptors and the glucocorticoid receptors 
(Onica et al., 2008).  Induction is known to occur with phenobarbitone. CYP2A6 is 
responsible for approximately 80% of hepatic metabolism of nicotine (Benowitz et 
al., 1994) and as smokers need to maintain levels of nicotine, increased activity of 
CYP2A6 has been linked to an increase in smoking. Tobacco is a source of 
cadmium, which is an inducer of CYP2A6 and therefore may be one of the 
mechanisms that increase smoking behaviour (Satarug et al., 2004). 
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4.10.1.3 Substrates and Reactions 
The most characteristic reaction for CYP2A6 is coumarin 7-hydroxylation (Yun et 
al., 2005). In addition to nicotine metabolism, it also metabolically activates 
tobacco-specific nitrosamines such as 4-methylnitrosoamino-1-(3-pyridyl)-1-
butanone and N-nitrosonornicotine (Tiano et al., 1993). 
 
4.10.1.4 Inhibitors 
A number of potent inhibitors with variable selectivity against CYP2A6 have been 
characterised. The most widely used in vitro inhibitors include tranylcypromine 
and methoxsalen (8-methoxypsoralen) (Pelkonen et al., 2008).  
 
4.10.1.5 Clinical Issues 
Clinical issues are often due to polymorphic variation. This variation alters the 
metabolism of substrates including therapeutic agents (halothane, valproic acid), 
toxins (nicotine, cotinine) and pro-carcinogens (Raunio et al., 2001).  
 
4.10.2 CYP2B6 
Until specific probes were developed, CYP2B6 was thought to be a minor CYP, but 
expression levels with 25-250 fold differences are now known (Aleksa et al., 2005, 
Hesse et al., 2000, Wang and Tompkins, 2008). CYP2B6 accounts for 2-10% of the 
total P450 content in human liver (Figure ‎4-4) (Wang and Tompkins, 2008, 
Shimada et al., 2004, Stresser and Kupfer, 1999) contributes to approximately 2% 
of drug metabolism but vales of 8-10% have also been quoted (Turpeinen, 2006).  
Importantly 25-30% of CYP3A4 substrates are also substrates for CYP2B6. 
(Walsky et al., 2006, Kharasch et al., 2008). 
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4.10.2.1 Sites of Expression 
CYP2B6 is expressed in the liver, though it differs from other CYPs in that it is 
located diffusely in the hepatic lobules and not in the centrilobular region (Murray 
and Reidy, 1990).  
 
CYP2B6 is also expressed in extra-hepatic sites including the brain, lung, kidney, 
intestine, endometrium, bronchoalveolar macrophages, peripheral lymphocytes and 
skin (Gervot et al., 1999, Janmohamed et al., 2001, Ding and Kaminsky, 2003).  
 
4.10.2.2 Regulation and Polymorphism 
Hepatic CYP2B genes represent the most inducible CYP isoforms by 
phenobarbital-type compounds in mammalian species (Wang and Tompkins, 
2008). The regulation of CYP2B6 transcription is thought to be one of the major 
underlying reasons for the large inter-individual variability seen.  
 
CYP2B6 is highly polymorphic with over 40 alleles identified (Figure ‎4-5), with 
various phenotypes. CYP2B6*6 is a clinically significant variant associated the slow 
metabolism of methadone, leading to increased concentrations of the drug and 
subsequent fatalities (Bunten et al., 2010).  
 
4.10.2.3 Substrates and Reactions 
CYP2B6 acts as an alternate pathway for 25% of CYP3A4 substrates. It is the 
predominant isoenzyme for the metabolism of several clinically important drugs 
including bupropion, artemisinin, propofol, methadone and pethidine (Hesse et al., 
2000, Faucette et al., 2000, Wang and Tompkins, 2008).  
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It has also been shown that CYP2B6 is able to metabolise drugs via different 
reaction pathways to other CYPs. The antiepileptic agent mephobarbital is 
metabolised by the CYP2C’s to the 4-hydroxylated metabolite but CYP2B6 
catalyses the N-demethylation of this compound (Kobayashi et al., 1999, 
Kobayashi et al., 2001). 
 
4.10.2.4 Inhibitors 
Several environmental chemicals are known to be potent inhibitors of CYP2B6, 
including the organophosphate chlorpyrifos (Abass et al., 2009). Therapeutic agents 
including the anti-platelet agents clopidogrel and ticlopidine are very potent 
inhibitors with IC50 values of 0.5 and 0.2 μM, respectively (Walsky et al., 2006). 
 
4.10.2.5 Clinical Issues 
As CYP2B6 is the major isoenzyme for the metabolism of several drugs with a 
narrow therapeutic index, the antiretroviral efavirenz for example, clinical issues 
can be life threatening. Elevated plasma levels of efavirenz can lead to CNS side 
effects and therapeutic failure (Rakhmanina and van den Anker, 2010).  
 
The anticancer agent cyclophosphamide requires activation by CYP2B6, increased 
activity increases the therapeutic effectiveness of this drug and induction of 
CYP2B6 may be used to enhance the effectiveness (Jounaidi and Waxman, 2004). 
Conversely it is logical to assume that inhibition or polymorphic variation causing 
decreased CYP2B6 activity would decrease therapeutic effectiveness.  
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4.10.3 CYP2C8 
CYP2C8 makes up approximately 7% of total microsomal human hepatic CYP 
(Figure ‎4-4) (Shimada et al., 1994, Rendic, 2002, Lai et al., 2009), and is 
responsible for approximately 1% of drug metabolism though values as high as 5% 
have been quoted (Totah and Rettie, 2005). Like all members of the CYP2C family, 
the gene for CYP2C8 is located on chromosome 10.  
 
4.10.3.1 Sites of Expression 
Expression of CYP2C8 is one of the highest in the kidney but it is expressed at low 
levels in the liver (Guengerich, 2005) Other extra-hepatic sites of CYP2C8 includes 
the adrenal glands, brain, uterus, lung, mammary gland and ovaries (Klose et al., 
1999, Guengerich, 2005). 
 
4.10.3.2 Regulation and Polymorphism 
The levels of CYP2C8 can vary 20 fold in human hepatic tissue (Bahadur et al., 
2002), and is induced by rifampicin (Rae et al., 2001). To date 14 different alleles 
have been identified (Figure ‎4-5). The most significant allelic variant is CYP2C8*3 
which occurs with high frequency and can account for a decrease in taxol 
metabolism. The level of decrease varies from 90% (Dai et al., 2001) to 25% 
(Soyama et al., 2001, Bahadur et al., 2002). CYP2C8*5 to CYP2C8*14 have only 
been detected in the Japanese population (Jiang et al., 2011). 
 
4.10.3.3 Substrates and Reactions 
The active site of CYP2C8 is a large site that can accommodate large substrates 
(Schoch et al., 2004). Therapeutic drugs metabolised by CYP2C8 include the 
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anticancer drugs taxol and paclitaxel (Rahman et al., 1994, Sonnichsen et al., 
1995), amiodarone (an antiarrhythmic drug) (Ohyama et al., 2000), troglitazone (an 
anti-diabetes drug) (Yamazaki et al., 1999), and carbamazepine (an antiepileptic 
drug) (Kerr et al., 1994). Additionally, CYP2C8 generally has low catalytic activity 
towards the known substrates for CYP2C9 and CYP2C19 (Guengerich, 2005). 
 
4.10.3.4 Inhibitors 
Inhibition of CYP2C8 is known to occur with high concentrations of 
furanocoumarins, which are present in plant products and complementary 
products. Gemfibrozil, a lipid lowering drug has also been identified as an inhibitor, 
furthermore this inhibition may be the cause for the interaction between gemfibrozil 
and the cholesterol lowering drug cerivastatin (Wang et al., 2002).  
 
4.10.3.5 Clinical Issues 
The disposition of taxol and paclitaxel may be one of the more significant clinical 
issues arising with CYP2C8. A potential interaction between the antimicrobial 
agent trimethoprim and the glucose lowering drug repaglinide has also been 
identified. Trimethoprim raises the plasma concentrations of repaglinide by 
inhibiting its CYP2C8-mediated biotransformation, this interaction increases the 
risk of hypoglycaemia (Niemi et al., 2003).  
 
4.10.4 CYP2C9 
CYP2C9 accounts for approximately 20% of total hepatic CYP content and 
approximately 15% of drug metabolism (Figure ‎4-4). 
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4.10.4.1 Sites of Expression 
CYP2C9 is considered primarily a hepatic CYP and is second to CYP3A4 in levels 
of abundance. This isoenzyme has also been detected in the small intestine, though 
variability as high as 18-fold have been reported (Ding and Kaminsky, 2003). 
 
4.10.4.2 Regulation and Polymorphism 
CYP2C9 is the only member of the CYP2C family that can be detected at 
significant levels in untreated human hepatocytes. Expression is induced by 
rifampicin, dexamethasone, phenobarbital (Raucy et al., 2002, Gerbal-Chaloin et 
al., 2001) and phenytoin (Miners and Birkett, 1998).  
 
 
CYP2C9 like other members of the CYP2C family is highly polymorphic, with over 
30 alleles identified to date (Figure ‎4-5). It is so polymorphic that up to 40% of the 
Caucasian population are carriers that encode partially defective enzymes (Rettie 
and Jones, 2005).  The CYP2C9*2 and *3 alleles (Rettie et al., 1994, Sullivan-Klose 
et al., 1996) cause reduced drug metabolic capacity. CYP2C9*5 also causes reduced 
metabolic activity, this allele has a higher frequency in the African population 
(Dickmann et al., 2001). 
  
4.10.4.3 Substrates and Reactions 
Many of the drugs metabolised by CYP2C9 have a narrow therapeutic index, 
including (S)-warfarin, tolbutamide and phenytoin (Rendic, 2002). Many of the 
anti-inflammatory agents including diclofenac and ibuprofen are also substrates for 
CYP2C9 (Rettie and Jones, 2005).  
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Using in vitro studies, CYP2C9 has also been shown to metabolise endogenous 
compounds including 5-hydroxytryptamine and linoleic acid (Fradette et al., 2004). 
 
4.10.4.4 Inhibitors 
As drugs with a narrow therapeutic index are metabolised by CY2C9, inhibition of 
this isoenzyme can cause adverse drug interactions. Many inhibitors are acidic, for 
example arylacetic acid. But neutral compounds may also bind with a high affinity 
(Miners and Birkett, 1998, Locuson et al., 2004). Sulfaphenazole is recognised as a 
highly selective competitive inhibitor of CYP2C9 (Veronese et al., 1990) with poor 
affinity for the other members of the CYP2C family (Ha-Duong et al., 2001). 
Tienilic acid is a mechanism-based inactivator (Beaune et al., 1987). 
 
4.10.4.5 Clinical Issues 
Clinical issues arising from CYP2C9 are common due to the high amount of allelic 
variance with this isoenzyme and the many substrates with a narrow therapeutic 
index that it is responsible for the metabolism of. Several NSAIDS are metabolised 
by CYP2C9, and variant alleles are more frequent in patients with NSAID-induced 
acute gastric bleedings (Martínez et al., 2004). 
 
As the (S)-enantiomer of warfarin is metabolised by CYP2C9 and this enantiomer 
is predominantly responsible for the anticoagulant effect of the drug, excess 
bleeding is of concern. In particular patients with CYP2C9*2 and *3 alleles have a 
significant warfarin reduction clearance and are more susceptible to bleeding 
(Kirchheiner and Brockmöller, 2005). 
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4.10.5 CYP2C19 
CYP2C19 accounts for approximately 5% of the total hepatic content, and this 
isoenzyme accounts for approximately 3-5% of drug metabolism (Figure ‎4-4). 
  
4.10.5.1 Sites of Expression 
Significant expression of CYP2C19 has been found in the liver (Guengerich, 2005) 
but low levels have also been detected in the small intestine, with variation up to 
17-fold known (Ding and Kaminsky, 2003).  
 
4.10.5.2 Regulation and Polymorphism 
CYP2C19 is induced by several drugs including rifampicin, dexamethasone and 
phenobarbital (Raucy et al., 2002). To date more than 30 allelic variants have been 
described (Figure ‎4-5) several of which are clinically important. CYP2C19*2 and *3 
(De Morais et al., 1994), have a reduced drug metabolic capacity for therapeutics 
such as mephenytoin and omeprazole. An increase in enzyme activity is seen with 
CYP2C19*17 (Sim et al., 2006). 
 
Attention on CYP2C19 polymorphisms has increased due to the pro-drug 
clopidogrel which requires activation by CYP2C19 (Kazui et al., 2010). Patients 
with the CYP2C19*17 allele have an improved protective effect of clopidogrel 
treatment (Tiroch et al., 2010), but this also increases the risk of bleeding (Sibbing et 
al., 2010). Decreased effectiveness of clopidogrel is seen in patients with the 
CYP2C19*2 and *3 alleles (Sibbing et al., 2010, Mega et al., 2010).  
CYP2C19 is absent in approximately 5% of the Caucasian population and 20% of 
the Asian population (Wrighton and Stevens, 1992). 
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4.10.5.3 Substrates and Reactions 
Drugs metabolised by CYP2C19 are usually amides or weak bases (Lewis, 2004). 
The classic reaction is hydroxylation of the S-isomer of mephenytoin and 
omeprazole 5-hydroxylation, the later commonly employed as a probe substrate. 
CYP2C19 is responsible for the metabolism of many drugs including diazepam, 
amitriptyline, phenytoin and omeprazole (Pelkonen et al., 2008). CYP2C19 also 
oxidizes steroids, including progesterone 21-hydroxylation and testosterone 17-
oxidation (Yamazaki and Shimada, 1997), additionally it inactivates the 
organophosphate insecticide diazinon (Kappers et al., 2001). 
 
4.10.5.4 Inhibitors 
Potent and selective inhibitors of CYP2C19 are not currently known.  Omeprazole 
and tranylcypromine are used in the laboratory as inhibitors, but these compounds 
also inhibit CYP3A4 and CYP2A6, respectively (Lampen et al., 1995, Draper et 
al., 1997). CYP2C19 is also inhibited by isoniazid and ticlopidine resulting in 
clinically relevant interactions (Donahue et al., 1997, Tateishi et al., 1999, 
Salminen et al., 2011, Venkatakrishnan and Obach, 2007). 
 
4.10.5.5 Clinical Issues 
Most clinical issues arise due to the polymorphic variation. In addition to 
clopidogrel (section ‎4.10.5.2), omeprazole a known substrate for CYP2C19 is more 
effective for the treatment of ulcers in individuals with low enzyme activity (Chiba 
et al., 1993, Karam et al., 1996).  
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4.10.6 CYP2D6 
CYP2D6 accounts for approximately 4% of the total CYP in liver (Zuber et al., 
2002) (Figure ‎4-4), and for approximately 15% of drug metabolism, though figures 
as high as 30% have been reported (Zuber et al., 2002, Evans and Relling, 1999). 
The CYP2D locus is located at chromosome 22q13.1 (Kimura et al., 1989). 
 
4.10.6.1 Sites of Expression 
CYP2D6 is mainly expressed in the liver (Correia and Ortiz de Montellano, 2005), 
and in several extra-hepatic sites including the brain (with higher levels in 
alcoholics)  (Zanger et al., 2004), and then long (low levels) (Lo Guidice et al., 
1997). Levels of CYP2D6 are low in the gastrointestinal tract, but are known to 
vary at this site as much as they do in hepatic tissue (Madani et al., 1999).  
 
4.10.6.2 Regulation and Polymorphism 
To date no inducers have been identified though more than 85 allelic variants of 
CYP2D6 have been classified (Figure ‎4-5), though not all of these have a clinical 
impact.  The CYP2D6 protein and enzymatic activity is completely absent in less 
than 1% of Asian people and in up to 10% of Caucasians. This absence in activity is 
due to two null alleles, which do not encode a functional P450 protein product 
(Zanger et al., 2004). The most frequent polymorphic variant in Caucasians is 
CYP2D6*4 which occurs with a frequency of 20-25% (Zanger et al., 2004).  
 
CYP2D6*9 is characterized as an allele associated with decreased enzyme activity 
(Broly and Meyer, 1993). Increased enzyme activity is seen in patients with 
multiple copies of functional CYP2D6 (Zanger et al., 2004).  
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The most significant variants of CYP2D6 are CYP2D6*2xn, CYP2D6*4, 
CYP2D6*5, CYP2D6*10, CYP2D6*17 (Johansson and Ingelman-Sundberg, 2010). 
 
4.10.6.3 Substrates and Reactions 
Substrates for CYP2D6 have a common characteristic, a basic nitrogen at a 
distance of 5-7 Å from the site of oxidation (Wolff et al., 1985). CYP2D6 
contributes to the metabolism of dextromethorphan, debrisoquine, and bufuralol, 
which all have been used as model substrates (Pelkonen et al., 2008).  
 
CYP2D6 metabolises a number of drugs that mainly target the central nervous and 
cardiovascular systems (Michalets, 1998, Rendic, 2002, Zhou et al., 2009b), 
amongst which are many drugs with a narrow therapeutic index. This includes the 
tricyclic antidepressants, antipsychotics, opioids (codeine and tramadol) and 
amphetamines (Wang et al., 2009). 
 
4.10.6.4 Inhibitors 
Many of the inhibitors for CYP2D6 are also substrates for the isoenzyme. 
Traditionally the anti-arrhythmic drug quinidine (which is not a substrate) has been 
utilised as a highly selective CYP2D6 inhibitor. Paroxetine and cimetidine are both 
mechanism based inhibitors, with the latter also being a reversible inhibitor 
(Bertelsen et al., 2003, Madeira et al., 2004). Antipsychotics including 
chlorpromazine and haloperidol are metabolised by CYP2D6 and also 
competitively inhibit the enzyme (Shin et al., 1999). 
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4.10.6.5 Clinical Issues 
For some drugs, the role of CYP2D6 is dominant and clinical manifestations of 
genetic polymorphisms are important and even deadly (Idle et al., 1978, Köhnke et 
al., 2002). CYP2D6 was suspected to be involved in the development of 
Alzheimer’s and Parkinson’s disease but to date no clear evidence of this link has 
been found (Gołab-Janowska et al., 2007).   
 
4.10.7 CYP2E1  
CYP2E1 is found predominantly in the liver and accounts for approximately 4% of 
drug metabolism (Figure ‎4-4). CYP2E1 was first discovered in 1965 (Orme-
Johnson and Ziegler, 1965) and the human gene was purified in 1988 (Umeno et 
al., 1988).  
 
4.10.7.1 Sites of Expression 
In addition to hepatic expression, CYP2E1 is also expressed in the lung (Shimada 
et al., 1996) and oesophagus (Huang et al., 1992). It is not present in foetal liver, 
but appears within hours of birth (Vieira et al., 1996).  
 
4.10.7.2 Regulation and Polymorphism 
The regulation of CYP2E1 expression depends on transcriptional, post-
transcriptional, and post-translational factors. The human CYP2E1 gene has been 
fully sequenced and lies on chromosome 10. Several genetic variants have been 
described. These variants may account for the enhanced gene transcription that can 
lead to an increased metabolic activation of carcinogens and consequent initiation 
of malignancies (Hayashi et al., 1991, Uematsu et al., 1991). 
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CYP2E1 is unlike other CYPs in terms of regulation of protein levels and enzyme 
activity. Whilst the main control over CYPs is at the level of transcriptional 
activation, CYP2E1 activity appears to be most affected by substrate binding and 
stabilisation of the protein or other factors that stabilise its mRNA and decrease 
protein degradation (Koop and Tierney, 1990). These post-transcriptional and post-
translational levels of control may explain why polymorphisms shown to modulate 
enzyme inducibility in vitro may not have predictable consequences in vivo. 
 
4.10.7.3 Substrates and Reactions 
CYP2E1 exhibits very broad substrate specificity, with over 80 substrates known 
(Ioannides, 2008). The main function of CYP2E1 is contributing to the metabolism 
of those xenobiotics that are metabolised primarily by other CYPs. It acts as an 
alternative demethylation pathway for a variety of substrates metabolised by 
CYP3A4. The substrates of CYP2E1 usually consist of hydrophobic and low 
molecular weight compounds, such as paracetamol, chlorzoxazone, benzene, 
ethanol, carbon tetrachloride, chloroform, vinyl chloride and anaesthetics 
(enflurane, halothane, methoxyflurane) (Gonzalez, 2005).  
 
This CYP is inducible by several of it own substrates (e.g. ethanol, acetone, 
imidazole, benzene and isopropanol). The expression of the enzyme is also altered 
in response to many different conditions, including gender, circadian rhythm 
(Klingenberg, 1958), nutrition (e.g. starvation and obesity), metabolic and 
endocrine disorders (e.g. diabetes), inflammation (in response to cytokines), viral 
infections (e.g. hepatitis C) and hepatocellular carcinoma (Ioannides, 2008).  
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4.10.7.4 Inhibitors 
Several substrates for CYP2E1 also act as inhibitors for the isoenzyme, in particular 
the low molecular weight solvents (Guengerich, 2005).  
The therapeutic drug disulfiram, used in the treatment of alcohol abuse, was found 
to inhibit CYP2E1. Inhibition of CYP2E1 is associated with reduced hepatotoxicity 
from chloroform, carbon tetrachloride, acetaminophen, and NDMA in rats (Brady 
et al., 1991).  
 
4.10.7.5 Clinical Issues 
The major clinical issues involve the role of CYP2E1 in the oxidation of certain 
drugs, alcoholism, oxidative stress, and risk from cancer (Guengerich, 2005).  
Levels of CYP2E1 are highest in the centrilobular zone of the liver (Ingelman-
Sundberg et al., 1998) which is also the region of the liver that is destroyed by 
toxins such as ethanol, acetaminophen, nitrosamines and carbon tetrachloride.  
 
Paracetamol overdose is a common cause of poisoning, being the leading cause of 
acute liver failure in the United States and the United Kingdom (Chun et al., 2009). 
Studies with CYP2E1 knockout mice indicated that CYP2E1 is a major 
determinant of acetaminophen toxicity, as the toxicity was considerably attenuated 
in null animals (Lee et al., 1996). 
 
4.11 CYP3 Family 
This family has been identified in 30 species and in humans contains 1 subfamily 
and is encoded by 10 genes (Cytochrome P450 Knowledgebase, 2006, Nelson, 
2009).  The CYP3 family is represented in the liver by only one subfamily, CYP3A. 
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CYP3A is the most prominent CYP enzyme in human liver and intestine and is 
involved in the metabolism of a large number of therapeutic agents.  
 
4.11.1 CYP3A4 
CYP3A4 is the most abundant CYP in humans and as can be seen in Figure ‎4-4, is 
the major CYP involved in drug metabolism, 48%. The gene is located at 
chromosome 7q22.1 (Inoue et al., 1992). 
 
4.11.1.1 Sites of Expression 
Levels of CYP3A4 are greatest in the liver, but it is also the most abundant CYP in 
the small intestine (Guengerich, 2005). Additionally CYP3A4 is also expressed in 
the lung, stomach, colon (Ding and Kaminsky, 2003, Raunio et al., 2005)  and the 
adrenal glands (Koch et al., 2002). 
 
4.11.1.2 Regulation and Polymorphism 
CYP3A4 is degraded by a ubiquitin linked pathway (Murray and Correia, 2001) 
and regulated by PXR (see section ‎4.7.1.4). The extent of induction is highly 
variable between individuals with reports of more than 10-fold differences in the 
induction of CYP3A4 protein and mRNA in liver and intestine (Lin and Lu, 2001). 
 
Polymorphic variations are known for CYP3A4 but to date none have been found 
to be clinically important (Johansson and Ingelman-Sundberg, 2010). CYP3A4*1B 
has been reported as increasing the risk of prostate cancer (Tayeb et al., 2003), 
though other studies have failed to find a statistically significant correlation (Sarma 
et al., 2008). 
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4.11.1.3 Substrates and Reactions 
The crystal structure of CYP3A4 reveals a large active site, consistent with the 
broad range of substrates and endogenous substances catalysed by this enzyme 
(Guengerich, 2005, Rendic, 2002). To date more than 50% of the therapeutic drugs 
on the market are metabolised by CYP3A4 (Rendic, 2002).  The active site can 
accommodate a large variety of molecules based on their size, from metyrapone 
(MW- 226 daltons) to cyclosporine (MW- 1203 daltons) (Zhou, 2008).  
 
Importantly due to its size and flexibility, multiple small molecules are able to be 
present simultaneously in the active site. CYP3A4 displays a high degree of region- 
and stereo-selectivity in may reactions, for example the hydroxylation of 
testosterone (Krauser and Guengerich, 2005). One of the classic and fastest 
reactions catalysed by CYP3A4 is 6β-testosterone hydroxylation (Guengerich et al., 
1986). Bioactivation of some procarcinogens such as aflatoxin B1 (Aoyama et al., 
1990) and PAHs (Hecht, 1999) are also mediated partially via CYP3A4.  
 
4.11.1.4 Inhibitors 
Inhibition of CYP3A4 is a major issue in the pharmaceutical industry. Inhibitors of 
CYP3A4 vary widely in structure and can act in a competitive or mechanism-based 
way (Zhou, 2008, Pelkonen et al., 2008). Clinically important inhibitors include 
azole antifungals (ketoconazole and itraconazole) (Back and Tjia, 1991), macrolide 
antibiotics (clarithromycin and erythromycin) (Jones et al., 2007), antidepressants 
(fluoxetine) (Mayhew et al., 2000), calcium channel blockers (verapamil and 
diltiazem) (Yeo and Yeo, 2001, Ma et al., 2000), and steroids (gestodene and 
mifepristone) (Jones et al., 2007). 
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4.11.1.5 Clinical Issues 
Clinical issues involving CYP3A4 arise due to the large number of therapeutic 
agents that are metabolised by this isoenzyme. High levels of enzyme activity 
toward a drug will reduce bioavailability and variations in levels of CYP3A4 can 
cause problems when the therapeutic window is narrow.  
 
A major interaction occurs with cyclosporine, which is used to prevent organ 
rejection post-transplant. Cyclosporine is a substrate for CYP3A4 and will not 
reach therapeutic levels in patients with increased CYP3A4 activity (Kronbach et 
al., 1989). 
 
As CYP3A4 is also present in the small intestine, oral administration of an inhibitor 
causes a direct and high level of exposure in the intestine. Therefore, even low 
doses of a CYP3A4 inhibitor may cause drug interactions in the intestine rather 
than in the liver (Tachibana et al., 2009). 
 
4.12 Species Differences in Cytochrome P450 
Differences between species are known not only in the distribution of the various 
CYP isoenzymes and substrate specificity, but also in total CYP content. 
Importantly a high degree of sequence identity does not automatically mean similar 
catalytic activity (Guengerich, 1997), and a single amino acid substitution may give 
changes in substrate specificity (Lindberg and Negishi, 1989). Therefore 
orthologous enzymes are not always comparable for catalytic specificity (Nelson et 
al., 1993). These differences complicate the extrapolation from animal studies to 
humans.  
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With regards to species extrapolation the four points below have been proposed 
(Guengerich, 1997); subsequent work has supported these statements (Bogaards et 
al., 2000, Guengerich, 1997). 
 
 1- CYP subfamilies in which species extrapolation appears to hold well: 
  2E1. 
 2- CYP subfamilies in which some caution is required in extrapolation: 
  1A1, 1A2 and 4A. 
 3- CYP subfamilies in which more caution is advised in extrapolation:  
  2D and 3A. 
 4- CYP subfamilies for which major problems in extrapolation exist:  
  2A, 2B and 2C. 
 
With these differences in mind, investigations into CYP activity ideally should 
utilise human tissue and/or cells to avoid discrepancies with the data due to species 
differences.  
 
4.13 Methods for Investigating Cytochrome P450 Inhibition 
As shown in Figure ‎4-3, there are many steps in the CYP catalytic cycle that can be 
monitored to give an indication of inhibition, though inhibition of substrate 
metabolism is the most common method used.  There are several technologies for 
measuring the inhibition of substrate metabolism and the generation of metabolites, 
which themselves may cause inhibition.  
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4.13.1 In Vitro Methods 
In vitro systems are commonly used to study human drug metabolism to identify 
principal metabolites preferably prior to the human ADME studies (Brandon et al., 
2003, Pelkonen and Raunio, 2005, Pelkonen et al., 2005).  
Whilst this review focuses on the in vitro methods used in the investigation of CYP 
inhibition it is important to note that in vitro investigations may address several 
metabolic issues, involving CYP and the other enzymes that may be involved in 
metabolism including: 
 Drug metabolic stability and metabolic profile. 
 Metabolite identification and structure clarification. 
 Prediction of in vivo pharmacokinetic parameters from in vitro data. 
 Identification of the enzymes involved in metabolism. 
 Species comparison to aid in the selection of species for pre-clinical studies. 
 Drug interactions due to enzyme induction/inhibition. 
 Drug toxicity associated with metabolism. 
 
 
There are many systems that can be used as part of the in vitro screening for CYP 
inhibition including cDNA expression systems, microsomes, S9 fraction, cell lines 
(including transgenic cell lines) hepatocytes, liver slices, liver perfusions; each with 
their own advantages and disadvantages. Several of these systems are discussed 
below and summarised in Table ‎4-2. 
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4.13.1.1 Expression of recombinant CYPs 
Recombinant CYPs or baculovirus-mediated expression of mammalian CYPs 
(baculosomes or supersomes) were first produced in 1989 (Asseffa et al., 1989). In 
these preparations, cytochrome P450 reductase is also co-expressed, and therefore 
does not have to be added exogenously (Ong et al., 1998, Chen et al., 1997). Some 
preparations also have cytochrome b5 expressed, providing the full complement of 
CYP redox partner proteins.  
 
However, exogenous NADPH or an NADPH regenerating system (e.g., glucose-6-
phosphate dehydrogenase conversion of NADP+ to NADPH in the presence of the 
substrate glucose-6-phosphate) must be added if it is not present in the preparation 
(Taavitsainen et al., 2000).  
 
A major limitation inherent to recombinant models are that concentrations of CYPs 
are far in excess of their relative amount in the human liver and that secondary 
metabolism cannot be identified. Additionally only a single isoenzyme is expressed, 
therefore the contribution of other involved enzymes (including other CYP 
isoenzymes) is not represented. 
 
The metabolic activities of expressed microsomal CYPs and human liver 
microsomes using probe substrates have been determined to be a reasonably 
accurate model of the in vivo situation with respect to Km values, although 
considerable variability was observed with respect to V max values (McGinnity et 
al., 1999). IC50 values of reference inhibitors are also comparable between 
baculosomes and microsomes (Turpeinen et al., 2006). 
 Chapter 4- Cytochrome P450 Inhibition   179 
Pharmacogenetic variability may contribute greatly to individual variety in drug 
metabolism, this genetic variation can be investigated with baculsomes that are 
commercially available (i.e. CYP2C9*1, CYP2C9*2, CYP2D6*1 and CYP2D6*2). 
 
4.13.1.2 S9 Fraction 
The S9 fraction is obtained as the supernatant from the centrifugation of the liver 
homogenate at 9000g, for 20-30 minutes, and contains both microsomal and 
cytosolic fractions.  Compared to microsomes, human liver S9 fractions offer a 
more complete representation of the in vivo situation, as they contain a wide 
variety of oxidative (also known as Phase I) and conjugative (also known as Phase 
II) enzymes including CYPs, flavin monooxygenases (FMOs), carboxylesterases, 
epoxide hydrolase, UDP glucuronosyltransferases (UGTs), sulfotransferases, 
methyltransferases, acetyltransferases, glutathione- S -transferases and other drug-
metabolizing enzymes (Brandon et al., 2003). 
 
Although this in vitro system is more complete in terms of the number of 
biotransformation enzymes present, some metabolites may remain unnoticed due 
to reduced enzyme activity. Compared to either microsome or supersome 
preparations, S9 fractions exhibit 20–25% lower enzyme activity (Kramer and 
Tracy, 2008).  
 
4.13.1.3 Liver Microsomes 
Human liver microsomes are the most popular in vitro model for CYP kinetic 
based studies. Microsomes consist of vesicles of the hepatocyte endoplasmic 
reticulum and are prepared by differential centrifugation (Pelkonen et al., 1974). 
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Microsomal preparations contain only enzymes localised to the endoplasmic 
reticulum, which include CYPs, FMOs and UGTs.  
 
As with other preparations from human tissue the activity of microsomes can vary 
substantially between individuals (Gómez-Lechón et al., 2004). This problem, 
however, can be successfully solved by the application of pooled (from multiple 
donors) microsomes, which results in a representative enzyme activity (Araya and 
Wikvall, 1999). Besides the relatively cheap costs and the ease of use, the major 
advantage of microsomes is that they allow the influence of specific isoenzymes to 
be studied in the presence of specific inhibitors (Birkett et al., 1993).  
  
The major disadvantage of microsomes is that they cannot be used for quantitative 
estimations of in vivo human biotransformation, because CYPs and UGTs are 
enriched in the microsomal fraction and there is no competition with other 
enzymes.  
This results in higher biotransformation rates in microsomes compared to the 
human in vivo situation, but also compared to primary hepatocytes and liver slices 
(Sidelmann et al., 1996). Additionally, the absence of other enzymes (e.g., NAT, 
GST, and ST) and cytosolic cofactors can leave metabolites formed in intact liver 
cells unnoticed (Crommentuyn et al., 1998).  
 
4.13.1.4 Primary Hepatocytes  
Hepatocytes can be held in suspension, in which case they remain viable for only a 
few hours, or maintained in monolayer culture for a maximum of 4 weeks. 
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Cryopreserved hepatocytes have been shown to retain the activity of most phase I 
and phase II enzymes (Annaert et al., 2001, Silva et al., 1999).  
 
Human hepatocytes in culture show active levels of major CYPs that are involved 
in drug metabolism (Rodríguez-Antona et al., 2002, Donato et al., 1999), though 
differences amongst preparations are found due to different donors (Donato et al., 
1995, Gómez-Lechón et al., 2007, LeCluyse, 2001). As mentioned in section ‎4.5 
there are many factors that can alter the expression and activity of the CYPs but 
additional changes occur in cultures of primary hepatocytes due to the 
microenvironment that the cells are cultured in. These limitations can be quantified 
but not overcome by characterising the cells. 
 
The expression of CYPs declines during culture and cells differentiate and become 
more similar to hepatoma cell lines. There is an initial rapid loss in mRNA (20-
40%) at 4-6 hours after culturing, this loss in mRNA precedes the decrease in CYP 
protein and activity (Gómez-Lechón et al., 2004, Rodríguez-Antona et al., 2002). 
Importantly not all CYPs degrade at the same rate due to stability of the individual 
enzymes (Gómez-Lechón et al., 2007). For some CYPs this loss becomes evident 
after a few days (CYP2E1 and CYP3A4), whilst others remain unaffected 
(CYP1A2 and CYP2C9) (George et al., 1997). 
 
A comparison of cultured hepatocytes and microsomes prepared from the same 
donor showed good correlation, although the activity in microsomes was higher 
(Gómez-Lechón et al., 2004). A disadvantage in using primary hepatocytes is the 
lack of liver non-hepatocyte cells.  
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Although hepatocytes account for the vast majority of the liver volume (about 
80%), other cells such as Kupffer cells are necessary for cofactor supply (Brandon et 
al., 2003). 
 
4.13.1.5 Immortalized Cell Lines 
Different human and animal cell lines are available (http://www.lgcpromochem-
atcc.com). Because of interspecies differences, animal cell lines cannot accurately 
predict human biotransformation (section ‎4.12). Human liver cell lines can be 
isolated from primary tumours of the liver parenchyma, developed after chronic 
hepatitis or cirrhosis (Crommelin and Sindelar, 1997). The most common human 
cell lines for biotransformation studies are HepG2 (hepatocellular carcinoma) 
(Galijatovic et al., 1999, Urani et al., 1998, Walle et al., 2000, Yoshitomi et al., 
2001), BC2 (hepatoma) (Gómez-Lechón et al., 2001) and the lung-derived line 
A549 (Hukkanen et al., 2000). 
 
Recently a new human hepatoma cell line, HepaRG, was derived from a 
hepatocellular carcinoma. The HepaRG cells express a large panel of liver-specific 
genes including several CYP enzymes such as CYP1A2, CYP2B6, CYP2C9, 
CYP2E1 and CYP3A4, which is in contrast to the other hepatoma cell lines such as 
HepG2. In addition to CYP enzymes, HepaRG cells have a stable expression of 
phase II enzymes, transporters and nuclear transcription factors over a time period 
of six weeks in culture (Aninat et al., 2006, Anthérieu et al., 2010, Kanebratt and 
Andersson, 2008).The major disadvantage of these cell lines is that they are derived 
from a single donor and therefore are very limited in the genetic variability. 
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4.13.1.6 Liver Slices 
Liver slices that are prepared as ultrathin sections provide the advantage of intact 
cellular interactions and normal spatial arrangements. They are a multicellular 
three-dimensional in vitro model. Potassium, protein and ATP-levels are well 
maintained for 8-24 hours (de Kanter et al., 2002, Vandenbranden et al., 1998), 
indicating the length of time that liver slices may be viable for.  
 
As with hepatocytes, CYP activity decreases by approximately 20% in 4 hours and 
by 65% at 24 hours with no detectable activity after 96 hours (Vandenbranden et 
al., 1998). This limitation is the biggest disadvantage of using liver slices. Advances 
in cryopreservation may prolong the life of the slices enabling them to be used more 
extensively.  
 





Table ‎4-2: Comparison of human in vitro enzyme sources used for inhibition studies with cytochrome P450- modified from (Pelkonen and 
Turpeinen, 2007). 
Enzyme Source Advantages Disadvantages 
Recombinant CYP 
Enzymes 
Can be used in a high-throughput screen. 
The role of individual CYPS can be studied. 
Data can be normalized (Rodrigues, 1999). 
Able to generate useable amounts of metabolic products (Friedberg et al., 
1999, Moody et al., 1999). 
Useful for when the enzyme being investigated is not present in high levels.  
Polymorphic variants can be studied. 
IC50 values are higher than those obtained with microsomes (Ogilvie et al., 
2008). 
Single enzyme studies in isolation. 
Metabolites need to be tested separately to rule out the reaction 
with a second CYP (Parkinson et al., 2010). 
S9 fraction Contains basically all hepatic enzymes. 
Can be easily prepared, pooled from multiple donors and stored. 
Loss of architecture. 
Requires co-factor addition.  
Microsomes Can be easily prepared, pooled from multiple donors and stored. 
Contain levels of cytochrome b5 and cytochrome P450-reductase similar to 
in vivo (Foti et al., 2010). 
Allows for the investigation of intermediates and metabolites. 
Contains only phase I enzymes and UGT. 
UGT levels decline over time (Ogilvie et al., 2008) 
Requires co-factor addition. 
Substrates utilized must be specific or antibodies are required. 
Hepatocytes Cellular architecture maintained. 
Best in vitro system to determine the generation of metabolites (Dalvie et 
al., 2009).  
Can detect metabolism by non-CYP enzymes (Parkinson et al., 2010). 
Difficult to pool. 
Enzyme levels decrease over the time of culture. 
Immortalized cell 
 lines 
Cells express a large panel of liver-specific genes including several phase I, 
phase II and transporters.  
Derived from single source so polymorphic variation is not present. 
Liver Slices Contains the whole complement of drug metabolising enzymes. 
Cell-to cell architecture maintained. 
Allows for the study of induction. 
Limited viability. 
Requires healthy donors. 
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4.13.2 Humanized In Vivo Modelling 
Transgenic mice with human CYPs have been developed and can be used for CYP 
investigations, though these mice usually express only one humanised isoenzyme, 
for example CYP2D6 or CYP3A4 (Corchero et al., 2001, Robertson et al., 2003, 
Zhang et al., 2003). 
 
Chimeric mice with humanised livers can be used to predict the human in vivo 
interaction of a chemical with the CYPs and the metabolites generated. The first 
reports of substantial repopulation of a mouse liver with human hepatocytes were 
published in 2001 (Dandri et al., 2001, Mercer et al., 2001). Investigations with 
these chimeric models have identified expression of human-specific mRNA for 
CYP1A1, CYP1A2, CYP2C9, CYP2D6 and CYP3A4 (Katoh et al., 2004).  
 
In vivo studies with probe substrates (debrisoquine and warfarin) have shown 
significantly higher concentrations of their human metabolites in chimeric mice 
than in control mice, though this finding was not consistent for all investigated 
substrates (amosulalol was lower than expected) (Kamimura et al., 2010). Chimeric 
mice are also of interest as they express Phase II enzymes and the transporters 
(Strom et al., 2010) This would allow for a more detailed metabolic profile and 
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4.13.3 In Silico Modelling 
In silico modelling is a rapidly growing area in all aspects of ADME predictions. 
These approaches can be classified as ligand-based (pharmacophore and 
quantitative structure-activity relationship (QSAR)), protein-based (crystallographic 
protein and homology models), and ligand-protein interactions models (ligand-
protein docking) (Sun and Scott, 2010, de Graaf et al., 2005).  
 
In silico modelling systems are capable of predicting potential sites of metabolism 
in drug molecules and provide metabolic trees and estimate the likelihood of 
metabolite production, and potential for inhibition (Turpeinen, 2006, Pelkonen and 
Raunio, 2005). 
 
Whilst these techniques are cost efficient, rapid and allow for the exploration of 
minor structural changes, they rely on knowledge of the chemical/xenobiotic being 
investigated. In the case of complementary products, the composition is often 
unknown and complex. In silico modelling may have a role in predicting the fate of 
specific constituents of complementary products when more information is 
available, but at this stage in silico modelling can not provide predictions on the 
metabolic outcomes and kinetic behaviour of these products. 
 
4.14 In Vitro – In Vivo Extrapolation for CYP Inhibition  
In vitro studies are often used as the basis for extrapolation for in vivo predictions, 
known as in vitro to in vivo extrapolation (IVIVE). IVIVE focuses on two major 
areas, the prediction of metabolic clearance and the prediction of drug interactions. 
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Whilst there are many factors that are involved in IVIVE this section will focus on 
those that are relevant to CYP inhibition.  
 
In vitro systems utilised for CYP studies each have their own advantages and 
limitations (Table ‎4-2) with regards to extrapolation of data to the in vivo situation. 
In vitro studies are used to determine the metabolism profile of a drug including the 
metabolite profile and the time for the drug to be metabolised. From this the 
metabolic fate in vivo is predicted.  
 
The extrapolation of in vitro data to in vivo requires scaling. This scaling consists of 
several factors, including the intrinsic clearance and the prediction of hepatic 
clearance, which is then used to calculate the oral bioavailability, total body 
clearance and half-life (Pelkonen and Turpeinen, 2007). Each of the in vitro systems 
used require different scaling factors. This requires the assumption of factors 
including protein binding, distribution to other tissues, hepatic blood flow and 
extra-hepatic routes of clearance. 
 
For investigations using hepatic microsomes, values are usually reported as 
millilitres per minute per milligram of microsomal protein and scaling further to a 
rate per gram of liver requires a factor known as milligrams of microsomal protein 
per gram of liver (MPPGL). A value of 32 mg g-1 (Barter et al., 2007a, Pelkonen 
and Turpeinen, 2007) and 40 mg g-1 (Hakooz et al., 2006)  for human liver 
MPPGL has been proposed. 
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4.15 Known Inhibitions by Complementary Products 
As CYP inhibition is a major cause of adverse drug reactions, it is important to 
investigate if complementary products are able to cause inhibition. Studies 
investigating complementary products interacting with CYPs are often conflicting 
though on further investigation the source of this conflict can usually be found. 
Most commonly the products used vary (manufacturer, formulation, composition) 
and/or the concentration and preparation of extracts for in vitro tests differs. 
 
As complementary products are often complex they contain many potentially 
pharmacologically active components including essential oils, tannins, flavonoids, 
anthraquinones, alkaloids and polyphenols (Liu et al., 2006, Zhou et al., 2004, 
Zhou et al., 2005, Izzo and Ernst, 2009). Several complementary products have 
been proven to interact with CYPs, St John’s Wort (Hypericum perforatum), garlic 
(Allium sativum), liquorice (Glycyrrhiza glabra) and ginseng (Panax ginseng), though 
not all of these are inhibitors of the CYPs. St John’s Wort is known to induce 
CYP3A4 (Henderson et al., 2002) 
 
Furanocoumarins isolated from grapefruit juice are mechanism-based inhibitors of 
CYP3A4 (Tassaneeyakul et al., 2000) and resveratrol has been shown to be 
mechanism-based inhibitor of CYP1A2 and CYP3A4 (Chan and Delucchi, 2000). 
Analysis of 30 herbal plants from Indonesia demonstrated their ability to inhibit 
CYP2D6 and CYP3A4 (Subehan et al., 2006). With an increase in the incubation 
time, five plants showed more than a 30% increase in CYP3A4 mechanism-based 
inhibition, and three showed a 30% increase in CYP2D6 mechanism-based 
inhibition.  
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CYP2E1 inhibitors from natural sources include compounds found in garlic (diallyl 
sulfide, diallyl sulfoxide, and diallyl sulfone) that were shown to competitively 
inhibit CYP2E1 (Gurley et al., 2005a, Brady et al., 1991). Two clinical trials 
implied that garlic oil may selectively inhibit CYP2E1, as revealed by the decreased 
6-hydroxychlorzoxazone/chlorzoxazone serum ratios (Gurley et al., 2005a). 
Ginseng has been shown to inhibit CYP2D6 (Gurley et al., 2008). 
 
With evidence that complementary products are capable of causing CYP inhibition 
there is a need to identify those products that are most likely to cause inhibition and 
therefore be responsible for drug interactions. A rapid screening method is required 
to investigate the large number of products and the variability of the products, for 
this reason and the advantages outline in Table ‎4-2, microsomes are the ideal 
testing system.  
 
4.16 Aims of the Present Study 
The general aims of this study was to investigate 10 complementary and herbal 
products that have the potential to interact with therapeutic agents in relation to 
their ability to inhibit the CYPs involved in drug metabolism. The specific goals 
include: 
 Establishing a standard extraction method that is easily reproducible.  
 Comparison of two methods for screening for potential CYP inhibition. 
 To determine if the more rapid N-in-one cocktail method can provide 
accurate results with complex mixtures such as extracts of 
complementary products.  
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4.17 Materials and Methods 
4.17.1 Chemicals 
Bupropion and hydroxybupropion were a generous donation from 
GlaxoSmithKline (Research Triangle, NC, USA), midazolam and 1-
hydroxymidazolam were obtained from F. Hoffmann-La Roche (Basle, 
Switzerland), and omeprazole, omeprazole sulphone and 5-hydroxyomeprazole 
were obtained from Astra Zeneca (Mölndal, Sweden). The metabolite standards 6-
hydroxychlorzoxazone, desethyl amodiaquine, hydroxytolbutamide, 6-hydroxy-
testosterone and dextrorphan were purchased from BD Biosciences Discovery 
Labware (Bedford, MA, USA). Formic acid and LichroSol GG acetonitrile were 
obtained from Merck KGaA (Darmstadt, Germany). Itraconazole, ticlopidine, 
montelukast, amodiaquine, tolbutamide, sulphaphenzole, dextromethorphan, 
quinidine, chlorzoxazone, pyridine and fluconazole were all purchased from Sigma 
Chemical Co. (St Louis, MO, USA). Water was in-house freshly prepared with 
Simplicity 185 (Millipore S.A., Molsheim, France) water purification system and 
was ultra pure grade (18.2M). All other chemicals were from Sigma Chemical Co. 
(St Louis, MO, USA) and were of the highest purity available.  
 
4.17.2 Preparation of Herbal Samples 
Herbal products were purchased from local suppliers in Victoria, Australia and 
were all of commercial quality Table ‎4-3. The methanolic and aqueous extraction 
method was modified from that previously described (Unger and Frank, 2004). 
Tablets were crushed and the contents of capsules emptied, extractions were either 
water or 80% methanol to allow for the aqueous and distinctly lipophilic 
components to be separated.  
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Solvent volumes were adjusted so that standardised extracts at 100 mg of 
product/ml were obtained. This was based on the manufacturers’ stated 
concentration of the active or principle component.  
 
Extracts were agitated in a shaking water bath at 37C for 30 minutes then 
centrifuged at 2500 g for 10 minutes. Standard extracts were diluted to final 
nominal concentrations of 20, 100 and 500 g/ml. Methanol was evaporated to 
dryness under vacuum and the final volume of methanol did not exceed 1% (v:v). 
Extracts were kept in the dark and shelf life set at 2 weeks. 
 
4.17.3 Liver Samples and Microsome Preparation 
Human liver samples were obtained from the University Hospital of Oulu as 
surplus from cadaver kidney transplantation donors. The collection of surplus tissue 
was approved by the Ethics Committee of the Medical Faculty, University of Oulu, 
Finland. All donors were Caucasians ranging in age from 21 to 62, four were 
female and six were male. Detailed information is shown in  
Table ‎4-4. Samples were transferred to ice immediately after surgical excision, 
dissected into pieces of approximately 1cm3 in size, and snap frozen in liquid 
nitrogen at -80C.  
 
Microsomes were prepared by standard differential ultra-centrifugation as described 
previously (Pelkonen et al., 1974). A microsomal pool of extensively characterised 
microsomes was used for all incubations. Previous studies have shown sufficient 
model activities, no known polymorphisms, expected effects of model inhibitors 
and quantitation of CYPs by Western blotting.  
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The final pellet was suspended in 0.1M phosphate buffer pH 7.4. Protein content 
was determined by the method of Bradford (Bradford, 1976). 
  





Table ‎4-3: Complementary products used to screen for the potential inhibition of cytochrome P450 enzymes in the single substrate and N-in-
one cocktail assays. 
Product Active or Principal 
 Component 
Concentration of active or 
principal component in 
each tablet/capsule 
Manufacturer Batch Number Reported benefit/Use 
Black Cohosh Cimicifuga racemosa 500mg Nature’s Own 302858 Eases the symptoms of menopause. 
Dong Quai Angelica polymorpha 520mg Nature’s Sunshine 00356532 Assist with menstrual cramps and the management of 
menstrual irregularity, fatigue and high blood 
pressure. 
Goldenseal Hydrastis Canadensis 500mg Nature’s Sunshine 01220333 Assist in the treatment of respiratory infections, anti-
inflammatory, and as laxative. 
Gotu Kola Centella asiatica 395mg Nature’s Sunshine 01223293 Eases anxiety and mood disorders.  
Horse Chestnut Aesculus 
hippocastanum 
2000mg NutraLife B4159 Treatment for blood stagnation. 
Horsetail Equisetum arvense 360mg Nature’s Sunshine 00243503 Used as a diuretic and in the treatment of urinary tract 
infections. 
Liquorice Root Glycyrrhiza glabra 425mg Nature’s Sunshine 00238614 Used as an expectorant anti-inflammatory agent. 
Primary adrenal tonic. 
Milk Thistle Silybum marianum  84mg Nature’s Own 302090 Assist the liver in detoxification. 
Saw Palmetto  Serenoa serrulata 550mg Nature’s Sunshine 00455693 Treatment of prostate hyperplasia. 
Valerian Valeriana officinalis 2250mg Bio-Organics 301338 Antispasmodic and muscle relaxant. Relieve nervous 
tension and anxiety. 
 
  





Table ‎4-4: Characteristics of human liver samples used for the cytochrome P450 inhibition studies. 
Liver Age Sex Cause of death Drug history Liver pathology 
HL20 54 M ICH Diazepama None 
HL21 44 M ICH Phenytoina, alcohol abuse Cirrhotic 
HL22 40 F ICH Dexamethasonea, nizatidinea, phenytoina None 
HL23 43 M ICH Diazepama, smoker None 
HL24 47 M ICH No medication, smoker None 
HL28 21 M Stroke Dexamethasonea, smoker None 
HL29 39 F ICH, SAH Dexamethasonea None 
HL30 53 F ICH, SAH No medication Steatosis 
HL31 44 F ICH, SAH No medication Steatosis 
HL32 62 M ICH, SDH Metformin, alcohol abuse, smoker None 
a Drugs were administered only during the 24 hours before death; M = male; F = female; ICH = intracerebral haemorrhage; SAH = 
subarachnoid haemorrhage; SDH = subdural haematoma 
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4.17.4 CYP Inhibition Assays: Single Substrate Incubations 
The incubation and analysis conditions used in the single substrate assays are 
summarised in Table ‎4-5. The isoenzymes investigated were: CYP1A1/2 
(ethoxyresorufin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2B6 
(bupropion hydroxylation), CYP2C8 (amodiaquine deethylation), CYP2C9 
(tolbutamide hydroxylation), CYP2C19 (omeprazole 5-hydroxylation), CYP2D6 
(dextromethorphan O-demethylation), CYP2E1 (chlorzoxazone 6-hydroxylation) 
and CYP3A4 (midazolam -hydroxylation and omeprazole sulphoxidation).  
 
Detailed information on the methodology can be found in the original papers 
(Table ‎4-5). The probe substrates and their metabolites are shown in 
Figure ‎4-7 and Figure ‎4-8. Known specific inhibitors were used for each of the 
isoenzymes investigated, Figure ‎4-9. As midazolam hydroxylation and omeprazole 
sulphoxidation both monitor CYP3A4 inhibition, the designations of (M)3A4 and 
(OS)3A4 (respectively) were used. 
 
For each assay, pooled microsomes were diluted to the required protein 
concentration (Table ‎4-5) with 0.1M phosphate buffer (pH = 7.4), substrate or 
inhibitor and test product were all pre-incubated for 2 minutes at 37C. The 
reaction was started with the addition of -nicotinamide adenine dinucleotide 
phosphate (NADPH) 10mM (CYP2B6, CYP2C8, CYP2C19 and CYP3A4) or 
cofactor mixture, containing 10mM MgCl2, 0.2M KCl, NADP (1.25 mM) glucose-
6-phosphate (6 mM), and 100 units of glucose-6-phospahte dehydrogenase, 
(CYP1A1/2, CYP2A6, CYP2C9, CYP2D6 and CYP2E1).  
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Incubations were maintained at 37C for the appropriate time (Table ‎4-5) in a 
shaking incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany), and 
stopped with the appropriate stop reagent: methanol (CYP1A1/2, CYP2C9, 
CYP2E1, CYP3A4) acetonitrile (CYP2B6, CYP2C8, CYP2C19) hydrochloric acid 
(CYP2D6) and trichloroacetic acid (CYP2A6). 
 
Once the reaction was stopped, incubations were kept on ice for a minimum of 5 
minutes then centrifuged for 15 minutes at 10,000 g. Supernatants were collected 
into clean tubes and stored at -20C until analysis. For analysis, incubations were 
thawed at room temperature, shaken and centrifuged for 10 minutes at 10,000 g.  
 
HPLC analysis was with a Shimadzu VP series HPLC system with Waters 
Symmetry C18 column (3.9x150mm, 5m, Waters Corp, Milford, MA) and 
Lichrospher 100 RP-18 guard column (4.0x4.0 mm, E. Merck, Darmstadt, 
Germany). Ethoxyresorufin O-deethylation (EROD) and coumarin 7-hyroxylation 
(ECOD) assays were read immediately following the incubations. The metabolites 
of ethoxyresorufin and coumarin were determined using a Hitachi F-1040 












Table ‎4-5: Summary of the single substrate in vitro assay parameters for the cytochrome P450 inhibition studies. 












1A1/2 7-Ethoxyresorufin Ethoxyresorufin  
O-deethylation 
 2.5 0.2 NADPH 
regenerating 
5 Fluorometric  
(530/585nm) 
(Burke et al., 1977) 
2A6 Coumarin Coumarin   
7-hydroxylation 
 10 0.1 NADPH 
regenerating 
10 Fluorometric  
(365/454nm) 
(Aitio, 1978) 
(Raunio et al., 1988) 
2B6 Bupropion Bupropion 
hydroxylation 
Ticlopidine 0.6 0.4 NADPH 15 UV-HPLC 
(204/214nm) 




(Hesse et al., 2000) 
(Faucette et al., 2000) 
2C8 Amodiaquine Amodiaquine  
deethylation 
Montelukast 12 0.1 NADPH 20 UV-HPLC  
(342nm) 




(Li et al., 2002) 
2C9 Tolbutamide Tolbutamide 
hydroxylation 
Sulfaphenazole 0.5 0.15 NADPH 
regenerating 
20 UV-HPLC  
(236nm) 






























2C19 Omeprazole Omeprazole  
5-hydroxylation 




buffer (A) and 
acetonitrile (B) 
 
(Äbelö et al., 2000) 
 
 
2D6 Dextromethorphan Dextromethorphan 
O-demethylation 








(Park et al., 1984) 
(Kronbach et al., 
1987) 
2E1 Chlorzoxazone Chlorzoxazone 6- 
hydroxylation 








(Peter et al., 1990) 
3A4 Midazolam Midazolam  
-hydroxylation  




60% water: 40% 
acetonitrile 
(Kronbach et al., 
1989) 
3A4 Omeprazole Omeprazole 
sulphoxidation 




buffer (A) and 
acetonitrile (B) 
(Äbelö et al., 2000) 
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4.17.5 CYP Inhibition Assays: N-In-One-Cocktail Incubations 
The incubation conditions and instrumentation used for the enzyme inhibition 
assays have all been previously described in detail covering the following CYP 
isoenzymes:  CYP1A1/2 (ethoxyresorufin O-deethylation), CYP2A6 (coumarin 7-
hydroxylation), CYP2C9 (tolbutamide hydroxylation), CYP2D6 
(dextromethorphan O-demethylation), CYP2E1 (chlorzoxazone 6-hydroxylation) 
CYP3A4/5 (midazolam -hydroxylation) (Taavitsainen et al., 2001). The assays 
for CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine N-deethylation) 
and CYP2C19 and CYP3A4 (omeprazole 5-hydroxylation and sulphoxidation) 
have all been described previously (Turpeinen et al., 2004, Turpeinen et al., 2006).  
 
The N-in one cocktail method was performed as previously described (Tolonen et 
al., 2007, Turpeinen et al., 2005) and is summarised in Table ‎4-6. The probe 
substrates and their metabolites are shown in Figures 4-7 and 4-8. As omeprazole-5-
hydroxylation and omeprazole demethylation both monitor CYP2C19 inhibition, 
the designations of (5)2C19 and (D)2C19 (respectively) were used. For CYP3A4, 
midazolam hydroxylation, omeprazole sulfoxidation, omeprazole-3-hydroxylation 
and 6β-testosterone hydroxylation, were monitored: and denoted (M)3A4, 
(OS)3A4, (3OH)3A4 and (T)3A4. 
 
Each incubation contained 0.5 mg microsomal protein/ml, 100mM phosphate 
buffer (pH7.4), 1mM NADPH and all ten-probe substrates. Substrates and their 
final concentrations for the incubations were: melatonin (4 µM), coumarin (2 M), 
bupropion (1 M), amodiaquine (2 M), tolbutamide (4 M), omeprazole (2 m), 
dextromethorphan (0.2 M), chlorzoxazone (6 M), midazolam (0.4 M) and 
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testosterone (1 M). Reaction mixture (final volume 200 l) was pre-incubated for 2 
minutes at +37ºC in a shaking incubator block (Eppendorf Thermomixer 5436, 
Hamburg, Germany) before the addition of NADPH to initiate the reaction.  
 
Each reaction was stopped after 20 minutes by the addition of 100 l of acetonitrile 
containing phenacetin (0.5 µM) (Figure ‎4-9) as an internal standard. Proteins were 
precipitated by cooling the samples in an ice bath for a minimum of 5 minutes then 
centrifuged for 15 minutes at 10,000 g. The supernatant was collected into clean 
tubes and stored at -20C until analysis. All incubations were run in duplicate on 
two separate occasions. For analysis, the incubations were thawed at room 
temperature, shaken and centrifuged for 10 min at 10,000 g. The supernatants were 
transferred to a Waters Total Recovery vial (waters Corporation, Milford, 

















Figure ‎4-7: Structures of the substrates utilised in the single substrate (#) and N-in-
one cocktail (*) cytochrome P450 inhibition enzyme assays, with the relevant  
metabolising  CYP. 
 
  




Figure ‎4-8: Structures of the metabolites detected in the single substrate (#) and N-
in-one cocktail (*) cytochrome P450 inhibition enzyme assays, with the relevant 
metabolising CYP. 
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Figure ‎4-9: Structures of the inhibitors utilised in the single substrate enzyme 
assays and the internal standard for the N-in-one cocktail cytochrome P450 







Table ‎4-6: Summary of the N-in-one cocktail in vitro assays parameters for the cytochrome P450 inhibition studies, adapted from Turpeinen et 
al. (Turpeinen et al., 2004). The Km values (Pelkonen et al., 1998), except for amodiaquine, (Li et al., 2002) bupropion (Hesse et al., 2000) and 
melatonin (Härtter et al., 2001). 
CYP Substrate Reaction Metabolite [Substrate] (M) Km (μm) Metabolite retention time (min) Extracted ions (m/z) 
1A2 Melatonin 6-Hydroxylation 6-OH-MEL 4 6 4.0 271 + 287 
2A6 Coumarin 7-Hydroxylation 7-OH-COU 2 2 5.4 163 
2B6 Bupropion Hydroxylation OH-BUP 1 90 4.4 238 + 256 
2C8 Amodiaquine Deethylation deEt-AMO 2 2.4 1.7 328 





















2D6 Dextromethorphan O-demethylation O-dem-DEX 0.2 5 4.1 258 
2E1 Chlorzoxazone 6-Hydroxylation 6-OH-CLZ 6 40 3.8 186 
3A4 Midazolam 1-Hydroxylation -OH-MDZ 0.4 4 6.2 342 
3A4 Testosterone 6-Hydroxylation 6-OH-TES 1 47 7.3 305 + 327 
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4.17.6 Data and Statistical Analysis 
4.17.6.1 Enzyme Assays- Single Substrate 
The concentration of the metabolite was calculated from peak height ratios of the 
UV chromatograms on the basis of standard calibration curves of authentic 
metabolites. The enzyme activity in the presence of the extracts was compared with 
control incubations into which only solvent was added.  
 
The IC50 values for the extracts (concentration causing 50% reduction of control 
activity) were determined from duplicate incubations run on two separate occasions 
by non-linear regression analysis (GraphPad Prism, v5.0). In order to interpret the 
results, the IC50 values were converted to reflect the volume one dose unit (one 
tablet or capsule) should be dissolved in to obtain the corresponding concentration 
as per the method described previously (Strandell et al., 2004).  
 
Metabolites of ethoxyresorufin and ethoxycoumarin were analysed fluorometrically 













S tandard ´10min´ 0.1mg(protein)
= pmol /min/mg(protein)
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4.17.6.2 Enzyme Assays- N-In-One-Cocktail 
Data is presented as the % activity of control for each of the products; each point is 
the average of duplicate incubations, conducted on two independent occasions 
where possible an IC50 was calculated using a non-linear regression analysis 
program (GraphPad Prism, v5.0). In order to interpret the results, the IC50 values 
were converted to reflect the volume one dose unit (one tablet or capsule) should be 
dissolved in to obtain the corresponding concentration as per the method described 
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4.18 Results 
4.18.1 Single Substrate Incubations 
4.18.1.1 General Comments 
The single substrate assays were all run in duplicate on two separate occasions. The 
inhibition for each of the extracts was determined from peak height ratios on the 
basis of standard calibrations and compared to control incubations. The variability 
between the two runs was negligible but was greater than the variability seen with 
the N-in-one cocktail assay (Appendix A). Between the individual incubations the 
variability did not exceed 15%. 
 
The inhibition potential for several extracts could not be determined due to 
limitations of the method; the metabolite peaks could not be resolved from the 
HPLC as the extracts themselves produced a peak adjacent to the metabolite peak. 
This interference with the peaks was seen most predominantly with Liquorice Root, 
with six of the aqueous extracts (CYP1A2, CYP2A6, CYP2C8, CYP2D6, CYP2E1 
and CYP3A4-using midazolam hydroxylation as the probe reaction), and 5 of the 
methanolic extracts (CYP2B6, CYP2C9, CYP2C19, and both CYP3A4 
incubations) not being able to be determined.  
 
4.18.2 CYP Inhibition 
Significant inhibition for at least two of the isoenzymes was seen for each of the 
products investigated. Inhibition was dose dependent; with the methanolic extracts 
causing more significant inhibition than the aqueous extracts, with higher levels of 
inhibition recorded and more isoenzymes being inhibited (Figure ‎4-10 - 
Figure ‎4-19). 
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With the aqueous extracts, inhibition >50% of the control did not occur for any of 
the isoenzymes investigated for Black Cohosh (Figure ‎4-10), Dong Quai 
(Figure ‎4-11), and Liquorice Root (Figure ‎4-16). Though in all cases, inhibition 
could not be determined for each of the isoenzymes investigated due to 
interference. For CYP2C9 and CYP2C8, inhibition >50% only occurred with 
Goldenseal and Saw Palmetto respectively (Figure ‎4-12, Figure ‎4-18). CYP3A4 was 
not inhibited >50% by any of the aqueous extracts for either of the reactions 
monitored. CYP2C8 was the most significantly inhibited isoenzyme for the 
aqueous extracts with four of the products causing >50% inhibition, Horsetail, Milk 
Thistle, Saw Palmetto and Valerian. Valerian was the most potent aqueous extract 
causing the inhibition of five isoenzymes at a level >50%, CYP2A6, CYP2B6, 
CYP2C8, CYP2D6 and CYP2E1 (Figure ‎4-19).  
 
The methanolic extracts all caused inhibition >50% of at least one of the 
investigated isoenzymes. As with the aqueous extracts, the most potent methanolic 
extract was Valerian, which caused inhibition of all the investigated isoenzymes 
except CYP2C9, which due to the problems of interference could not be determined 
(Figure ‎4-19). CYP2C19 was the isoenzyme most inhibited, with all 9 extracts 
except for Liquorice Root (which could not be determined due to interference 
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4.18.3 Inhibition Constants (IC50) 
The IC50 values were determined by non-linear regression and those that produced 
an IC50 <100 µg/ml are shown in  
Table ‎4-7. The most potent inhibition for the aqueous extract was seen with Horse 
Chestnut, with an IC50 of 18.23 µg/ml for CYP2E1. The methanolic extracts caused 
the most potent inhibition of CYP2C19 with all except Liquorice Root, which 
could not be determined, producing an IC50 <100 µg/ml. The most potent was the 
methanolic extract of Goldenseal, which was determined to have an IC50 of 5.7 
µg/ml with the IC50 for Saw Palmetto being 5.9 µg/ml for CYP2B6. 
 
In order to interpret the results, the IC50 values were converted to reflect the volume 
one dose unit (one tablet or capsule) should be dissolved in to obtain the 
corresponding concentration as per the method described previously (Strandell et 
al., 2004), with results shown in Table ‎4-8. A converted IC50 value of 5 litres/dose 
unit indicates that one dose unit diluted to approximately the blood volume (of an 
average person) would result in a concentration of inhibitory substances equivalent 
to the recorded IC50 of CYP enzyme inhibition. Whilst this produces a conservative 
figure it is useful to identify potentially clinically relevant CYP inhibition. The most 
potent aqueous extract using this method was Horse Chestnut, which produced an 
inhibition in L/dose units of 109.7. The most potent methanolic extract was 
Valerian, which produced an inhibition of 286 L/dose units for CYP2B6 and 232.5 









Figure ‎4-10: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Black Cohosh for the cytochrome P450 isoforms 
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Figure ‎4-11: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Dong Quai for the cytochrome P450 isoforms 
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Figure ‎4-12: % Inhibition of control for aqueous (Aq) and methanolic (Meth) extracts of Goldenseal for each of the cytochrome P450 isoforms 
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Figure ‎4-13: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Gotu Kola for each of the cytochrome P450 
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Figure ‎4-14: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Horse Chestnut for each of the cytochrome P450 
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Figure ‎4-15: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Horsetail for each of the cytochrome P450 
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Figure ‎4-16: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Liquorice Root for each of the cytochrome P450 
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Figure ‎4-17: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Milk Thistle for each of the cytochrome P450 
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Figure ‎4-18: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Saw Palmetto for each of the cytochrome P450 
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Figure ‎4-19: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Valerian for each of the cytochrome P450 isoforms 
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Table ‎4-7: Estimated IC50 (g/ml) for the products investigated for CYP inhibition using the single substrate assay. IC50 calculated using a non-
linear regression analysis program (GraphPad Prism, v5.0).  
Product Extract 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 (M)3A4 (OS)3A4 
Black Cohosh Aq           
Black Cohosh Meth   24.5   32.8  11.38   
Dong Qui Aq           
Dong Quai Meth  93.8 17.74   19.7  87.65   
Goldenseal Aq       *    
Goldenseal  Meth   8.75   5.7 10.17 6.22 35.32 12.98 
Gotu Kola Aq           
Gotu Kola Meth      11.46  12.76  60.91 
Horse Chestnut Aq  53.52      18.23   
Horse Chestnut Meth   *   26.07  9.59   
Horsetail Aq  79.97  93.56       
Horsetail Meth 14.83  21.18   22.63     
Liquorice Root Aq * *  *   * * *  
Liquorice Root Meth 23.4  * 34.45 * * 21.25 16.66 * * 
Milk Thistle Aq   *  61.7      
Milk Thistle  Meth   31.1 *  10.5  *   
Saw Palmetto Aq           
Saw Palmetto Meth   5.9 76.3 * 6.8   15.5  
Valerian  Aq           
Valerian Meth 56.5  7.9 12.0 * 9.7 52.8 17.6  76.6 







Table ‎4-8: Inhibition of CYP isoenzymes by extracts that produced an IC50 <100 g/ml in the single substrate assay. IC50 values are expressed 
as litre/dose unit.  
Product Extract 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 (M)3A4 (OS)3A4 
Black Cohosh Aq           
Black Cohosh Meth   20.4   15.2  43.9   
Dong Quai Aq       *    
Dong Quai Meth  5.5 29.3   26.4  5.9   
Goldenseal Aq           
Goldenseal  Meth   57.2   87.7 49.2 80.4 14.2 38.5 
Gotu Kola Aq           
Gotu Kola Meth      34.5  31.0  6.5 
Horse Chestnut Aq  37.4      109.7   
Horse Chestnut Meth   *   76.7  208.5   
Horsetail Aq  4.5  3.9       
Horsetail Meth 24.3  17   15.9     
Liquorice Root Aq * *  *   * * *  
Liquorice Root Meth 18.2  * 12.3 * * 20 25.5 * * 
Milk Thistle Aq   *  1.36      
Milk Thistle  Meth   2.7 *  8.0  *   
Saw Palmetto Aq           
Saw Palmetto Meth   93.2 7.2 * 80.3   35.4  
Valerian  Aq           
Valerian Meth 39.8  286 187.7 * 232.5 42.7 127.8  29.4 
Aq = aqueous extracts, Meth = methanolic extracts. * Inhibition could not be determined. 
  
Chapter 4- Cytochrome P450 Inhibition   222 
4.19 N-in-one Cocktail Assays 
4.19.1 General Comments 
The N-in-one cocktail assays were all run in duplicate on two separate occasions. 
The inhibition for each of the extracts was determined against the control and was 
shown to be dose dependant for the extracts investigated (Figure ‎4-20 - 
Figure ‎4-29). The variability between the two runs was negligible and less than the 
variability seen in the single substrate assay with the variability between individual 
incubations not exceeding 10% (Appendix A). 
 
Unlike the single substrate assays, the N-in-one cocktail assay did not have the 
same problems of interference. As the N-in-one cocktail method utilises time of 
flight mass spectrometry which is a more sensitive and discriminatory (i.e. 
resolution is superior) method than the HPLC the substrates and metabolites could 
be determined for all of the investigated extracts, as the detection of ions is based on 
the exact mass/charge (m/z) ratio. 
 
4.19.2 CYP Inhibition 
As with the single substrate incubations, the methanolic extracts caused more 
significant inhibition than the aqueous extracts, with higher levels of inhibition 
recorded and more isoenzymes being inhibited. Inhibition was dose dependent for 
all of the extracts investigated (Figure ‎4-20 - Figure ‎4-29).  
 
With regards to the aqueous extracts, inhibition >50% did not occur for any of the 
isoenzymes investigated for Black Cohosh (Figure ‎4-20) and Dong Quai 
(Figure ‎4-21), this pattern was also seen with the single substrate incubations.  
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CYP2B6 and CYP2C9 were only significantly inhibited by Valerian (Figure ‎4-29) 
and Milk Thistle (Figure ‎4-27), respectively. The most potent aqueous extract was 
Valerian which caused >50% inhibition at the highest investigated concentration of 
6 isoenzymes (Figure ‎4-29).  
 
CYP2D6 and CYP2E1 were both significantly inhibited by 3 products, whilst 
CYP2A6 and CYP2C8 were both significantly inhibited by 4 products. CYP3A4 
inhibition varied depending on the reaction being monitored. No significant 
inhibition was seen for any of the aqueous extracts using midazolam hydroxylation 
((M)3A4) or omeprazole sulfoxidation ((OS)3A4), but significant inhibition was 
detected using the omeprazole 3-hydroxylation ((3OH)3A4) and testosterone 
hydroxylation ((T)3A4). 
 
The methanolic extract of Valerian significantly inhibited all of the isoenzymes 
investigated (Figure ‎4-29). CYP2C19 was the most significantly inhibited 
isoenzyme with all of the methanolic extracts inhibiting this isoenzyme using both 
probe reactions (omeprazole 5-hydroxylation and omeprazole demethylation). 
CYP2E1 was inhibited by all of the extracts except Milk Thistle. CYP1A2 and 
CYP2D6 were both inhibited significantly by 3 of the methanolic extracts. CYP2A6 
was only significantly inhibited by 2 of the methanolic extracts, Dong Quai and 
Valerian. CYP2C8 and CYP2C9 were significantly inhibited by 4 and 5 of the 
methanolic extracts respectively. CYP3A4 inhibition varied as it did with the 
aqueous extracts. Goldenseal, Saw Palmetto and Valerian all caused significant 
inhibition of CYP3A4 with all 4 probe reactions.  
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4.19.3 Inhibition Constants (IC50) 
Estimated IC50s were determined for the extracts that produced significant 
inhibition (<100 g/ml) and are shown in Table ‎4-9. The most potent aqueous 
extract was Goldenseal with an IC50 of 6.7 µg/ml for CYP2D6. Valerian produced 
and IC50 <100 µg/ml for all of the isoenzymes except CYP2A6. The most potent 
methanolic extract was Milk Thistle, which produced and IC50 of 2.9 µg/ml for 
CYP2C9.  
 
In order to interpret the results, the IC50 values were converted to reflect the volume 
one dose unit (one tablet or capsule) should be dissolved in to obtain the 
corresponding concentration as per the method described previously (Strandell et 
al., 2004), Table ‎4-10. Using this method to represent the data the methanolic 
extract of Valerian is the most potent inhibitor of the CYP isoenzymes investigated, 
with 5 CYPs (CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1) having an 
inhibition in L/dose units over 100 L. The methanolic extracts of Goldenseal, 
Horse Chestnut, Liquorice Root and Saw Palmetto all produced an inhibition >100 
L/dose units for four isoenzymes. With the aqueous extracts, only Horse Chestnut 
produced an inhibition >100 L/dose units for both CYP2A6 and CYP2E1 with 











Figure ‎4-20: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Black Cohosh for each of the cytochrome P450 
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Figure ‎4-21: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Dong Quai for each of the cytochrome P450 
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Figure ‎4-22: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Goldenseal for each of the cytochrome P450 






































































CYP Isoenzyme Assay 
Aq 20 ug/ml 
Aq 100 ug/ml 
Aq 500 ug/ml 
Meth 20 ug/ml 
Meth 100 ug/ml 








Figure ‎4-23: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Gotu Kola for each of the cytochrome P450 
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Figure ‎4-24: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Horsetail for each of the cytochrome P450 
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Figure ‎4-25: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Horse Chestnut for each of the CYP isoform 
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Figure ‎4-26: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Liquorice Root for each of the cytochrome P450 
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Figure ‎4-27: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Milk Thistle for each of the cytochrome P450 
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Figure ‎4-28: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Saw Palmetto at for each of the cytochrome P450 
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Figure ‎4-29: % Inhibition of control for the aqueous (Aq) and methanolic (Meth) extracts of Valerian for each of the cytochrome P450 isoforms 
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Table ‎4-9: Estimated IC50 (g/ml) for the products investigated for CYP inhibition using the N-in-one cocktail assay. IC50 calculated using a 
non-linear regression analysis program (GraphPad Prism, v5.0).  
Product Extract 1A2 2A6 2B6 2C8 2C9 (5)2C19 (D)2C19 2D6 2E1 (M)3A4 (OS)3A4 (3OH)3A4 (T)3A4 
Black Cohosh Aq              
Black Cohosh Meth   49.2   36.3 23.9  11.5     
Dong Quai Aq              
Dong Quai Meth  94.7 11.4   13.7 14.3       
Goldenseal Aq        6.7      
Goldenseal  Meth   6.5   4.8 4.9 6.3 3.9 26.7 10.1 3.6 9.7 
Gotu Kola Aq              
Gotu Kola Meth   14.0   8.3 7.8  9.5    58.4 
Horse Chestnut Aq  17.8       16.8   66.1  
Horse Chestnut Meth   18.0   21.3 20.0  8.6   4.4  
Horsetail Aq  18.3  93.0          
Horsetail Meth 12.6  11.3   15.5 7.9       
Liquorice Root Aq  41.8      97.2 8.8     
Liquorice Root Meth 28.7  4.2 22.6 3.6 5.1 3.7 13.7 6.6 73.0 44.5 3.6  
Milk Thistle Aq     64.2         
Milk Thistle  Meth   7.7  2.9 4.8 4.2     15.5  
Saw Palmetto Aq              
Saw Palmetto Meth   3.9 68.9 4.1 5 12.3  12.6   3.5  
Valerian  Aq              
Valerian Meth 55.8  5.8 4.3 5.1 5.2 6 54.1 19.7  91 3.6 56.2 







Table ‎4-10: Inhibition of CYP isoenzymes by extracts that produced an IC50 <100 g/ml in the N-in-one cocktail assay. IC50 values are 
expressed as litre/dose unit.  
Product Extract 1A2 2A6 2B6 2C8 2C9 (5)2C19 (D)2C19 2D6 2E1 (M)3A4 (OS)3A4 (3OH)3A4 (T)3A4 
Black Cohosh Aq              
Black Cohosh Meth     10     13.8 20.9   43.5         
Dong Quai Aq              
Dong Quai Meth   5.5 45.6     38 36.4             
Goldenseal Aq               74.6           
Goldenseal  Meth     76.9     104.2 102 79.3 128.2 18.7 49.5 138.9 51.5 
Gotu Kola Aq              
Gotu Kola Meth     28.2     47.6 50.6   41.6       6.8 
Horse Chestnut Aq   112.4             119     30.3   
Horse Chestnut Meth     111     93.9 100   232.6     454.5   
Horsetail Aq   19.7   3.9                   
Horsetail Meth 28.6   31.9     23.2 45.6             
Liquorice Root Aq   10.2           4.4 48.3         
Liquorice Root Meth 14.8   101.2 18.8 118.1 83.3 141.7 31 64.4  5.8 9.6 118.1 4.2 
Milk Thistle Aq         10.9                 
Milk Thistle  Meth     91   24.1 145.8 166.7         129.6   
Saw Palmetto Aq              
Saw Palmetto Meth     141 8 134.1 110 44.7   43.7     157   
Valerian  Aq              
Valerian Meth 40.3   387.9 523.3 441.2 432.7 375 41.6 114.2   24.7 0.6 40 
Aq = aqueous extracts, Meth = methanolic extracts. 
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4.20 Discussion and Conclusions  
4.20.1 Product Selection 
The products selected for this study are amongst the top selling products in 
Australia (Table ‎4-3). As the cytochrome P450 enzymes are the main drug 
metabolising enzymes in the body and responsible for the metabolism of the 
majority of therapeutic drugs then selecting products based on product market share 
is a rational starting point.  
 
Several products selected were done so on the basis of interaction potential with 
therapeutic drugs based on the traditional reported use of the product (Table ‎4-3). 
Horse chestnut is reported to be useful in the treatment of “blood stagnation” based 
on this therapeutic indication there is a risk of concurrent use with anti-coagulant 
drugs such as warfarin. As warfarin has a narrow therapeutic index, any drug 
interaction resulting in increased or deceased bioavailability of warfarin could be 
life threatening. 
 
4.20.2 Selection of Inhibition Assay Method 
Using pooled microsomes to investigate CYP inhibition allows for multiple 
isoenzymes to be investigated from multiple donors, this gives a better 
representation of the in vivo situation.  
 
‘The single substrate assays employs HPLC and fluorescence detection of CYP 
specific substrates and their metabolites. These substrates are well characterised and 
routinely used to investigate interactions with CYPs. The disadvantage of this 
technique is that only CYP can be monitored at once.  
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To increase the throughput of these assays and reduce the amount of human tissue 
and labour required, the N-in-one cocktail assay can be used. With this assay the 
simultaneous monitoring of multiple CYPs in the one reaction can be undertaken. 
The substrates are specific for a CYP or multiple CYPs with different metabolites 
generated for the different CYP. The assay requires LC/MSMS analysis to identify 
the 10 substrates and 13 metabolites. 
 
4.20.3 General Discussion of Results 
The fact that CYPs are critical for the disposition of a large percentage of clinically 
important drugs is well established and consequently any interference of this 
enzyme system can lead to unexpected and adverse events. It has been estimated 
that the majority of 200 important drugs are dependent on drug metabolism for 
their elimination and CYPs played a dominant role in this metabolism (Williams et 
al., 2004, Evans and Relling, 1999, Zanger et al., 2008). Members of the CYP3A 
family contributed to the metabolism of 37% of the drugs, followed by CYP2C9 
(17%), CYP2D6 (15%), CYP2C19 (10%), CYP1A2 (9%), and CYP2C8 (6%). 
CYP2B6 and other CYP isoforms (CYP2A6 and CYP2E1) participated in the 
metabolism of 4% and 2% of the drugs, respectively (Zanger et al., 2008). In light of 
this, complementary products need to be investigated for their potential to interact 
with and inhibit CYP enzymes.  
 
Studying complementary products in this context presents a number of challenges, 
including the fact that these products are complex preparations of variable 
composition.  
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Isolating individual components is one method that can be used to assist in the 
determination of the kinetic profiles of these products but this is time consuming 
and in the end may not provide the answers required as these products are not 
taken as isolated components but as complex mixtures.  
 
As variability is known to occur with these products between the manufacturers 
and even between seasons and geographic locations of the raw materials (Song et 
al., 2010, Strandell et al., 2004), ongoing screening is required. Screening for CYP 
inhibition rather than simply testing for isolated components is more clinically 
significant as components often interact to produce an effect and any single 
component responsible for CYP inhibition may not be the components being 
isolated and quantified. 
 
Representing the IC50 in litres/dose gives some insight into the possibility of 
reaching in vivo concentrations that may be significant. For example, an IC50 of 5-
litres/dose units indicates that one recommended dose unit diluted into a volume 
equivalent to the approximate blood volume of the average person would result in a 
concentration of inhibitory substances equivalent to the IC50 of CYP enzyme 
inhibition. Obviously the likelihood of a notable inhibition being associated with a 
product that has IC50s reaching into the range of 100 L or more is much greater. 
Strandell et al. used litres/dose to present their data and concluded that IC50 of less 
than 0.88 L/dose would not be inhibitory (Strandell et al., 2004). This method of 
representing the data whilst producing a conservative figure is an attempt to provide 
information that will aid in prioritising the products that require more urgent 
investigation.  
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Another challenge associated with complementary products is the choice of 
extraction method. For these studies, the choice was made on the basis of the 
relevance of the extract to patient use of these products. The products are generally 
administered as tablets or water infusions (‘teas’). Therefore aqueous and alcohol 
(methanol) extracts were prepared, methanol was selected to extract distinctly more 
lipid soluble components. 
 
4.21 Black Cohosh  
Black Cohosh (Cimcifuga racemosa) is a shrub like plant native to the Eastern forests 
of North America. Because of reports proposing benefit in alleviating symptoms of 
menopause and the subsequent reports of hepatotoxicity, Black Cohosh is one of 
the most investigated herbal products. Although several in vitro and in vivo studies 
on some CYP activities have been conducted (Gurley et al., 2005b, Gurley et al., 
2006b, Gurley et al., 2008), this is the first report of Black Cohosh being screened 
for inhibition potential against a full panel of CYPs and also using an N-in-one 
cocktail approach. 
 
Whilst none of the aqueous extracts resulted in an IC50 <100 µg/ml, three 
isoenzymes recorded an IC50 below 100 µg/ml with the methanolic extracts, 
CYP2B6, CYP2C19 and CYP2E1 with values of 24.5, 32.8 and 11.38 µg/ml 
respectively, using the single substrate assay method and 49.2, 23.9-36.3 and 11.5 
µg/ml respectively, using the N-in-one cocktail method.  
 
Previous studies with Black Cohosh have highlighted the problems with data 
interpretation that arise when these complex and variable products are assessed.  
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In vivo studies in humans initially found that Black Cohosh may weakly inhibit 
CYP2D6 to the value of 7% (Gurley et al., 2005b), but later studies conducted by 
the same group concluded that Black Cohosh had no inhibitory effect (Gurley et 
al., 2008). In both these studies the method for determining inhibition is the same 
but the product investigated was different. The 2005 study used a Black Cohosh 
that was standardized to 0.2% triterpene glycosides per tablet, whilst the 2008 study 
used a product that was standardized to 2.5% triterpene glycosides per tablet. This 
finding suggests that whilst the triterpene glycosides are often reported as the 
principle component of these preparations it may not be this component that causes 
CYP inhibition and that other components in these preparations may be capable of 
causing inhibition. 
 
Human in vivo studies have also found that there is no inhibition of CYP3A4 with 
Black Cohosh (Gurley et al., 2006b, Gurley et al., 2005b) and our data is in 
agreement with this. In vitro studies using human liver microsomes also found no 
significant inhibition of CYP3A4 but did demonstrate the difference in inhibition 
patterns that arises with various manufacturers products (Wanwimolruk et al., 
2009). Induction of CYP3A4 has been investigated, CYP3A11 in mice which is the 
homolog of CYP3A4 was shown to be up-regulated specifically in the liver but this 
may not be mediated by PXR (Houston and Galetin, 2010).  
 
The inhibition of CYP2B6 may be significant as several important pharmaceutical 
drugs including cyclophosphamide and verapamil are substrates for this isoenzyme 
(Turpeinen et al., 2006). Polymorphic variation in CYP2B6 has also been shown to 
be an important factor in drug metabolism (Xie et al., 2003). 
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4.22 Dong Quai  
Dong Quai (Angelica sinensis), also known as female ginseng, is indigenous to 
China. Traditionally it has been used to treat gynaecological ailments, fatigue, 
anaemia and high blood pressure. Previously it has been shown to induce CYP2D6 
and CYP2A4 in rodent species (Tang et al., 2006). To date there have been no 
reports of inhibition of CYP enzymes with Dong Quai though other species of 
Angelica appear to inhibit CYP2A6 (Yoo et al., 2007). 
 
As with Black Cohosh, none of the aqueous extracts resulted in an IC50 <100 
µg/ml. The methanolic extracts caused significant inhibition of three isoenzymes: 
CYP2A6, CYP2B6 and CYP2C19 with IC50’s of 93.8, 17.7 and 19.7 µg/ml for the 
single substrate assays and 94.7, 11.4 and 13.7-14.3 µg/ml respectively for the N-in-
one cocktail assays. Inhibition by Dong Quai may be significant as inhibition by 
other CYP2C19 inhibitors including isoniazid (Ki = 25.4 M) are known to cause 
adverse clinical interactions when administered concurrently with diazepam or 
phenytoin (both are substrates for CYP2C19) (Kay et al., 1985, Ochs et al., 1981). 
 
Inhibition of CYP2B6 with the methanolic extract of Dong Quai was the most 
significant, IC50 of 45.6 L/dose units (from the N-in-one cocktail assay), which is 
greater than the 5 L/dose unitss that would approximate blood volume of the 
average person. This inhibition along with the potential for interaction with 
CYP2C19 (36.4 L/dose units from the N-in-one cocktail assay) inhibition helps to 
prioritise Dong Quai as a product that requires further investigation.  
 
  
Chapter 4 – Cytochrome P450 Inhibition 243 
Using the formation of 1-OH midazolam as the probe reaction, other species of 
Angelica have been shown to inhibit CYP3A4 weakly (unpublished data from our 
laboratory). These investigations did not show significant inhibition of CYP3A4. 
Using testosterone as the probe substrate, the aqueous 500 µg/ml extract caused 
43% inhibition of control (Figure ‎4-12).  
 
4.23 Goldenseal  
Goldenseal (Hydrastis canadensis) is a perennial herb that is native to south-eastern 
Canada and north-eastern United States. It is used as an antimicrobial and a 
laxative. In vitro studies using human microsomes have shown inhibition of 
CYP2D6 with two components of Goldenseal, berberine and hydrastine, IC50 = 45 
M and 350M respectively (Chatterjee and Franklin, 2003). In vivo studies 
conducted in healthy human subjects also concluded that inhibition of CYP2D6 
and CYP3A4 occurs with Goldenseal (Gurley et al., 2008).  
 
In vitro investigations have shown Goldenseal to be an inhibitor of CYP2C9, 
CYP2D6 and CYP3A4 with IC50 values of 0.98, 0.66 and 0.18% of control 
respectively (Chatterjee and Franklin, 2003). In addition to these isoenzymes, 
CYP2C19 has been shown to be inhibited by Goldenseal in vitro up to 80% of 
control (Taavitsainen, 2001). 
 
The data indicates that aqueous extracts of Goldenseal causes significant inhibition 
of CYP2D6 (IC50 = 6.7 µg/ml, 74.6 L/dose units), though no inhibition was 
detected using the single substrate assays.  
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Inhibition of CYP2D6 may be clinically significant as dextromethorphan, a 
substrate of CYP2D6 and used to treat coughs, may be used concurrently with 
Goldenseal.  
 
The methanolic extract caused significant inhibition with 5 of the isoenzymes 
CYP2B6, CYP2C19, CYP3A4, CYP2D6 and CYP2E1. This is the first report of 
inhibition of CYP2B6 and CYP2E1 with Goldenseal. The most potent inhibition 
was seen with CYP3A4 with and IC50 of 35.32 and 26.7 µg/ml for the single 
substrate and N-in-one cocktail respectively. This data was obtained using the 
midazolam hydroxylation reaction; lower levels of inhibition were detected using 
the other probe reactions. This variability in the inhibition of CYP3A4 highlights 
the need for multiple probe reactions to be monitored for CYP3A4 investigations in 
order to gain a true representation of the inhibition potential of the compound being 
investigated.  
 
4.24 Gotu Kola  
Gotu Kola (Centella asiatica) is a small plant native to several countries including 
India, Sri Lanka, Indonesia and Iran. It is used in the treatment of stress, anxiety 
and depression. Previous in vitro studies determined that tea made from Gotu Kola 
at a concentration of 25 mg/ml caused a weak to moderate inhibition of CYP2C9 
(24.8%), CYP2C19 (42.2%), CYP2D6 (23.9%) and CYP3A4 (51.5%) 
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No significant inhibition was seen with the aqueous extracts in our studies. Whilst 
it did not reach significant levels, inhibition of CYP1A2 with the aqueous extract 
was moderate with inhibition reaching 75 and 78% of control, for the single 
substrate and the N-in-one cocktail assays respectively, at the highest concentration 
(500 µg/ml) investigated (Figure ‎4-13 and Figure ‎4-23). This finding is of concern 
as many antidepressants including the tricyclics are substrates for CYP1A2. The 
potential for herb-drug interactions is therefore possible in patients who are taking 
antidepressants and concurrently taking Gotu Kola (which claims to help in the 
treatment of anxiety and mood disorders) to aid in their condition.  
 
Using cDNA expressed isoforms, CYP2C9 was shown to be inhibited by the 
ethanolic and dichloromethane extracts of Gotu kola with a Ki of 39.1 and 26.6 
µg/ml, with S-mephenytoin as the probe substrate (Pan et al., 2010). Whilst in our 
studies inhibition of CYP2C9 was not detected (using tolbutamide as the probe 
substrate), previous work has shown that the IC50 values of model inhibitors differs 
dependent on the models and methods used (Turpeinen et al., 2006). Additionally 
CYP2C9 has been reported to be more catalytically active in cDNA expressed 
enzymes than human microsomes (Venkatakrishnan et al., 2000).  
 
The methanolic extracts of Gotu Kola caused significant inhibition of CYP2B6, 
CYP2C19, CYP2E1 and CYP3A4 with IC50 values of 14, 7.8-8.3, 9.5 and 58.4 
µg/ml respectively, with the N-in-one cocktail assays, though CYP2B6 inhibition 
was not detected using the single substrate assays.  
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Importantly the inhibition of CYP3A4 was detected only with the 6β-testosterone 
hydroxylation reaction, which once again demonstrates the importance of using 
multiple probe reactions when investigations into this isoenzyme are undertaken.  
  
The IC50 in litre/dose unit indicate that the greatest potential for inhibition and 
therefore interactions occurs with CYP2C19 with values of 34.5 and 47.6 -50.6 
L/dose units for the single substrate and the N-in-one cocktail respectively. 
CYP2C19 is responsible for the metabolism of omeprazole (Äbelö et al., 2000), 
phenytoin (Guengerich, 2005) and amitriptyline (Venkatakrishnan et al., 1998), 
therefore inhibition of CYP2C19 may cause adverse drug interactions due to 
increased concentrations of phenytoin leading to toxicity. 
 
4.25 Horse Chestnut  
Horse Chestnut (Aesculus hippocastanum) is a large tree that is native to the Balkans 
and temperate regions of Europe. It is used for chronic venous insufficiency and 
haemorrhoids. To date very few investigations have been carried out into the 
potential for Horse Chestnut to inhibit CYP enzymes with most studies focusing on 
its anti-platelet activity (Felixsson et al., 2010, Wu et al., 2012) and the toxicity 
associated with the alkaloids present in the plant. The induction potential of Horse 
Chestnut has been assessed in cultured human hepatocytes and was found to be 
negative for CYP2C19 (Hellum et al., 2009). 
 
In vitro studies using a cDNA baculovirus system concluded that inhibition of 
CYP3A4 did occur but a high IC50 was determined (1173 g/ml) using the 6β-
testosterone hydroxylation as the probe reaction (Hellum and Nilsen, 2008).  
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These investigations have also shown inhibition of CYP3A4, this was dependent on 
the specific probe reaction used with the 3-OH-omeprazole probe reaction being the 
most sensitive with the aqueous and methanolic extracts having an IC50 of 66.1 and 
4.4 µg/ml, respectively, for the N-in-one cocktail assay. Inhibition was not detected 
using the single substrate assays. Not being able to detect inhibition with the single 
substrate assays may have been caused by interference from the products with the 
analytical method.  
 
CYP2B6 was significantly inhibited by the methanolic extract with IC50 value of 
18.0 g/ml, though this was only with the N-in-one cocktail assay as the data from 
the single substrate assay could not be obtained due to interference from the 
product with the HPLC peak detection (see section ‎4.18.1.1). The methanolic 
extract also caused significant inhibition of CYP2C19 with IC50 of 26.07 g/ml for 
the single substrate assay and 20.0-21.3 g/ml for the N-in-one cocktail assay.  
 
The inhibition of CYP2C19 is of concern as there is a potential for concurrent use 
of Horse Chestnut which is taken to prevent blood stagnation, and the anti-platelet 
drug clopidogrel which is a pro-drug that is converted to its active metabolite by 
CYP2C19. This potential for an interaction to occur is not only strengthened by the 
potential for concurrent use of these products but also the potential for Horse 
Chestnut to reach a concentration that may be significant as demonstrated by the 
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Our results also indicate that the Horse Chestnut can significantly inhibit CYP2E1. 
The aqueous and methanolic extracts having IC50 of 18.2 and 9.59 µg/ml for the 
single substrate and 16.8 and 8.6 µg/ml for the N-in-one cocktail assays. To date no 
clinically significant interactions have been reported with regards to CYP2E1 
inhibition, but inhibition of this isoenzyme may alter the disposition of alcohol, 
benzene and carcinogens such as azoxymethane, which are all, metabolised by 
CYP2E1.  
 
Inhibition of CYP2A6 was seen with aqueous extract, IC50 of 17.8-53.52 g/ml. 
Inhibition of CYP2A6 is potentially significant because of the role this isoenzyme 
plays in the metabolism of several drugs with a narrow therapeutic index including 
valproic acid. 
 
4.26 Horsetail   
Horsetail (Equisetum arvense) is a bushy plant that is native to the Northern 
hemisphere and is used to aid in the treatment of urinary tract infections, cystitis 
and prostate problems. In vitro studies have previously indicated that ethanol 
extracts can cause inhibition of CYP3A4 (22% of control) (Scott et al., 2006) using 
a fluorescent probe substrate (dibenzylfluorescein). Though our studies did not 
detect any inhibition of CYP3A4 this may be either due to differences in the herbal 
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The aqueous extracts significantly inhibited CYP2A6 and CYP2C8 with IC50 values 
80.0 and 93.6 g/ml for the single substrate assays, and 18.3 and 93.0 g/ml for the 
N-in-one cocktail assays, respectively. The methanolic extracts also caused 
significant inhibition of CYP1A2, CYP2B6 and CYP2C19 with IC50’s of 14.8, 21.2 
and 22.6 g/ml respectively, for the single substrate assays and 12.6, 11.3 and 7.9-
15.5 µg/ml respectively, for the N-in-one cocktail assays. Inhibition of these 
isoenzymes has not been previously reported. 
 
Clinically the inhibition of CYP2C8 may be significant; this is despite the low IC50 
litre/dose unit of 3.9 as many of the loop diuretics are substrates for CYP2C8. 
Adverse reactions may arise in patients with urinary tract infections and cystitis 
who may use Horsetail concurrently with antibiotics such as trimethoprim, which is 
also an inhibitor of CYP2C8. This potential interaction may lead to increased 
concentrations of trimethoprim in the serum, which can lead to adverse effects such 
as rashes, GIT disturbances and folate deficiency. 
 
4.27 Liquorice Root  
Liquorice Root (Glycyrrhiza glabra) is a plant that is native to southern Europe and 
parts of Asia and is one of the most potent CYP inhibitors investigated in this 
study. It is used in the treatment of acute viral hepatitis, to relieve cough and in 
autoimmune diseases. It is a known inhibitor of CYP2B6, CYP2C9 and CYP3A4 
(Kent et al., 2002). Constituents of liquorice have been well studied and the 
furanocoumarins including bergamottin and the isoflavone glabridin are known to 
be the major constituents causing CYP inhibition.  
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Extracts of Liquorice Root caused the most interference with the single substrate 
assays (section ‎4.18.1.1). The inhibition for the aqueous extracts could not be 
determined for CYP1A2, 2A6, 2C8, 2D6, 2E1 and (M)3A4. For the methanolic 
extracts CYP2B6, 2C9, 2C19 and both of the 3A4 assays the inhibition could not be 
determined.  
 
The aqueous extract caused significant inhibition of CYP2A6, CYP2D6 and 
CYP2E1 with IC50’s of 41.8, 97.2 and 8.8 g/ml with the N-in-once cocktail assays. 
Due to the interference problems mentioned, inhibition could not be detected with 
the single substrate assays for these isoenzymes.  
 
The aqueous extract caused significant inhibition of CYP2A6, CYP2D6 and 
CYP2E1 with IC50’s of 41.8, 97.2 and 8.8 μg/ml with the N-in-one cocktail assays. 
Due to the interference problems mentioned, inhibition could not be detected with 
the single substrate assays for these isoenzymes. 
 
The methanolic extracts significantly inhibited all isoenzymes except CYP2A6. The 
inhibition of CYP3A4 varied depending on the probe substrate being used. The 
data indicates that the formations of 3-OH-omeprazole and OH-midazolam were 
the most and least sensitive assays, respectively.  Inhibition was not detected using 
the 6β-hydroxylation of testosterone as the probe reaction. 
 
The inhibition caused by Liquorice Root is not only extensive but also potent as 
four of the isoenzymes have an IC50 >100 L/dose units, i.e. CYP2B6, CYP2C9, 
CYP2C19 and CYP3A4 with values of 101.2, 118.1, 141.7 and 118.1 L/dose units. 
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This high value indicates that the potential for one dose unit to cause significant 
inhibition is possible. As Liquorice Root is used to treat a wide variety of conditions 
as well as a product added to many herbal remedies to “harmonize” the ingredients 
in the formula and “regulate the meridians” (Bensky et al., 2004) it is a product that 
certainly should be investigated in more detail for its ability to inhibit CYPs. 
 
4.28 Milk Thistle  
Milk Thistle (Silybum marianum) is a flowering plant that is native to the 
Mediterranean regions of Europe, North Africa and the Middle East. It is 
commonly used as a liver tonic. For this reason this product presents a unique 
problem in that many of the patients consuming this may have pre-existing liver 
damage and therefore a decreased capacity to metabolise xenobiotics. Several in 
vivo and in vitro investigations have been conducted with Milk Thistle. No 
clinically significant inhibition of CYP1A2, CYP2D6, CYP3A4 and CYP2E1 was 
determined in healthy human subjects (Gurley et al., 2004, Gurley et al., 2006b, 
Gurley et al., 2008). 
 
Our work indicates that inhibition of CYP2C9 occurs with the aqueous extract, 
with an IC50 of 61.7 µg/ml (1.36 L/dose units) and 64.2 µg/ml (1.3 L/dose units) 
for the single substrate and the N-in-one cocktail assays respectively (Figure ‎4-17 
and Figure ‎4-27). Inhibition of CYP2C9 may warrant further consideration and 
investigation even though there is a low risk with the IC50 in L/dose units being <5, 
as warfarin, a vitamin K antagonist, has a narrow therapeutic index and the S-
enantiomer is metabolised by CYP2C9 (Yamazaki et al., 1998).  
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Inhibiting CYP2C9 increases the biological availability of warfarin and may cause 
increased risk in bleeding.  
 
The methanolic extract caused significant inhibition of CYP2B6 (IC50 7.7 μg/ml), 
CYP2C9 (IC50 2.9 μg/ml), CYP2C19 (IC50 4.2-4.8 μg/ml) and CYP3A4 (with only 
the omeprazole-3-hydroxylation reaction, IC50 15.5 μg/ml) in the N-in-one cocktail 
assays (Table ‎4-9). This potential for CYP inhibition should be considered in 
patients with decreased liver function who may be taking Milk Thistle to aid in 
their condition concurrently with therapeutic agents that are metabolised by these 
CYPs including warfarin and phenytoin.  
 
4.29 Saw Palmetto  
Saw palmetto (Serenoa repens) is a fruit extract that is used in the treatment of 
urinary and reproductive disorders. Investigations into Saw Palmetto are 
increasingly urgent as the use of this product is increasing and as reports of benefit 
in the treatment of benign prostatic hyperplasia continue to emerge (Tacklind et al., 
2009). 
 
In vitro studies concluded that Saw Palmetto was a potent inhibitor of CYP3A4 
with an IC50 of 7.41 µg/ml (Budzinski et al., 2000), though this was not supported 
by in vivo studies. In vivo studies have shown no inhibition of CYP1A2, CYP2D6, 
CYP2E1 and CYP3A4 using the dose recommended by the manufacturer (Gurley 
et al., 2004, Markowitz et al., 2003).  
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None of the aqueous extracts caused significant inhibition of any of the isoenzymes 
investigated. The methanolic extracts caused significant inhibition of CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2E1 with the N-in-one cocktail 
assays (Table ‎4-9). With the single substrate assays, CYP2B6, CYP2C8, CYP2C19 
were the only three significantly inhibited isoenzymes (Table ‎4-7). When the IC50 is 
determined in L/dose units, 4 isoenzymes are significantly inhibited. The 
isoenzymes inhibited were CYP2B6, CYP2C9, CYP2C19 and CYP3A4 and the 
respective IC50 values in L/dose units’ were 141.0, 134.1, 110 and 157 (Table ‎4-10). 
 
The IC50 for CYP2C9 was 4.1 µg/ml with the N-in-one cocktail assay, but 
inhibition was not detected with the single substrate assay. As both of these 
methods use the same probe reaction, tolbutamide hydroxylation, the discrepancy 
may be due to the greater sensitivity of the N-in-one cocktail method or interference 
from the product with the HPLC results. 
 
4.30 Valerian  
Valerian (Valeriana officinalis) is a flowering plant that is native to Europe and Asia 
and is used in the treatment of insomnia. Previous studies in vitro have reported 
that Valerian caused inhibition of CYP3A4 (Lefebvre and Foster, 2004, Hellum 
and Nilsen, 2008b) but investigations in vivo did not correlate with these findings 
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None of the CYP isoenzymes investigated were significantly inhibited by the 
aqueous extracts of Valerian with either of the assay methods used. Inhibition of 
CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP2D6 and CYP2E1 was 
seen with the methanolic extracts with both the single substrate and the N-in-one 
cocktail assays (Table ‎4-7 and Table ‎4-9). This wide variety of CYPs inhibited by 
Valerian and the many reported uses of the product including sleep disorders, 
anxiety and muscle relaxant has the potential to lead to adverse reactions. 
 
When the IC50 is converted to L/dose units we see that not only does Valerian 
inhibit the most isoenzymes, but it is also the most potent inhibitor with CYP2C8 
producing an IC50 of 523.3 L/dose units. This is particularly important when the 
therapeutic agents metabolised by CYP2C8, including paclitaxel, cerivastatin, 
repaglinide, rosiglitazone and pioglitazone (Jaakkola et al., 2006, Wang et al., 
2002, Rahman et al., 1994) are considered.  Increases in the plasma level of 
paclitaxel which occurs when metabolism is inhibited may lead to hypersensitivity 
and hypotension (Panchagnula, 1998). 
 
4.31 Comparison Between the Methods 
Whilst these studies have highlighted potential important inhibition of CYPs with 
commonly used complementary products, it has also shown that the N-in-one 
cocktail method can be used to screen these complex mixtures. By using the N-in-
one cocktail method the problems of interference with peak detection with HPLC 
are avoided. Additionally the variability in the estimated inhibition is lower with 
the N-in-one cocktail than with the single substrate assay (Appendix A). 
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The inhibition of CYP3A4 is of key importance as it is the most abundant CYP in 
the liver and accounts for the metabolism of over 50% of therapeutic agents (Evans 
and Relling, 1999, Zanger et al., 2008). Inhibition of CYP3A4 can be determined 
using a variety of probe substrates. As multiple binding sites are known on the 
enzyme, and binding may occur simultaneously at multiple sites, it has been 
proposed that inhibition of CYP3A4 should be investigated using multiple probe 
substrates (Kenworthy et al., 1999).  
 
Midazolam and testosterone have previously been described as substrates that 
belong to two distinct groups, the benzodiazepines and the large molecular weight 
groups respectively. These studies highlights that of the 4 probe reaction monitored 
these two follow a pattern with similar levels of inhibition, for example the aqueous 
extract of Black Cohosh recording an inhibition of 76% and 71% at the highest 
tested concentration for midazolam and testosterone respectively (Figure ‎4-20).  
 
Omeprazole, a pyridine, is a probe substrate for CYP2C19 but can also be used as a 
substrate for CYP3A4. Omeprazole hydroxylation was the most sensitive probe 
reaction investigated in our studies, though it does not correlate with omeprazole 
sulfoxidation. This highlights the importance of using multiple probe substrates 
when investigating the potential inhibition of CYP3A4 ( 
Table ‎4-7 and Table ‎4-9).  
 
The IC50’s are comparable between the two methods, though in general the IC50 was 
higher with the single substrate assays than with the N-in-one cocktail assay ( 
Table ‎4-7 and Table ‎4-9).  
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One of the most significant differences between the methods is with CYP3A4 using 
omeprazole sulfoxidation as the probe reaction for the methanolic extract of Horse 
Chestnut. The IC50 using the single substrate assay was 69 g/ml but was >100 
g/ml for the N-in-one cocktail method (108 g/ml), both assay methods were 
negative for inhibition when midazolam was used as the probe substrate.  
 
4.32 Conclusions 
There is sufficient reason to be aware of the real possibility of complementary 
products inhibiting CYP enzymes. The consequences of adverse clinical reactions 
resulting from such inhibition are of concern and should receive adequate attention. 
The difficulties of conducting systematic studies of these products with respect to 
their potential CYP inhibition are the number of products available and the 
inherent variability in these products. Quantitative evaluation of CYP inhibition is 
essential to detect clinically significant interactions with herbal products. However, 
screening of this nature serves as an alert for clinicians.  
 
The multiple forms of CYPs playing a major role in drug metabolism, is an 
additional challenge. However, the N-in-one cocktail method allows for the rapid 
screening for CYP inhibition by these products with data comparable to the more 
commonly used single substrate method. The N-in-one method also allows for 
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Those interactions which are deemed to be significant from a clinical perspective 
should be prioritised for further monitoring and study based on the likelihood of 
being used concurrently with medications with a narrow therapeutic index and with 
those that have a high IC50 in L/dose units (Table ‎4-8 and Table ‎4-10). 
 
Extraction efficiency is always a vexing question when dealing with poorly 
characterised plant or animal extracts. Until a thorough analysis of the extracts 
exists, one needs to rely on rigid adherence to an adopted extraction method. These 
studies have shown that the extraction method selected is reproducible as the data 
from the incubations is derived from extractions on separate occasions (Appendix 
A). One of the important points of this study is that it permits the screening of 
unresolved complex mixtures. The next stage of these investigations would be to 
fractionate the products showing significant inhibition. The fractionation would 
permit detailed study the inhibition potency by the individual components.  
 
The N-in-one cocktail is a rapid and reliable method that can be used as an initial 
screen to prioritise which products require further investigation and also can be 
applied to monitor the variation that can arise in these products. 
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Chapter 5 - Concluding Discussion: 
 
The primary objective of this project was to identify reliable and reproducible 
methods that can be employed to detect key pharmacokinetic interactions with 
complementary products and conventional medications. 
 
5.1 Interaction Potential 
The inescapable reality is that majority of patients resorting to the use of 
complementary products are likely to be treated with prescription or over the 
counter drugs (MacLennan et al., 2002, Eisenberg et al., 1998).  
 
Additionally these patients see multiple therapists along with medical practitioners. 
In combination this is a basis for significant therapeutic problems. The therapeutic 
problems are primarily product interactions with prescription and over the counter 
medications. The pharmacokinetic interactions can be grouped into four major 











   Figure ‎5-1: Pharmacokinetic interactions based on absorption, protein binding, metabolism and excretion (Baxter, 2010). 
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The experimental work presented in this thesis addresses pharmacokinetic 
interaction issues that relate to absorption, protein binding and metabolism. 
Studying these with pure compounds is relatively uncomplicated however 
complementary products presents a number difficult problems which must be 
solved in order to conduct any meaningful studies with them. These problems 
include: 
 Product selection. 
 Extraction method. 
 Constituent concentration. 
 
We have addressed these for the purposes of the experimental work presented here 
and as possible criteria for regulatory studies that we recommend. 
 
5.1.1 Product Selection 
Products are initially selected for testing based on the likelihood for concurrent use 
with therapeutic agents with a high risk. This high risk may be due to a narrow 
therapeutic index (i.e.: digoxin, zidovudine, warfarin and phenytoin) or because of 
a potential synergistic effect between the complementary product and the 
therapeutic drug (i.e.: the anticoagulant warfarin and the herbal treatment for blood 
stagnation Danshen). In the case of a specific investigation i.e.: binding to albumin, 
a product may be selected for testing if there is likely to be concurrent use with a 
therapeutic agent known to have significant binding to albumin. 
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The product selection for the experimental purposes here also serves as a guideline 
for practitioners of complementary products in their practice. They need to be 
vigilant when products are concurrently used with selected conventional medicines. 
 
5.1.2 Extraction Method 
Another challenge associated with complementary products is the choice of 
extraction method. For these studies, the choice was made on the basis of the 
relevance of the extract to the patient use of the product. As these products are 
generally administered as tablets or infusions (‘teas’) an aqueous and alcohol 
(methanol) extract was prepared. Methanol was selected to extract the distinctly 
more lipid soluble components. There was never an intention to fractionate these 
products into their individual constituents as they are consumed as complex 
mixtures and therefore should be studied in this form. 
 
5.1.3 Constituent Concentration 
In interaction studies with pure substances molar concentrations are easily 
calculated. With complementary products, which are complex mixtures this is not 
possible. A different approach is needed to achieve meaningful results. 
 
The chemical composition of these products is not always known and even in cases 
where it is known, it may be highly variable. A reference point that can be used is 
the recommended dose and the manufacturers labelling as it reflects what the 
patients will consume. It will be reflective of plasma concentrations of the various 
active and inactive constituents.  
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As the products used were manufactured in Australia under GMP, the information 
contained on the product label was assumed to be accurate. In absence of chemical 
profiling, routine studies with these products can be based on this criterion. Whilst 
it is possible to determine the concentration of the labelled ingredient this was not 
conducted with these studies as the labelled ingredient may not be responsible for 
the activity seen in the assays. A better approach would be to determine if a product 
requires further investigation and from that point, fractionate and identify the 
component responsible for the activity seen. 
 
5.1.4 Metabolites 
The absorption, distribution, metabolism and elimination (ADME) of a xenobiotic 
are often considered distinct from each other but a series of complex interactions 
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Figure ‎5-2: Schematic representation of the interrelationship of the 
pharmacokinetic processes; absorption, distribution, metabolism and elimination. 
Adapted from Ionescu and Caira (Ionescu and Caira, 2005). 
 
 
As most complementary products are taken orally, the bioavailability is low or 
reduced due to incomplete absorption. Orally absorbed products may be subjected 
to extensive metabolism, most commonly in the intestine and/or the liver. These 
metabolites can be the cause of a pharmacokinetic interactions or responsible for 
direct toxicity. The complexity of these products may give rise to multiple 
metabolites.  
 
Ginkgo biloba is a herbal product that is known to have key metabolites that have 
their own kinetic profile. Several of the parent ginsenosides are converted to 
metabolites by gut microbiota. The metabolite Compound K, possess significantly 
stronger cancer chemoprevention activity than the parent compounds. 
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Pharmacokinetically, the active metabolites of ginseng differ in distribution and 
clearance from that of the parent compound (Qi et al., 2011).  
 
The example of Ginkgo biloba highlights the need to investigate the potential for 
metabolites of complementary products to cause adverse interactions. These studies 
would involve the generation of the product metabolites by incubating the parent 
product with the major metabolising systems of the body: the gastrointestinal tract 
and the liver.  
 
5.2 Conclusions From the Experimental Work 
With the experimental work, 24 of the 34 extracts tested were found to result in 
pharmacokinetic interactions (Table 5-1). 
 
 
The interactions involve protein binding, transport protein and CYP
inhibition. Detailed results for each of the parameters were previously detailed; 
protein binding (Table ‎2-5 and Table ‎2-6), P-glycoprotein inhibition (Table ‎3-4 and 












Table ‎5-1: Summary of the experimental work for the pharmacokinetic parameters 
investigated with the extracts of complementary products. 
Product Extract HSA AGP P-gp CYP450 










Astragalus Aq   X     
Astragalus Meth   X     
Black cohosh Aq      X X 
Black cohosh Meth      * * 
CoEnzyme Q10 Aq X *      
CoEnzyme Q10 Meth X *      
Cordyceps Aq    *    
Cordyceps Meth    X    
Danshen Aq X X      
Danshen Meth X *      
Dong quai Aq X X    X X 
Dong quai Meth X X    * * 
Echinacea Aq   X     
Echinacea Meth   X X    
Ginkgo Biloba Aq X X X X    
Ginkgo Biloba Meth X * X     
Goldenseal Aq X X    X * 
Goldenseal Meth * *    * * 
Gotu Kola Aq   X   X X 
Gotu Kola Meth   X   * * 
Horse Chestnut Aq      * * 
Horse Chestnut Meth      * * 
Horsetail Aq      * * 
Horsetail Meth      * * 
Liquorice Root Aq      X * 
Liquorice Root Meth      * * 
Milk Thistle Aq    X  * * 
Milk Thistle  Meth    *  * * 
Saw Palmetto Aq      X X 
Saw Palmetto Meth      * * 
Slippery Elm Aq    *    
Slippery Elm Meth    *    
Valerian Aq   X X  X X 
Valerian Meth   X X  * * 
Aq -Aqueous extracts  Meth -Methanolic extracts 
* -Significant interaction  X -No significant interaction  
HSA -Binding to human serum albumin, site I and II. Significance at Kd <1mg/ml. 
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AGP -Binding to alpha-1-acid glycoprotein. Significance at Kd <1mg/ml. 
P-gp inhibition -Calcein AM extrusion. Significance at IC50 <100 μg/ml. 
P-gp inhibition -ATPase activity. Significance at IC50 <100 μg/ml. 
CYP450 inhibition -Single substrate assays. Significance at IC50 <100 μg/ml. 
CYP450 inhibition –N-in-one cocktail assays. Significance at IC50 <100 μg/ml. 
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5.3 General Recommendations 
In addition to recognising the interactions discovered here that deserve vigilance in 
clinical use, the following general recommendations to improve the safety of 
complementary products are proposed based on the literature. 
 
Due to the complex nature of these products and the specific challenges associated 
with them, pharmacovigilance needs to be expanded from the categories that are 
currently used with conventional medicines. Additional categories required include 
the origin of the product, presence of contaminant and adulterants and the name 
attributed to the product (traditional, botanical, common). If this information was 
available to regulators worldwide then consistent risk assessments could be carried 
out and the risk to patients dramatically decreased. 
 
Table 5.2, summarises the information that should be provided to regulatory 
authorities, these parameters have been recommended based on the required 







Table ‎5-2: Parameters recommended for inclusion in the information submitted to regulators and the basis of the recommendations. 
Parameter Basis Recommendation 
Positive product identification Misidentification of raw material has lead to toxicity, 
Aristolochia fangchi, which is nephrotoxic, was mistakenly 
identified as the safe Stephania tetrandra.  
Identification should be made by a qualified botanist and confirmed 
with genetic identification. 
Source of the raw material Geographical location can alter the composition of the raw 
material. 
Confirmation of collection site, location and date of raw material to 
be provided. 
Plant parts used Chemical composition varies with the part of the plant i.e.: 
root, leaves, flowers, to be used. 
Correct identification of which part of the plant, or in the case of 
multiple parts how much of each part, to be provided. 
Constituent composition Composition of the raw material is altered due to many factors 
including, geographical location, season, and soil conditions. 
Chemical identification to be provided, marker compounds may be 
used if well characterized.  
Historical use  The history of the use of the product may give an indication of 
toxicity and will also provide information on the patient group 
most likely to consume this product. 
Full history from the relevant pharmacopeia to be provided. 
Intended use Intended use of the product will give an indication of the 
patient group likely to consume this product. The risk of 
concurrent use with therapeutic agents can be established. 
Therapeutic claims and the condition/disease for which the product 
is to be clearly stated. Evidence for therapeutic claims must be 
provided.  
Quality control in 
manufacturing 
Lack of good manufacturing practice resulted in widespread 
withdrawal of substandard products and eventual closure of 
Pan Pharmaceuticals. 
Therapeutic agents and foods are all required to manufactured under 
GMP. Complementary products to be subjected to the same 
manufacturing regulations. 
Microbial content Contamination may arise during processing or storage with 
bacterial and fungal elements. 
Testing for microbial contamination and their toxic secondary 
metabolites i.e. mycotoxins.  
Heavy metal content Heavy metals including lead and arsenic are known toxic 
contaminants of particularly Ayurvedic products. 
Testing to ensure that heavy metals are at a safe level for consumers. 
Adulterant detection Adulterants particularly therapeutic agents (steroids, analgesics, 
sedatives and erectile dysfunction drugs) are frequently found in 
herbal products to enhance the therapeutic claims. 
Testing to be conducted to ensure adulterants are not present or if 









Parameter Basis Recommendation 
Toxicological information A number of example of direct toxicity have been reported over 
many years including Aristolochia and Danshen. 
In absence of unequivocal historical evidence of safety, standard 
pre-clinical safety evaluation as well as ADME properties should be 
conducted. 
Pharmacovigilance Both direct toxicity and interactions of low frequency can be 
only detected by observing substantial patient populations 
A harmonized reporting system for these products to allow rapid 
identification adverse events.  
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5.4 Future Directions 
This work provides clear directions for investigating pharmacokinetically based 
interactions involving complementary products. Specifically, plasma protein 
binding and displacement interactions, inhibition of cytochrome P450 and 
inhibition of P-glycoprotein. The obvious extension of this work should include 
potential drug interactions due to other pharmacokinetic parameters: 
 CYP induction. 
 Induction of p-glycoprotein. 
 Inhibition and induction of other drug transporters including the organic 
anion and cation transporters.  
 Inhibition and induction of phase II metabolism enzymes including 
sulfotransferases and glutathione S-transferase. 
 The interactions caused by the metabolites of the products. 
As many of these pharmacokinetic parameters are connected there is also work that 
can be conducted on the interplay that is possible in the in vivo situation.  
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Figure ‎5-3: Schematic representation of the interplay of transporters and enzymes 
in the hepatocyte. Cytochrome P450 (CYP) and other hepatic enzymes such as 
epoxide hydrolase (EH), conjugating enzymes, UDP glucuronyl transferase (UGT), 
sulphotransferase (SULT) or glutathione S-transferase (GST) are important in 
metabolic handling of xenobiotics. The enzymes depend on molecular oxygen and 
NADPH (CYP), UDPG (UGT), PAPS (SULT) and reduced glutathione (GSH) 
(GST). The cellular membrane has many transporters, OATS, ABC transporters 
and OCTS, which are important for the transmembrane flux of many xenobiotics 
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Another approach can be developed based on the plant families. By working with 
families of plants, it may be possible to identify broader classifications of raw 
material that have similar drug interactions. This should focus the research to the 
products most likely to cause adverse drug interactions. 
 
Finally, there are the so-called ‘omics’ technologies that may provide unexpected 
advances in the identification and ongoing monitoring of these products. In 
particular the NMR and LC-MS based metabonomics can track biomarkers that 
could reveal both adverse effects and interactions in vivo (Ouedraogo et al., 2012, 
Liang et al., 2010). Additionally these technologies have applications in identifying 
the components of these products and chemical variability (Yang et al., 2012, 
Sheridan et al., 2012) 
 
Evidence for using gene based ‘omics’ technologies with interesting outcomes has 
involved products such as kava-kava. In these studies kava-kava was administered 
to rats and subsequent genome wide gene-expression revealed differences in the 
expression of drug metabolizing enzymes from the control group, and alterations in 
the mitochondrial function and oxidative stress response pathways (Guo et al., 
2010b, Guo et al., 2009). Microarrays have also been used to identify gene 
expression changes. Ginkgo Biloba has been shown to alter a number of genes in a 
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This work has outlined approaches to study complex and variable mixtures such as 
complementary products and made recommendations for improving the patient 
safety in face of a bewildering array of herbal and other complementary products 
which have a total market value of some $83 billion per year. The dollar value 
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Chapter 6 - Appendix A: 
This appendix contains all the data relating to the inhibition of cytochrome P450 
for the aqueous and methanolic extracts for the 10 complementary products 
(Table ‎4-3). The raw data is shown for the single substrate and the N-in-one cocktail 
incubations.  
  









Figure ‎6-1: % Inhibition of control for individual incubations for the extracts of 
Black Cohosh at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-2: % Inhibition of control for individual incubations for the extracts of 
Dong Quai at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-3: % Inhibition of control for individual incubations for the extracts of 
Goldenseal at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-4: % Inhibition of control for individual incubations for the extracts of 
Gotu Kola at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
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Figure ‎6-5: % Inhibition of control for individual incubations for the extracts of 
Horse Chestnut at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-6: % Inhibition of control for individual incubations for the extracts of 
Horsetail at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
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Figure ‎6-7: % Inhibition of control for individual incubations for the extracts of 
Liquorice Root at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-8: % Inhibition of control for individual incubations for the extracts of 
Milk Thistle at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-9: % Inhibition of control for individual incubations for the extracts of 
Saw Palmetto at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  










Figure ‎6-10: % Inhibition of control for individual incubations for the extracts of 
Valerian at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
single substrate incubations.  
() Aqueous extracts () Methanolic extracts 
 
  









Figure ‎6-11: % Inhibition of control for individual incubations for the extracts of 
Black Cohosh at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-12: % Inhibition of control for individual incubations for the extracts of 
Dong Quai at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-13: % Inhibition of control for individual incubations for the extracts of 
Goldenseal at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-14: % Inhibition of control for individual incubations for the extracts of 
Gotu Kola at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-15: % Inhibition of control for individual incubations for the extracts of 
Horse Chestnut at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-16: % Inhibition of control for individual incubations for the extracts of 
Horsetail at 20, 100 and 500 g/ml for each of the CYP isoform assays using the N-
in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-17: % Inhibition of control for individual incubations for the extracts of 
Liquorice Root at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
  








Figure ‎6-18: % Inhibition of control for individual incubations for the extracts of 
Milk Thistle at 20, 100 and 500 g/ml for each of the CYP isoform assays using the 
N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
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Figure ‎6-19: % Inhibition of control for individual incubations for the extracts of 
Saw Palmetto at 20, 100 and 500 g/ml for each of the CYP isoform assays using 
the N-in-one cocktail assay.  
() Aqueous extracts () Methanolic extracts 
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Figure ‎6-20: % Inhibition of control for individual incubations for the extracts of 
Valerian at 20, 100 and 500 g/ml for each of the CYP isoform assays using the N-
in-one cocktail assay. 
() Aqueous extracts () Methanolic extracts 
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